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Abstract 
 Disease due to Streptococcus pneumoniae is a major cause of mortality and morbidity globally. 
Pneumococcal conjugate vaccines (PCVs) are being routinely introduced in immunisation 
programmes with support from Gavi, the Vaccine alliance, in low-income countries but 
uncertainty remains around the impact of different PCV introduction strategies in such settings, 
and in particular catch-up campaigns (CCs), which so far have not been conducted in Gavi-
supported countries due to supply constraints.  
 
This thesis explored the potential impact on nasopharyngeal carriage and disease of 
introducing PCV with and without CCs, in Nha Trang, Vietnam, through a dynamic transmission 
model. Vietnam is yet to introduce PCV vaccination, as are most South-East Asian countries. 
Additional studies on the vaccine efficacy against carriage (VEC) and its waning, social contact 
patterns relevant for pneumococcal transmission, and age-specific epidemiology of carriage 
and serotype distribution were also conducted, the results of which fed directly into the 
transmission model. 
 
A meta-analysis provided the first ever-global estimates of VEC and its waning, by serotype and 
schedule.  A large survey in southwest Uganda, collecting data on both social contact patterns 
and carriage from the same participants, shed light on which social contacts are important for 
pneumococcal transmission, showing that the frequency of close contacts, but not casual 
contacts, increased the colonisation risk, thereby informing the parameterisation of the 
transmission model. Results from the latter predicted elimination of vaccine type (VT) serotypes 
with near-complete replacement by non-VT across all age groups, within 10 years of PCV 
introduction with 90% coverage.  The predicted benefit of CCs to expanded age groups was 
most pronounced in the first three years after PCV introduction, insofar that CCs result in 
limited introduction delays. 
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This thesis provided important insight into the epidemiology and transmission dynamics of 
pneumococci, to inform policy in countries that have not yet introduced PCV. 
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1. Introduction 
1.1. Pneumococcal carriage and disease 
Disease due to Streptococus pneumoniae (the pneumococcus) is a leading cause of morbidity 
and mortality, causing about 11% of deaths in children under five globally [1]. Community 
acquired pneumonia accounts for most of the severe pneumococcal disease burden worldwide, 
although the risk of severe morbidity and death is highest for invasive pneumococcal disease 
(IPD) such as bacteraemic pneumonia, meningitis and sepsis [1].  
 
Carriage of Streptococcus pneumoniae in the nasopharynx is a precondition for pneumococcal 
disease, and the main reservoir for human-to-human transmission of the pathogen [2-4].  
Pneumococci are part of the commensal nasopharyngeal flora, and as such, colonisation by 
pneumococci is both a frequent and generally asymptomatic event [5]. Infants generally 
become colonised within the first few weeks or months of life, and most children will have had 
at least one episode of nasopharyngeal colonisation in their first year of life [5-7].  Overall, the 
prevalence of carriage in children under five years of age is high, varying between settings from 
about 25% to 90% [8-10], and decreasing with age [10]. Colonisation rates tend to be higher in 
more deprived communities [11, 12], and are generally higher in developing than developed 
countries [8, 9]. Risk factors for carriage, other than age, include individual factors such as HIV 
infection, malnutrition or sickle cell disease [13-16], and community or ecological factors 
including seasonality [17, 18], pollution, inadequate hygiene, and increased social contact, 
particularly with and between young children. Several studies have shown that day-care centre 
attendance is associated with carriage prevalence among young children [19-23].  
The extent to which some of the abovementioned factors explain differences in carriage 
prevalence rates between settings and countries remains insufficiently explored, but it is likely 
 18 
 
that the sociodemographic structure and social mixing patterns are important factors 
explaining higher colonisation rates in low-income settings.  
 
Although carriage is asymptomatic,  it is a necessary precursor to disease; acquisition can 
occasionally lead to local mucosal disease, such as acute otitis media (AOM) or sinusitis, more 
rarely to lower respiratory tract infections and pneumonia, and in rare cases can lead to invasive 
disease [24]. The burden of pneumococcal disease tends to be disproportionally high in low 
income settings, not only because acquisition events tend to be more frequent, but also 
because underlying individual vulnerability factors such as malnutrition, HIV [13, 25, 26], sickle 
cell anaemia [27], as well as inadequate access to health services, can increase the risk of severe 
disease and death, particularly in infants and young children [28-32].   
 
Pneumonia remains one of the main causes of mortality and morbidity in children under five 
years of age [1, 33].  In 2010, an estimated 1.4 million deaths due to pneumonia occurred 
globally, 43% of which were in Africa, and another 32% in South East Asia [33]. Although the 
aetiological ascertainment of radiological or clinical pneumonia remains difficult, Streptococcus 
pneumoniae is known to be one the main causative agents for both primary infection as well as 
secondary infection during upper respiratory viral illness such as measles or influenza [1, 26, 34]. 
Evidence from pneumococcal conjugate vaccine trials have consistently shown a reduction in 
the burden of radiological pneumonia among vaccinated children, with intervention studies 
from the Gambia [35, 36], South Africa [37], the Philippines [38], and among Navajo Indian 
Americans in the US [39] all showing substantial reductions in all-cause pneumonia among 
vaccinated arms, albeit of varying magnitude.   
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1.2. Immune response to carriage and disease 
 
Immunity resulting from natural exposure to Streptococcus pneumoniae in the nasopharynx is 
complex, and remains incompletely understood [40]. 
 
As nasopharyngeal carriage is a precondition to disease, and the main mechanism by which 
pneumococci are transmitted from person-to-person, elucidating the immune mechanisms 
against carriage is paramount. It is known that the local mucosal immune response plays an 
important role in clearance of acquired S.pneumoniae, and other pathogens of the commensal 
flora such as moraxella catarrhalis, H influenzae and others [24]. 
 
Carriage occurs through adherence of pneumococci to the epithelial lining of the nasopharynx, 
which is mediated by surface proteins, such as the pneumococcal surface protein A (PspA) or 
pneumococcal surface protein C (PspC) [24, 41]. It then requires the generation of inflammatory 
markers – as for example triggered during upper respiratory viral infections – to activate an 
inflammatory cascade that may result in the transcellular migration of pneumococci into the 
endothelium, resulting in invasive disease [24]. However, in the vast majority of cases, carriage 
acquisition remains asymptomatic, and the pathogen tends to be cleared within days or weeks.  
 
There are nearly a 100 different known serotypes, which differ by the nature of their 
polysaccharide capsule and are thus immunologically distinct, even though common 
polysaccharides between certain serotypes results some degree of natural or vaccine-induces 
cross-protection (e.g. 6A and 6B). The polysaccharide capsule is the main virulence factor of 
pneumococci, as it allows the bacteria to evade phagocytosis, to some extent [5].  
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Differences in the nature of the polysaccharide likely explain some of the epidemiological 
characteristics of pneumococci in carriage and disease. Generally, serotypes with thicker 
capsules tend to escape opsonophagocytosis better than serotypes with thinner ones, and as 
such are also found more frequently in carriage, are carried for longer periods of time [42], and 
tend to predominate in carriage (and disease) among younger age groups. Epidemiological 
studies have consistently found that carriage decreases with age, and that the serotype 
distribution in carriage also tends to shift from being predominantly ‘paediatric serotypes’ in 
early childhood – which tend to be the most commonly found serotypes and are the serotypes 
targeted by the pneumococcal conjugate vaccines – to proportionally fewer of such serotypes 
as age increases [10]. Likewise, serotypes found in invasive disease tend to differ between age 
groups. For example, before the introduction of PCV, studies in England, Denmark and Germany 
found that serotype 1 and 5 accounted for about 20 – 25% of all serotypes isolated in IPD in 
neonates, whereas fewer than 5% of cases were due to such serotypes in older infants in the 
same studies [43-45]. Similarly, disease due to ‘paediatric serotypes’ tends to be proportionally 
much rarer amongst adults [46].  
 
Those epidemiological findings support the evidence from laboratory and clinical studies that 
acquired anti-capsular (i.e. serotype-specific) immunity against nasopharyngeal colonisation, 
which requires the activation of the classic complement pathway, is one of the most important 
immune mechanisms against S.pneumonaie [47-49]. However, the exact mechanism underlying 
the protection against acquisition of carriage is still unclear and may involve memory B cells 
residing in the nasopharyngeal compartment responding to carriage and secreting local IgG or 
IgA rather than pre-existing circulating serum IgG. For example, studies have shown that both 
serotype-specific IgG and IgA antibodies can be found in the saliva of children colonised with a 
homologous serotype, further supporting a major role of a local serotype-specific immune 
reaction against pneumococcal polysaccharides as immune protection mechanism [50, 51].  
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Anti-capsular immunity is also central to the immune response to invasive infection. In 
particular, antibody binding to neutrophils, macrophages and other antigen presenting cells 
from the lung, liver or spleen, is crucial for opsonophagocytosis during invasive infections, and 
explains why asplenia, liver cirrhosis, or chronic splenic dysfunctions such as sickle cell anaemia 
tend to be risk factors for severe invasive infections[49]. 
 
In addition to antibody-mediated immunity against the capsule polysaccharide, there is now 
good evidence of acquired immunity to pneumococcal proteins, which are not common 
between serotypes [49, 52, 53]. Virolainen et al. [41] showed that children with lower antibody 
titres to PspA tended to be colonised more frequently with pneumococci than those with 
higher titres.  Through a large household study in the UK, Goldblatt et al. [48] found that 
carriage induced a strong anticapsular response, but also a moderate antiprotein antibody 
response. As for anticapsular immunity, there is evidence that antibody-mediated immunity 
against pneumococcal surface proteins increase as children age [40]. 
 
In addition, there are also more recent studies suggesting that CD4+ T-helper 1 (Th1) and Th17 
cells have an important role in clearance of carriage [54, 55]. Cell-mediated immunity is also 
thought to play an important factor in protecting against invasiveness, as suggested by studies 
showing that HIV positive individuals tend to be more prone to invasive infections, through 
deregulation of the T-cell response, before the CD4+ depletion [56].  
 
In summary, both serotype-specific and non-specific immunity have important functions in the 
prevention against colonisation, and disease. Immunity from natural exposure to pneumococci 
can thus be summarised into three broad categories, namely (i) serotype-specific antibody-
mediated immunity to the polysaccharide capsule of Streptococcus pneumonia, (ii) antibody-
mediated immunity against pneumococcal surface proteins and (iii) cell-mediated antibody 
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independent immunity to pneumococcal proteins and the cell-wall polysaccharide, as described 
by Li et al. [40]. Antibody-mediated immunity will activate the classic complement route to 
opsonophagocytosis, whereas the cell-mediated immune mechanism includes CD4 cells that 
will activitate neutrophils and/or macrophages through the secretion of interleukin, and thereby 
kill S.pneumonia [40]. 
 
However, natural immunity is known to be imperfect, allowing for recurrent carriage episodes 
throughout life [42]. In young children in particular, immature immune systems tend to result in 
poor natural anti-capsular mediated immunity.  For a few serotypes, such as serotype 14, anti-
capsular immunity is known to provide good protection against re-acquisition (~90% for 
serotype 14), while for most other serotypes the antibody-mediated anti-capsular immunity is 
at best weak, hovering around 50% or less protection against reacquisition [57-59]. 
 
1.3. Pneumococcal conjugate vaccines 
 
A pneumococcal polysaccharide vaccine covering 23 of at least 94 known S.pneumoniae 
serotypes (PPSV23) was licensed in 1983, and is still currently used particularly in the elderly 
and adult risk groups to prevent against invasive disease [60].  However, the protection 
conferred by polysaccharide vaccines in children is limited, due to poor immune responses to 
the polysaccharide antigens [61].  Conjugation of the capsular polysaccharide to a carrier 
protein enables the activation of T-cell mediated responses in children, and immunological 
memory. In addition, unlike PPSV23, pneumococcal conjugate vaccines provide mucosal 
immunity, also acting upon nasopharyngeal carriage acquisition, and thereby providing an 
indirect effect in addition to a direct community effect [62]. 
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In contrast to natural immunity, vaccine-induced immunity through conjugate vaccines is 
reasonably good, with efficacies against carriage acquisition ranging by serotypes from about 
40% to 80% [63], while the efficacy against invasive disease is higher, at about 90% overall [64]. 
 
In PCVs, the conjugation of capsule polysaccharides with protein carriers activates a T-cell help 
mechanism, which results in the generation of serotype-specific antibodies and B cell memory 
that much high protection against carriage acquisition than natural immunity [65, 66].  
 
Nevertheless, although more immunogenic than natural immunity, PCV vaccination nonetheless 
requires multiple doses, particularly when given at a young age, and a booster dose >12 
months of age to increase both the level and duration of protection [63]. Conjugate vaccines 
are also complex and costly to manufacture, given the different antigenic properties of each 
serotype. In addition, despite their success, problems of serotype replacement [67, 68], have 
brought researchers to explore alternative options to existing conjugate vaccines. 
 
New vaccines in development target other immune mechanisms. These include targeting 
conserved surface protein antigens common to most (or all) pneumococci that are clinically 
relevant, in a serotype-independent way to provide broad cross serotype protection. A new 
range of vaccines are under development to target various proteins including pneumolysin, 
pneumococcal surface protein A (PspA) and protein C (PspC), pneumococcal surface antigen A 
(PsaA), neuraminidase enzymes, among others, most often as multi-component protein-based 
vaccine formulations [69-72]. 
The antibody-independent CD4+ T cell immune mechanism is also a target for vaccines in 
development, with the acapsular whole cell vaccine having now advanced through several 
stages of clinical trials [73].   
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A sevent-valent pneumococcal conjugate vaccine (PCV7) was first introduced into the US 
childhood immunisation programme in 2000, and subsequently into the vaccination 
programmes of many other high-income countries. The introduction of PCV7 in low-income 
countries was limited by affordability issues (PCV are among the most expensive vaccines to 
manufacture) as well as a lower coverage by the vaccine of serotypes most commonly found in 
invasive disease in those countries [74].  For example, while in North America before PCV 
introduction more than 80% of all cases of IPD in children younger than five years were due to 
one of the seven serotypes included in PCV7 (4, 6B, 9V, 14, 18C, 19F, 23F), those serotypes only 
accounted for about 50% of IPD isolates in Africa and Asia [74]. 
 
Higher valency vaccines covering 10 serotypes (PCV10, Synflorix, manufactured by 
GlaxoSmithKline), and 13 serotypes (PCV13, Prevnar13, manufactured by Pfizer) have now 
replaced PCV7 in the routine vaccination schedule of most high-income settings. The expanded 
valency offers a better coverage of the main disease causative strains in developing countries, 
and both PCV10 and PCV13 have therefore steadily been introduced over the last few years in 
the routine immunisation programmes of low and lower-middle income countries, with support 
from Gavi, the Vaccine Alliance, through the pneumococcal Advance Market Commitment 
(AMC) [75, 76].  The three additional serotypes included in PCV10 (1, 5, 7F) are not very 
common in carriage, but can cause severe disease (particularly serotypes 1 and 5) with 
epidemic potential. PCV13 includes all PCV10 serotypes, in addition to serotypes 3, 6A and 19A, 
which are found commonly in both carriage and disease [9, 74, 77].   
 
Pneumococcal conjugate vaccines prevent disease through two synergistic mechanisms; first, by 
providing some degree of protection against nasopharyngeal carriage acquisition of serotypes 
covered by the vaccine [63], and second, by preventing against further progression to disease, 
as a result of carriage [64], through serotype-specific antibody mediated immunity. 
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Through their effect on carriage, PCVs reduce the infection pool of targeted serotypes, thereby 
limiting the transmission of such serotypes in both vaccinated and unvaccinated individuals 
across age groups [78-81].  Such ‘herd effect’ has been observed in most  high-income settings 
following PCV7 introduction [82, 83], and similar dynamics have been observed in developing 
countries, such as Kenya following PCV10 introduction [84], the Gambia following PCV7 and 
then PCV13 introduction [85].  Further evidence should be available from low-income settings 
in the coming years, given that at least 15 Gavi countries are currently conducting observational 
studies of PCV impact and effectiveness on disease and carriage endpoints [86]. 
 
One of the challenges posed by conjugate vaccines is that their impact on the transmission of 
the selected number of serotypes included in the vaccine formulation  results in a (often 
proportional) increase in serotypes not covered by the vaccine, which fill the ecological niche 
vacated by vaccine-type (VT) serotypes [87-90]. Such ‘serotype replacement’ was first suggested 
by Lipsitch [90] in a simple illustrative mathematical model of colonising bacteria, where the 
potential replacement effects after vaccination were shown through the interplay of dyads of 
strains competing ‘for space’ and maintaining an equilibrium before vaccination;  and where a 
rupture of this equilibrium through vaccination results in a lack of competition, and 
consequently an increased transmission of strains not targeted by the vaccine (i.e. 
‘replacement’). Replacement effects in nasopharyngeal carriage has been seen in most – if not 
all – settings following PCV introduction, for all types of commercially available pneumococcal 
conjugate vaccines, and in different types of epidemiological settings [68].  
While serotype replacement has therefore tempered the impact of PCVs,  the introduction of 
such vaccines in routine immunisation programmes  has nevertheless resulted in a substantial 
reduction in the burden of pneumococcal disease, in both high and low income settings, due to 
the lower pathogenicity of replacing serotypes [83, 88, 89, 91-94]. 
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However, despite consistent evidence from intervention studies and observational studies that 
the vaccine reduces severe disease, the magnitude of the effect varies across settings. For 
example, in a study evaluating the impact of PCV on IPD across 19 different surveillance sites 
from 13 different countries (including the USA, Canada, Australia, New Zealand, Great Britain, 
Czech Republic, Switzerland, Greece, Norway, Denmark, the Netherlands, Israel and Uruguay), 
the relative reduction in IPD incidence among <5 year olds of PCV7 introduction varied 
significantly between settings [95], some settings showing more than 50% decrease in the first 
year after PCV introduction whereas in other settings no change was yet observed; and relative 
reduction at 3 years varied from 24% to 83% reduction [95]. The routine introduction of the 
vaccine in high-income settings has also shown good evidence of herd protection against 
invasive disease, albeit of mixed magnitude [96].   While evidence of the impact on IPD in low-
income settings is limited by the availability of robust surveillance capacity, evidence from 
surveillance settings such as in The Gambia and Kenya has consistently shown important 
reductions in VT carriage, and herd effects, following PCV introduction, but as in other settings, 
the magnitude of impact varies [85, 97, 98]. 
  
Differences in impact estimates between settings likely result from a combination of factors, 
including variations in vaccination coverage, vaccination schedules and introduction strategies, 
social mixing patterns and demographic composition, and baseline serotype composition in 
carriage and disease before PCV introduction. The latter in particular is the main predictor and 
likely driver of the long term impact of PCV [68].  In the shorter term, before the population 
impact of PCV reaches its new ‘equilibrium’ and before replacement effects are complete, 
factors such as the transmission rates in the population, itself linked to the frequency and age 
structure of social contacts, in addition to service delivery components such as vaccination 
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coverage and PCV introduction strategies, are likely to be key determinants of the speed with 
which population effects will be established, and resulting disease prevented.  
 
1.4. Vaccination strategies, and problem statement 
 
Routine childhood pneumococcal vaccination worldwide is a priority for WHO, particularly in 
countries where under five mortality is greater than 50 per 1,000 live births, most of which are 
in sub-Saharan Africa [99]. WHO currently recommends introducing PCV with either a ‘2+1’ 
schedule, where two primary doses are administered in early infancy and a booster dose is 
given between the ages of 12 and 15 months, or with a ‘3+0’ schedule, where three primary 
doses are provided before six months of age [100].  Although evidence suggests that the 
immune response obtained after a booster dose is higher than that obtained after the third 
primary dose [101], the epidemiological and long term impact of one or another schedule 
remains unclear. Currently, WHO recommends that schedules should be adapted to the 
setting’s local epidemiological characteristics; a 3-dose primary schedule tends to be favoured 
over a 2-dose with a booster in countries where the burden of pneumococcal disease in infancy 
is particularly high and hence optimal protection in the first year is prioritised [100], with a first 
dose that can be administered as early as 6 weeks of age.  As of December 2015,  54 countries 
had introduced PCV routinely, with four other introductions planned for 2016, including in 
Kyrgyzstan, Myanmar, Mongolia and Haiti [102]. 
 
Catch-up campaigns among older children at the introduction of PCV into childhood 
immunisation programmes can accelerate the impact of PCV, however there is no official 
recommendation from WHO about how to best implement those [100]. The benefits of catch-
up campaigns include a more rapid establishment of direct vaccine effects on carriage and 
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disease on targeted cohorts, but also potentially a faster way for indirect population (i.e. ‘herd’) 
effects of the vaccine to settle in, due to a larger age cohort of vaccinated children having social 
contacts with unvaccinated individuals in the community [103].  While it is obvious that 
targeting more age groups through campaigns will lead to a more rapid population effect of 
the vaccine, potential additional health gains need to be balanced against health service, 
resource, and financial constraints.  As of October 2016, at least 54 countries had introduced 
PCV with Gavi’s support, and with the exception of a few surveillance and research settings 
(such as in Kilifi, Kenya [104], or the Basse region in The Gambia [85]), no nationwide catch-up 
campaigns at vaccine introduction have been conducted in countries supported by Gavi, due to 
resource and supply constraints [102].   In addition, decisions about catch-up strategies may 
have been delayed by the limited evidence on the cost benefit of campaigns in such settings, as 
well as supply constraints, the potential disruptive effect of campaigns on routine services, and 
remaining questions on how to best optimise campaigns, and maximise their impact on disease 
with the resources and vaccine supplies available.   
Although post-PCV surveillance data exist for countries that have introduced PCV with a catch-
up campaign, such as the UK [105] or Uruguay [106], there is no population-based study 
providing direct comparison of the differential impact of various strategies.  Such comparisons 
could be undertaken through large intervention studies in settings that have not yet introduced 
the vaccine, but require time, resources and sophisticated epidemiological design.  In the 
absence of evidence from intervention studies, modelling approaches can be used to explore 
potential impact of different vaccination options, and guide related policy questions. 
 
This thesis was driven by two initial key and interlinked questions related to the pneumococcal 
catch-up strategies at the introduction of PCV in a Gavi-eligible country, which were 
approached through a dynamic model of pneumococcal transmission. The questions were as 
follows: 
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1) First, compared to a routine introduction of the vaccine, what is the likely impact on 
carriage and disease of catch-up strategies targeting infants only (<1 year), young 
children (<2 years) or all children <5 years? 
 
2) Second, given supply constraints, could a delayed introduction of PCV to allow for a 
catch-up campaign have any benefit over a timelier introduction of PCV in a routine-
only vaccination strategy? 
 
These questions are particularly timely in the current policy context. Last year, with the 
exception of Nigeria, vaccine supplies have increased to now meet demand in all other Gavi 
countries, easing off some of the supply constraints and enabling Gavi and eligible countries to 
consider PCV introduction plans that would include catch-up campaigns without compromising 
the introduction to other settings or existing programmes [102].  Research to establish the best 
use of vaccines in high burden settings is also high on WHO’s agenda [107].   
 
While modelling approaches may provide further insight into the potential short, medium and 
long term impact of vaccination options, models crucially depend on the robustness and 
validity of assumptions made about how pathogens are transmitted between humans, what 
contact events are important for transmission, and the structure of effective interpersonal 
encounters in the population [108-110], and, in the context of pneumococcal dynamics, what 
the characteristics are of carriage and serotype distribution across population age groups 
before the vaccine is introduced.    Other central questions in the exploration of alternative 
pneumococcal strategies through modelling include how well the vaccine protects against 
carriage and disease, for primary, booster or catch-up doses, and how long the vaccine would 
protect for.   Although carriage is a key determinant of the impact of the vaccine in a defined 
population, the majority of PCV trials have overlooked the impact of the vaccine on 
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colonisation, or have considered the impact on carriage on small study samples and over a 
short period of time, particularly given that the impact  of PCV on nasopharyngeal carriage was 
not considered in the licensure process [111].  
 
Hence, a number of questions around the consolidation of our knowledge about PCV efficacy 
on carriage acquisition, dynamics of carriage in the community, and how pneumococci are 
transmitted in the community underpinned the work of this thesis, also feeding directly into the 
structure and parameterisation of the transmission model. 
 
1.5. Dynamic transmission models of Streptococcus pneumoniae  
Dynamic mathematical models of infectious disease transmission are increasingly used to better 
understand underlying mechanisms and factors contributing to transmission, predict disease 
trends, and disease control options and strategies, including vaccination [108]. 
 
Transmission models are, by definition, a simplification of a complex interplay between 
ecological and human population processes.  The structure of a model and its degree of 
sophistication will depend, in part, on the questions to address.   
 
Lipsitch designed one of the first transmission model for colonising bacteria such as 
Streptococcus pneumoniae [90], drawing on the experience from previous models of between-
strain interaction [112] and superinfection [113, 114]. Lipsitch’s compartmental model, initially 
for two colonising (and mutually competing) serotypes and later extended to multiple 
serotypes, was designed to explore the potential impact of between-serotype competition on 
serotype replacement when introducing serotype-specific vaccines.  In this model, individuals 
were assumed to be in one of four compartments of carriage state namely (i) susceptible to 
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colonisation by any strain, (ii) colonised by one strain, (iii) colonised by another strain, or (iv) co-
colonised; and reverting back to a susceptible state after carriage assuming no natural 
immunity (i.e. a ‘Susceptible – Infected – Susceptible’ (SIS) model). The model was designed 
more as an illustrative piece of work, exploring the potential impact on carriage and disease 
dynamics of introducing serotype-specific vaccines under different assumptions about 
between-serotype competition, vaccine efficacy and vaccine types.  While the model has 
inherent limitations and simplifications, it laid out the basis for dynamic models based on a 
similar ‘diamond-shaped’ structure, which are discussed hereafter.    
 
In line with Lipsitch’s model structure, Choi et al. [115] and Melegaro et al. [116] designed 
deterministic compartmental models to predict the long term impact on carriage and disease of 
introducing PCV7 [115, 116] as well as the differential impact on IPD of switching to PCV13 after 
several years of PCV7 use [117].  Melegaro et al. [116] first developed an age-specific 
deterministic SIS model of carriage acquisition and clearance, allowing for co-infection. In 
Melegaro’s model serotypes are not modelled individually but are pooled instead, with the 
group of vaccine type (VT) serotypes modelled jointly and separately from the group of non-
vaccine type (NVT) serotypes, although the model allows for co-colonisation with one VT and 
one NVT serotype.  Vaccination is introduced in the model as a factor reducing the force of 
infection of VT serotypes among vaccinated individuals, thereby creating two levels of vaccine-
induced protection (vaccinated or not) for each of the four model compartments (susceptible, 
VT colonisation, NVT colonisation and VT-NVT dual colonisation).  The model was fitted to 
carriage and disease data and long term IPD trends were predicted based on estimations of 
vaccine efficacy, competition between VT and NVT serotypes, and assumptions about duration 
of carriage, vaccination coverage and the stability of the pathogenicity of the group of VT and 
NVT serotypes over time. The model was later expanded to better account for the dose-specific 
efficacy of PCV, with weaker and shorter-lived vaccine-immune protection conferred by two 
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primary infant doses and stronger and longer protection acquired after the booster dose [115].  
Choi et al. [117] also further expanded the model to specifically explore the impact of replacing 
PCV7 by PCV13 in the UK’s routine immunization programme, and therefore included the 
group of the six PCV13 serotypes not included in PCV7 as a third group of serotypes in the 
model structure.  A similar model structure was used by De Cao et al. [118] in a model applied 
to the Netherlands, to predict the long-term impact of PCV13 on carriage and disease.   
 
 In all models where serotypes are grouped, replacement effects result from competition 
parameters between such groups (i.e. a reduction in the likelihood of acquisition in the 
presence of carriage with another serotype in the group), which in the models described above 
is dichotomised between carriers of serotypes that are either vaccine serotypes or serotypes not 
targeted by the vaccine.  Although competition between groups of serotypes rather than single 
strain competition moved these models away from more realistic biological processes (i.e. 
different serotypes compete between themselves regardless of their inclusion or not in the 
vaccine), such deterministic models have performed well at capturing the overall population-
wide pneumococcal dynamics post vaccine introduction and as such, are useful in helping plan 
and optimise vaccine introduction strategies. While individually modelling each of the nearly 
100 serotypes may not be particularly useful, given the very low prevalence of some and lack of 
complete data in most cases, dividing groups of serotypes into smaller distinct groups of 
serotypes – for example by pathogenicity of prevalence – may more closely represent the 
transmission dynamics, although the optimal number of subgroups remains unknown. 
In a model applied to the Gambia, Bottomley et al. [119] categorised serotypes into six different 
classes, based on the serotype’s pre-PCV prevalence, with three classes for groups of NVT 
serotypes of different carriage prevalence (high, medium and low) and three groups of VT 
serotypes (of high, medium and low prevalence  In that model, serotype coexistence results 
from a proportion of colonised individuals gaining lifelong immunity.   Results from Bottomley 
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et al. predicted a rapid decline in the carriage prevalence of vaccine serotypes of low and 
medium pre-PCV prevalence, incomplete reductions at 10 years of the prevalence of VT 
serotypes of high prevalence before PCV introduction, and little overall change in carriage 
prevalence due to serotype replacement.   Nurhonen et al. [120] developed an individual 
contact network model, with serotypes divided into 11 classes, based on a combination of 
characteristics of invasiveness, carriage prevalence and inclusion or not in the vaccine 
formulation, and applied to a population with the demographic and epidemiological 
characteristics of Finland. Unlike the ‘diamond shaped’ models previously mentioned[115, 118], 
in Nurhonen’s microsimulation model replacement by NVT is not proportionally to their 
prevalence before PCV introduction, but rather to the fitness of non-vaccine serotypes. 
However, the scientific gain from such modelling approach remains to be evaluated. Results 
from Nurhonen et al. [120] were broadly in line with the findings from simpler deterministic 
models described earlier, and in concordance with epidemiological studies post PCV 
introduction, showing near-elimination of vaccine-type serotypes within 5 – 10 years after 
vaccine introduction, with a vaccination coverage of 90%, and assuming a vaccine efficacy 
against carriage acquisition of 50%.  
 
Other dynamic models have also been used to predict and understand post-vaccination trends, 
conduct economic evaluations and inform vaccination policy. Van Effelterre et al. [121] used a 
deterministic model to explore and compare the relative contribution of PCV7 and antibiotic 
pressure to the increase in serotype 19A IPD cases observed among <2y olds in the USA among 
following PCV7 implementation.  The model resembles those described earlier [115, 116], 
although it specifically includes antibiotic treatment with compartments of colonised and non-
colonised children with and without treatment. Wu et al. [122] applied a dynamic SIS 
transmission model to data from Taiwan to undertake an economic evaluation of the impact of 
introducing PCV13. Zhang et al. [123] used a dynamic deterministic model to help understand 
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the influence of temporary immunity and prevalence levels on competition. Here, unlike 
previous SIS models a compartment of temporary resistance to carriage acquisition (R) was 
added (SIRS model) to better understand the influence of temporary immunity to colonisation 
on prevalence levels and ecological competition between serotypes. 
 
Models applied to communities in the USA and in Sweden have also been used to explore the 
relative contribution of different social factors on the transmission of S.pneumoniae, including 
household size, day care attendance and class size [124, 125].  
 
In the context of PCV vaccination policy, models such as those described earlier can be used to 
add to the evidence from trials and observational studies, and allow one to address questions 
that may be difficult to address through other epidemiological approaches for reasons such as 
a lack of follow-up time, difficulties of comparing the population impact of many different 
introduction strategies in observational trials due epidemiological, logistical and programmatic 
challenges, or where intervention studies may be unethical, such as exploring the impact of PCV 
catch-up campaigns in a context of low vaccine uptake. In addition, models provide a tool to 
explore the longer-term impact of interventions, and help policy-makers appraise the different 
policy options based on medium- or long-term impact estimates, also feeding into economic 
evaluations.  
However, the inherent (and purposely) simplification of complex transmission dynamics and the 
departure – to some extent – from pathogen dynamics by pooling all serotypes into defined 
groups, make the abovementioned models less suitable to understand underlying biological 
and immunological mechanisms explaining the observed epidemiological patterns.  
 
Markov transition models were applied to longitudinal carriage data from Finland [126], 
Denmark [2],  Kenya [127] and the UK [128], to estimate clearance and competition parameters 
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between serotypes in a steady-state situation, and transition models were used to model 
acquisition rates for multiple colonisation among families in Bangladesh [126].   
 
More complex individual-based models such as those developed by Cobey and Lipsitch [42] as 
well as by Flasche et al. [129] have been developed to explore underlying mechanisms to the 
ecological and epidemiological patterns of S.pneumoniae carriage. Such theoretical and mostly 
data-free modelling approaches shed light on the joint contribution of serotype-specific and 
nonspecific immunity on serotype competition and coexistence, and their implications for the 
impact of pneumococcal vaccines. Both models here assume some level of serotype-specific 
and nonspecific immunity following colonisation. Although assumptions made about level and 
duration of immunity differed between studies, both studies reached similar conclusions about 
the key contribution of immunological factors to epidemiological patterns, including serotype 
coexistence, prevalence of carriage and the emergence of epidemic strains, and their 
implication for vaccine development and policy.  Interestingly, a theoretic finding from Flasche 
et al.’s work [129] is the synergistic effect of competition and selective vaccination in 
eliminating targeted serotypes when such vaccines would otherwise fail to reach the herd 
immunity threshold. Cobey and Lipsitch’s model [42] showed that reductions in nonspecific 
immunity as a result of carriage reduction following vaccination could lead to the re-emergence 
of previously eliminated serotypes. Compared to the deterministic models mentioned earlier 
[115-117, 121-123, 130], the advantage of individual-based serotype-specific models is to 
better explore the biological mechanisms of acquisition and transmission, and to appraise the 
contribution of several underlying factors to the epidemiological and ecological patterns of 
Streptococcus pneumoniae.  
 
In the context of the roll out of PCV in many developing countries, carefully designed 
mathematical models could offer new insights into the impact of the vaccine on carriage and 
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disease across all age groups and in particular explore the differential impact on transmission, 
morbidity and mortality of various vaccination scenarios, including catch-up campaigns. As 
such, models therefore add onto the evidence from existing or planned observational or 
interventional studies, or offer an alternative to such studies when design, financial, logistical 
and ethical challenges may limit their implementation.  
1.6. Aims and objectives 
1.6.1. Main aim 
 
The main aim of this thesis is to study pre-vaccination transmission dynamics of Streptococcus 
pneumoniae in a Gavi-support eligible setting, predict the likely impact on carriage and disease 
of routine vaccination, and explore the differential impact of catch-up campaigns at PCV 
introduction on carriage and invasive pneumococcal disease dynamics across age groups. 
 
1.6.2. Specific objectives, and structure of the thesis 
For this to be achieved, the thesis is articulated around the following main objectives: 
 
1. To undertake a systematic review and meta-analysis of the prevalence and serotype 
distribution of S.pneumoniae in carriage, for groups of vaccine types and non-vaccine 
serotypes,  such as to predict the prevalence in older age groups as a function of that in 
children under five years of age, and parameterise the model for Nha Trang (Vietnam) 
accordingly. 
 
2. To estimate the vaccine efficacy against carriage acquisition, and the duration of 
protection against carriage, through a meta-regression model of available trial data, in 
order to parameterise the model applied to the population of Nha Trang. 
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3. To undertake a study of social mixing patterns and of S.pneumoniae carriage in South 
West Uganda, in order to determine whether particular contacts and transmission 
patterns are associated with S.pneumoniae acquisition. 
 
4. To use the evidence generated in the first three specific objectives to develop and 
parameterise a dynamic transmission model of S.pneumoniae, and explore two specific 
questions, namely, (i) what is the differential impact on carriage and disease of 
introducing PCV with and without catch-up campaigns targeting three different age 
groups (<1 years, <2 years, <5years) and (ii) under resource constraints, how would 
introduction delays with a catch-up campaign impact on carriage and disease 
compared  to a more timely introduction of PCV routinely, without such campaign. 
 
1.7. Structure of the thesis 
The abovementioned objectives were addressed through specific independent research 
projects, with different collaborators and study groups, and were conducted in the order 
described above.  
 
The results have been published (or submitted) in five different manuscripts, which form the 
five main results chapters of this thesis. The third objective was divided into two separate 
chapters; one about the details of social mixing patterns in this setting, and the other one 
exploring the type of social contacts associated with pneumococcal carriage.   
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In addition to the published papers, some sections have been expanded with appendices to 
expand on aspects from the methods or results which could not be addressed in details in each 
publication. 
 
The differential impact of catch-up campaigns was studied through a model applied to the 
population of Nha Trang in Vietnam. Few Asian countries have introduced PCV; in 2012 
Pakistan was the first Asian country to routinely vaccinate infants with PCV, followed by Nepal, 
Cambodia and Lao PDR [102]. Vietnam is one of seven countries that has not yet applied for 
Gavi’s support through AMC due to a mix of sustainability concerns and prioritisation of 
rotavirus vaccine but is eligible to do so [102].  Work in Vietnam has therefore direct relevance 
for local vaccine policy, and could inform introduction strategies both in Vietnam, and in other 
neighbouring countries with similar epidemiology and transmission dynamics.  Absence of 
colonisation data in adults and elderly, and the lack of post-vaccination data for this setting 
motivated the first two chapters of the thesis, namely (i) to better understand (and predict) the 
prevalence of carriage and serotype distribution in older age groups based on carriage 
estimates in children under five years of age and (ii) obtain robust estimates of the efficacy and 
duration of protection of PCV against nasopharyngeal carriage acquisition.  
 
Objective 3 was addressed through a field survey in Uganda, which included a nasopharyngeal 
carriage survey, and a study of social contacts among a subsample of the same study 
participants. The combination of carriage data and social contact data made it possible to  
explore in finer details how individual social behaviour shapes individual-level risk of 
S.pneumoniae, and thereby what social contacts are important to include in pneumococcal 
transmission models.  
Additional work on pneumococcal dynamics and vaccine optimisation will follow from the study 
in Uganda, but is beyond the scope of this thesis (see Chapter 7). 
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Abstract  
Introduction 
Data on the prevalence of nasopharyngeal carriage of S.pneumoniae in all age groups are 
important to help predict the impact of introducing pneumococcal conjugate vaccines (PCV) 
into routine infant immunization, given the important indirect effect of the vaccine. Yet most 
carriage studies are limited to children under five years of age. We here explore the association 
between carriage prevalence and serotype distribution in children aged ≥5 years and in adults 
compared to children.  
Methods 
We conducted a systematic review of studies providing carriage estimates across age groups in 
healthy populations not previously exposed to PCV, using MEDLINE and Embase. We used 
Bayesian linear meta-regression models to predict the overall carriage prevalence as well as the 
prevalence and distribution of vaccine and nonvaccine type (VT and NVT) serotypes in older 
age groups as a function of that in <5y olds. 
Results 
Twenty-nine studies compromising of 20,391 individuals were included in the analysis. In all 
studies nasopharyngeal carriage decreased with increasing age. We found a strong positive 
linear association between the carriage prevalence in pre-school childen (<5y)  and both that in 
school aged children (5 – 17y olds) and in adults. The proportion of VT serotypes isolated from 
carriers was consistently lower in older age groups and on average about 73% that of children 
<5y among 5-17y olds and adults respectively. We provide a prediction model to infer the 
carriage prevalence and serotype distribution in 5-17y olds and adults as a function of that in 
children <5 years of age. 
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Conclusion 
Such predictions are helpful for assessing the potential population-wide effects of vaccination 
programmes, e.g. via transmission models, and thus assist in the design of future pneumococcal 
conjugate vaccination strategies. 
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2.1. Introduction 
Colonization of the nasopharynx by Streptococcus pneumoniae is the reservoir for 
S.pneumoniae transmission and a prerequisite for pneumococcal disease [1]. Pneumococcal 
conjugate vaccines (PCV) reduce nasopharyngeal carriage of serotypes included in the vaccine 
by conferring capsular-specific immunity. Experience from countries where conjugate vaccines 
have been introduced has shown rapid and sustained carriage reduction of vaccine serotypes 
(VT) following vaccination. Those trends have been observed not only among vaccinated 
children but more widely across all age groups through a strong herd immunity effect [2,3]. 
Despite evidence of almost complete serotype replacement in many settings, whereby non-
vaccine serotypes (NVT) colonise the space left vacant by vaccine type (VT) serotypes [4], 
pneumococcal conjugate vaccination programmes have led to a substantial reduction in severe 
disease due to the lower propensity of replacing serotypes to cause disease [4,5]. 
Ten- and thirteen-valent pneumococcal conjugate vaccines (PCV10 and PCV13) are now being 
introduced into the routine immunization programmes of many developing countries 
(www.jhsph.edu/ivac/vims.html), where their impact is expected to be high, given the 
disproportionate burden of pneumococcal disease in such settings [6]. 
Estimates of the potential impact of routinely introducing pneumococcal conjugate vaccines 
(PCVs), however, crucially depend on the nasopharyngeal carriage prevalence in the population 
before the introduction of PCV, the distribution of serotypes (VT and NVT) within the 
population, including among older children, adults and the elderly, and the propensity of 
replacing serotypes to cause disease across age groups.  
Most carriage surveys are limited to children under five years of age, in whom the disease 
burden is high and for whom sample size requirements for precision are reasonable given the 
high carriage prevalence. As a result, nasopharyngeal carriage estimates in other age groups 
are scarce. However, such estimates are important to help predict the overall population impact 
of vaccination programmes as well as the specific impact among unvaccinated age groups. 
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Routine infant PCV vaccination has been found to also impact substantially on the elderly in 
whom the likelihood to develop severe pneumococcal disease as a result of carriage is high 
[7,8]  and who present the highest overall burden of pneumococcal associated disease in 
developed countries [9]. Hence this age group has also played an important role in the cost 
effectiveness considerations of pneumococcal conjugate vaccination [10,11].  With the 
proportion of population of >60 years old growing at its fastest pace ever [12], the indirect 
effect of PCV vaccination programmes may become increasingly important, including in 
developing countries.   
The overall aim of this study was to explore a possible correlation between the prevalence and 
distribution of S.pneumoniae serotypes carried in the nasopharynx of children <5y and that in 
older children (5-17y olds) and adults (≥18y olds), based on nasopharyngeal carriage surveys, 
and further establish predictors for carriage prevalence and serotype distribution in adults and 
older children as a function of the carriage prevalence and serotype distribution in the 
nasopharynx of children under five years of age.   
 
2.2. Methods 
 
2.2.1. Search strategy 
We conducted a systematic review to identify articles reporting nasopharyngeal carriage 
prevalence estimates for different age strata. We used MEDLINE and Embase electronic 
databases to retrieve articles published between the date of the earliest articles compiled on 
MEDLINE (1946) or Embase (1947) and 23
rd
 August 2013 (i.e. week 35), and used the following 
combination of search terms: ‘(pneumonia OR pneumoniae OR pneumococcal OR 
pneumococcus) AND (carriage OR colonization OR colonisation)’ in the title or the keywords or 
the abstract. No language restriction was applied.  
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There is no registered protocol for this systematic review. 
Our systematic review and meta-analysis was conducted in accordance with the PRISMA 
checklist (http://www.prisma-statement.org/statement.htm, see Supporting Information) and 
MOOSE guidelines [13], which compile guidelines for the reporting of meta-analysis of 
observational studies.  
 
2.2.2. Eligibility criteria 
We included studies based on seven main eligibility criteria. 
Articles were considered for inclusion if they provided (i) pneumococcal nasopharyngeal 
carriage prevalence estimates (ii) in a population not previously exposed to PCV, with (iii) 
nasopharyngeal sampling and transport procedures as well as S.pneumoniae culture based on 
WHO guidelines [14], (iv) where the study was not restricted  to specific serotypes or to 
S.pneumoniae with specific patterns of antibiotic sensitivity.  Studies were further considered 
for inclusion if they provided carriage estimates in young children, as well as in older age 
groups and (vi) in individuals not suffering from any acute respiratory infection or any 
confirmed pneumococcal disease, and (vii) were not based on particular at risk population 
groups such as HIV positive individuals. 
No design restriction was applied. 
 
2.2.3. Data extraction 
The articles were screened and reviewed with inclusion criteria appraised in the order described 
above. When primary data published in a study were also used in subsequent studies, we 
screened the latter too to find any data that may not have been published in the original paper. 
For each study meeting the aforementioned inclusion criteria we calculated the prevalence of 
nasopharyngeal carriage by age group, as well as the prevalence of VT and NVT by age group 
when provided, for PCV7 and/or PCV10 and/or PCV13, depending on available data. In most 
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studies the group of NVT comprised of NVT serotypes as well as non-typeable (NT) serotypes, 
while in a few studies estimates for NT by age group were provided separately and were 
therefore not included in the group of NVT serotypes. 
In some studies, estimates were provided by age or for smaller age bands, and such estimates 
were therefore pooled to obtain estimates for the main four age groups considered. 
In longitudinal studies where multiple nasopharyngeal swabs were taken for each individual, the 
number of individuals tested positive was approximated by the age-specific average number of 
positive swabs over the study period.  
In a few studies the actual number of carriers had to be estimated based on reported 
prevalence estimates and the number of study participants in each age group.  
More details on how the data were extracted from the different studies can be found in the 
Supporting Information. 
 
2.2.4. Analysis 
We considered the following age groups: <1y (infants); <5y (pre-school children including 
infants); 5-17y (school aged children) and ≥18y (adults). Because age groups were not 
standardised between studies, the category of <5y olds included studies reporting estimates in 
<4y olds as well as studies reporting estimates in <6y olds. The category of school-aged 
children included any age group from between 4 to 6 years up to any age between 10 years 
and 19 years, and we considered the prevalence among adults to be that in individuals aged at 
least 15 years and above. 
We explored the association between the carriage prevalence and VT or NVT distribution in 
older age groups and that in young children using Bayesian linear meta-regression analysis. The 
use of Bayesian over a frequentist approach was motivated by the natural way in which each 
study’s contribution to the meta-regression is weighted in a Bayesian approach, and also 
because Bayesian linear regression is the recommended tool by the Cochrane Collaboration to 
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account for uncertainty around both  the outcome and the exposure variables in a meta-
regression [15]. 
2.2.5. Age-dependent overall carriage prevalence and carriage prediction 
We obtained prediction intervals for the carriage prevalence in adults and in 5-17y olds as a 
function of that in either <5y olds or <1y olds using a Bayesian linear meta- regression model. 
For the  studies included in each analysis,  
 
 
, with    = prevalence in either adults or 5-17y olds in study i ,  =prevalence in either <5y 
olds or <1y olds in study i  and = random error in study   ~ N(0,  2) 
The true prevalence  and  are unknown, however  the observed number of carriers in each 
study (  and ) follows a binomial distribution. Hence, based on these and on the sample 
sizes (  and ) it follows that   ~ Binomial( , )  and ~ Binomial( , ) 
We provided prior distributions for the parameters of interest ,  and  and assigned 
uniform uninformative priors to  (unif (-1,1)) and  (unif (-5,5)) and to 
 
(unif (0,0.4)). 
The posterior distributions were obtained through a Markov Chain Monte Carlo (MCMC) Gibbs 
sampling algorithm, with 100,000 iterations of 2 chains running in parallel, after a burn-in of 
5,000 iterations. We retained one in five iterations in the posterior sample to limit 
autocorrelation. Convergence of the chains was examined visually. We obtained the 95% 
posterior credible intervals (CrI) for the model regression line as well as the posterior credible 
intervals for the prediction of individual studies by including the prediction error (which we will 
refer to as the “prediction interval” in the results section).  
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 We further explored the possible association of socio-demographic and geographic 
characteristics of the populations studied through Bayesian multivariable meta-regression. The 
explanatory variables considered for meta-regression included the proportion of children <5y 
of age and the % <15y of age in the country or area in which the study took place based on 
figures obtained from UN Population data (http://esa.un.org/wpp/),  categories of national 
income level in the country or area in which the study took place, based on estimates from the 
World Bank (http://data.worldbank.org/), and broad geographical areas or continents in which 
studies took place. Variables were added one after another in the model and were retained if 
the 95% posterior probability interval for their coefficient excluded 0. 
 
2.2.6. Age-dependent distribution of VT serotypes 
We then explored (i) the distribution of the group of VT serotypes among carried serotypes in 
children <5y and in older age groups, and the association between such distributions, as well as 
(ii) the relationship between the prevalence of VT carriage and NVT carriage in adults and in 5-
17y olds compared to children <5 years of age 
For each study providing serotype-specific information we calculated (i) the proportion of VT 
serotypes (for PCV7 or PCV10 or PCV13) among carriers in children and older age group, and 
their 95% confidence interval (CI) and (ii) the carriage prevalence of such groups of serotypes, 
by age category and 95% CI.  
We further explored the relationship between (i) the proportion of VT carriers and (ii)  the VT 
and NVT carriage prevalence across age groups using Bayesian linear meta-regression. We 
used the same uniform priors for ,  and 
2 
than in the analysis of overall carriage 
prevalence, as well as the same analytical strategy to obtain posterior estimates. 
The code used for the Bayesian linear meta-regression can be found in the Supporting 
Information and is fully annotated.  In addition, the code also provides an opportunity for 
 60 
 
readers to obtain posterior distributions of the carriage prevalence in 5-17y olds and adults 
based on study-specific estimates of nasopharyngeal carriage in <5y olds, making it possible to 
use this as a carriage prediction tool based on specific data of carriage in <5y olds. 
Analyses were performed using R software and the JAGS package in R (http://mcmc-
jags.sourceforge.net/). 
 
2.3. Results 
 
A total of 8,886 citations were found, which amounted to 4,648 citations after duplicates were 
excluded. Of those, 376 original studies provided pre-PCV nasopharyngeal carriage estimates in 
healthy individuals. A flowchart of the number of studies screened and reasons for exclusion is 
displayed in Figure 1.  
A total of 29 studies were included in the meta-analysis, comprising a total of 20,391 
individuals, including 7931 children <5y, 3936 school aged children and 8524 adults. 
 
2.3.1. Age dependent prevalence of nasopharyngeal carriage 
Seven studies were conducted in Africa, 6 in Asia, 6 in the Middle-East, 5 in Europe, 2 in the 
North America (Alaska, USA) and 3 in South America. Table 1 displays the main characteristics 
of the studies included in the final analysis, as well as the estimates of carriage prevalence by 
age group.  
 
We found a strong positive correlation between carriage prevalence in younger age groups and 
that in older age groups. Figure 2 displays a scatter plot of the study specific estimates for the 
prevalence in adults and in 5-17y olds as a function of that in either <5y olds or <1y olds.  
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Figure 1: Flow chart of the study selection process. 
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The figure also displays the fitted regression line from the Bayesian linear meta-regression 
model, including the median posterior estimate, the 95% credible interval around the median, 
as well as the 95% prediction intervals for all four analyses. The model coefficients of all four 
models can be found in Table 2.  
 
We explored whether the results from the regression model were confounded by the socio-
demographic and geographic characteristics of the study population, but found no evidence 
that the proportion of children, the national income level or the geographic region of the 
included studies were associated with the outcome in any of the models considered.  
Figure 2: Overall carriage prevalence in older age groups against <5y olds: scatter plot and fitted 
model (<5y (left panels) and <1y (right panels) vs. 5 – 17 y olds (upper panels) and 
adlults (lower panels)) 
 
Legend: Each circle corresponds to one study, with the circle size proportional to the study size (i.e. number of 
individuals contributing to the x and y axis estimates). The lines correspond to the fitted Bayesian linear meta-
regression model. The dashed black line shows the median posterior estimate and the grey shaded area the 95% 
credible interval around the median. The red dotted lines represent the 95% prediction interval. 
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Table 1: Studies included in the Bayesian linear meta-regression of the overall carriage prevalence    
 
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H: Health care setting, C: Community setting 
1
Maela refugee camp at the Thailand-Myanmar border. 
2
Gaza strip. *Data from the study extracted from Darboe et al. [58]. ** Data were extracted from Flasche et al. [20]. RX: Random 
sample from a cross section survey; RH: random outpatient sample; SC: school cohort (i.e. all children or staff or a particular school/DCC/class); M: Mothers, F: Family members; BC: Birth cohort. Italicised are the samples where adults are 
parents or staff members looking after the young children included 
 
   
No carriers/total individuals (%), by age group 
 
Study population characteristics 
by age group 
Authors 
Country or 
region 
Setting <1y olds <5y olds 5-17y olds ≥18 years Age groups <1y <5y 
5-
17y 
≥18y 
Abdullahi et al. (2008) [17] Kenya C 58/98 (59%) 198/349 (57%) 55/213 (55%) 16/302 (5%) <1y;<5y; 5-19y; ≥20y RX RX RX RX 
Adetifa IM., et al.  (2012) [34] Nigeria C 143/193(74%) 375/524 (72%) 63/125(25%) 90/356 (25%) <1y;<5y; 5-14y; ≥15y  RX RX RX 
Bello Gonzales et al.  (2010) [35] Venezuela C 
 
58/84 (69%) 
 
7/64 (11%) <5y; ≥18y  RX  M 
Cekmez et al. (2009) [36] Turkey H 
 
0/125 (0%)* 25/375 (7%) 
 
<4y ; 4-12y  RH RH  
Chen et al. (2007) [37] Taiwan C 
 
25/94 (27%) 18/196 (9%) 0/137 (0%) 3-4y; 5-17y; ≥18y  SC SC HC 
Dagan et al. (2000) [38] Israel C 
 
59/84 (70%) 71/199 (35%) 27/174 (15%) <6y; 6-15y;≥16y  RX RX RX 
Darboe  MK., et al. (2007) [39]* Gambia C 143/196 (73%) 
  
26/196 (13%) <1y; ≥18y BC   M 
Dhakal et al. (2010) [40] India H 
 
18/79 (23%) 26/120 (22%) 
 
<4y ; 4-12y  RH RH  
Granat et al. (2007)  [41] Bangladesh C 49/99 (49%) 86/172 (50%) 45/117 (38%) 12/154 (12%) <1y;<5y;5-18y;≥19y BC F F F 
Greenberg et al. (2004) [42] Israel H 
 
147/216 (68%) 
 
33/216(15%) <5y; ≥18y  RH  M 
Hammitt et al. (2006) [3] Alaska (USA) C 
 
377/639 (59%) 
 
275/2115 (13%) <5y; ≥18y  RX  RX 
Henriqus Normark et al.(2003) [43] Sweden C 
 
246/611 (40%) 
 
2/123 (2%) 1-6y; 19-59y  SC  SC 
Hill PC., et al. (2006)[19] Gambia C 141/145(97%) 621/666 (93%) 621/735 (84%) 821/1471 (55%) <1y;<5y;5-14y; ≥15y RX RX RX RX 
Hussain et al. (2005) [18]** UK C 
 
87/180 (48%) 15/71 (21%) 18/237 (8%) <5y; 5-17y; ≥18y  RX RX RX 
Inostroza et al.(1998) [44] Chile C 
 
10/55 (18%) 5/16 (31%) 2/38 (5%) <5y; 5-15y; ≥18y  SC SC HC 
Kaltoft et al. (2008) [45] Denmark C 
 
340/584 (58%) 
 
23/109 (21%) 
mean 23m (n=123) and mean 52m 
(n=461); ≥18y 
 SC  
F& 
SC 
Leino et al. (2008) [46] Finland C 
 
15/59 (25%) 4/31 (13%) 4/123 (3%) mean 4y, 8y 35y  SC F 
F& 
SC 
Lloyd-Evans N., et al. (1996) [47] Gambia C 
 
323/414 (78%) 188/342 (55%) 18/67 (27%) <5y;5-18y; ≥19y  RX F F 
Lo  et al. (2003) [48] Taiwan H 
 
75/360 (21%) 20/118 (17%) 
 
<6y; 6-14y  RH RH  
Mueller et al. (2012) [49] Burkina Faso C 43/62 (69%) 81/128 (63%) 57/196 (29%) 28/195 (14%) <1y;<5y; 5-19y; ≥20y RX RX RX RX 
Nunes et al. (2013) [50] South Africa C 83/123 (69%) 
  
21/123 (17%) <16m; ≥18y BC   M 
Parry et al. (2000) [51] Vietnam C 
 
192/389 (49%) 212/522 (41%) 
 
<5y; 5-16y  RX RX  
Regev-Yochay et al. (2004) [16] Israel H 38/90 (42%) 214/404 (53%) 
 
52/1300 (4%) <1y;<7y;≥18y RH RH  RH 
Regev-Yochay et al. (2012) [52] 
Occup. Palest 
Terr.
2
 
C 43/90 (48%) 189/379 (50%) 
 
30/376 (8%) <1y;<5y; ≥18y RX RX  F 
Reichler et al. (1992) [53] USA C 16/25 (63%) 107/166 (64%) 10/53 (19%) 
 
<18m;<5.5y; 5-10y SC SC SC  
Reis JN. et al. (2008) [54] Brazil C 
 
33/50 (66%) 43/95 (45%) 19/117 (16%) <5y; 5-17y; ≥18y  RX RX RX 
Sener et al. (1998) [55] Turkey C 
 
71/248 (29%) 87/412 (21%) 
 
<6y;6-11y  SC SC  
Turner et al. (2012) [56] Thailand
1
 C 188/234 (80%) 
  
57/231 (25%) <2y; ≥18y BC   M 
van Gils E. et al (2009) [57] Netherlands C 214/319 (67%) 
  
67/300 (22%) 12m ; ≥18y BC   F 
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Specific estimates in older adults were provided in two studies included in the analysis, one in 
Israel with data in >65y olds [16] and another in Kenya with data in >50y olds [17]. Based on 
the reported data there was no evidence that the carriage prevalence among older adults 
differed substantially from that in younger adults (Israel: 3.7% in 18-65y vs. 4.6% in >65y, 
p=0.573 and Kenya:  5.6% in 20-49y olds vs. 4.6% in ≥50y olds, p=0.719). 
Table 2: Model coefficients for each of the Bayesian linear meta-regression models used 
Model Intercept (β0) 
median (95% CrI) 
Slope (β1) 
median (95% CrI) 
 median (95% CrI) median (95% CrI) 
Overall carriage prevalence  
Adults vs. <5y -0.18 (-0.31; -0.05) 0.57 (0.35;0.80) 
Adults vs. <1y -0.36 (-0.49; -0.15) 0.83 (0.52; 1.03) 
5-17y vs. <5y -0.00 (-0.10 ; 0.10) 0.68 (0.48 ; 0.86) 
5-17y vs. <1y -0.38 (-0.49 ; -0.09) 1.22 (0.79 ; 1.40) 
VT carriage prevalence 
Adults vs. <5y -0.06 (-0.17; 0.05) 0.34 (0.05; 0.62) 
5-17y  vs. <5y -0.10 (-0.41; 0.20) 0.73 (0.00; 1.43) 
NVT carriage prevalence  
Adults vs. <5y -0.10 (-0.30; 0.09) 0.76 (0.11; 1.46) 
5-17y  vs. <5y -0.04 (-0.21; 0.14) 1.27 (0.63; 1.89) 
VT proportion among carriers 
Adults vs. <5y -0.07 (-0.41; 0.33) 0.73 (0.06;1.32) 
5-17y  vs. <5y -0.03 (-0.41; 0.33) 0.73 (0.10; 1.37) 
 
 
2.3.2. Age-dependent prevalence of VT carriage and distribution of VT 
serotypes  
A total of eleven studies provided estimates of the distribution of VT and NVT serotypes in 
young children and in older children and/or adults. Estimates from a study in Israel [16] were 
based on outpatients, including a proportion of patients with upper respiratory tract infections 
(URTI), as serotype specific estimates could not be obtained for the healthy study participants 
only.  Data on the serotype distribution among participants of two studies [18,19] were 
extracted from subsequent manuscripts [20,21] as the information was unavailable in the 
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original articles. Two studies included in the analysis only provided estimates in <2y olds rather 
than <5y olds. However, as meta-regression coefficients, obtained with and without the 
inclusion of such studies, were similar we included both studies in the final analysis. 
Table 3 provides details of the studies included in the analysis. The proportion of VT serotypes 
isolated from positive swabs was consistently lower in older age groups compared to children 
under five, and that of NVT serotypes consistently higher. This finding was consistent across 
studies.  
Table 3: Studies included in the Bayesian meta-regression of VT and NVT distribution, with 
proportion of VT out of positive samples, by age group 
Studies Country/Area 
PCV 
valency 
Age VT/all (%VT) VT/all (%VT) VT/all (%VT) 
NT** in 
denom.  
    <5y olds 5-17y olds Adults  
Hill PC.,(2006)[19] data in 
[21] 
Gambia 
PCV7 + 
6A 
<5y 108/197 (55%) 226/617 (37%) 186/674 (28%) Yes 
Adetifa IM., et al.  (2012[34] Nigeria PCV7 <5y 173/375 (46%) 19/63(30%) 39/90 (43%) Yes 
Adetifa IM., et al.  (2012) 
[34] 
Nigeria PCV10 <5y 174/375 (46%) 19/63(30%) 41/90 (45%) Yes 
Adetifa IM., et al.  (2012) 
[34] 
Nigeria PCV13 <5y 264/375 (70%) 27/63(43%) 52/90 (58%) Yes 
Darboe et al (2012) [39]*, 
data in [58] 
Gambia PCV13 <1y 97/143 (68%) 
 
6/26 (23%) No 
Mueller et al. (2012) [49] Burkina Faso PCV13 <5y 45/80 (56%) 20/57 (35%) 9/28 (32%) No 
Turner et al. (2012) [56]* Thailand
1
 PCV13 <2y 105/188 (56%) 
 
16/57 (28%) No 
van Gils E. et al (2009) [57]* Netherlands PCV7 <2y 115/213 (54%) 
 
27/67 (40%) Yes 
Reis JN. et al. (2008)[54] Brazil PCV7 <5y 12/33 (36%) 12/43 (28%) 7/19 (37%) Yes 
Hammitt et al (2006) [3] USA (Alaska) PCV7 <5y 209/377 (55%) 
 
78/275 (28%) Yes 
Regev-Yochay (2012) [52] 
Occup. Palest 
Terr.
2
 
PCV7 <5y 65/189 (34%) 
 
6/30 (20%) Yes 
Regev-Yochay (2012) [52] 
Occup. Palest 
Terr. 
PCV10 <5y 69/189 (37%) 
 
6/30 (20%) Yes 
Regev-Yochay (2012) [52] 
Occup. Palest 
Terr. 
PCV13 <5y 93/189 (49%) 
 
9/30 (30%) Yes 
Regev-Yochay e(2004) [16]* Israel PCV7 <5y 87/200 (44%) 
 
8/29 (28%) No 
Hussain (2005) [18] data in 
[20] 
UK PCV7 <5y 57/87 (66%) 8/15 (53%) 9/18 (50%) No 
Hussain (2005) [18] data in 
[20] 
UK PCV13 <5y 72/87 (83%) 11/15 (73%) 10/18 (55%) No 
1
Maela refugee camp at the Thailand-Myanmar border. 
2
Gaza strip. *data marked with (*) are based on approximation. 
**Non-typeable serotypes included in denominator (yes/no). See the Supporting Information section for further details. 
 
We found a positive linear relationship between the proportion of VT serotypes isolated from 
carriers in children under five and that in 5-17y olds or in adults (Figure 3). The intercept was 
centred around zero in both models, and the slope of the coefficient was 0.73 (Credible 
intervals (CrI) 0.10 – 1.37) in 5-17y old and 0.73 (95%CrI 0.06; 1.32) in adult carriers compared to 
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the proportion of VT serotypes in children <5y. Further details on the model coefficients are 
provided in Table 2. 
Figure 3: VT proportion in carried serotypes among <5y and older ages: scatter plot and fitted 
model  
 
We then analysed the relationship between VT and NVT carriage prevalence in <5y olds and 5-
17y olds or adults. As for the overall carriage prevalence, there was good evidence of a linear 
trend, with the prevalence of both VT and NVT in older age groups increasing with increasing 
VT and NVT prevalence in <5s (Figures 4 and 5).  
 
However, given the shift in VT/NVT distribution in older age groups, the prevalence of VT 
serotypes in 5-17y olds and adults compared to that in children under five was comparatively 
lower than that of NVT serotypes (Table 3). 
 
We performed subgroup analyses for VT serotypes included in PCV7 and VT serotypes included 
in PCV13, and found no difference in the coefficient obtained. Hence for studies reporting 
estimates for both PCV7 and PCV13 we included in the final analysis estimates with VT 
serotypes included in the higher valency vaccine.  
 
 67 
 
 
Figure 4: VT and NVT prevalence in 5-17y olds against <5y olds: scatter plot and fitted model 
 
Legend for Figures 3 and 4: Each circle corresponds to one study, with the circle size proportional to the study size (i.e. 
number of individuals contributing to the x and y axis estimates). The lines correspond to the fitted Bayesian linear 
meta-regression model. The dashed black line shows the median posterior estimate and the grey shaded area the 95% 
credible interval around the median. The red dotted lines represent the 95% prediction interval. 
 
Figure 5: VT and NVT prevalence in adults against <5y olds: scatter plot and fitted model 
 
Each circle corresponds to one study, with the circle size proportional to the study size (i.e. number of individuals 
contributing to the x and y axis estimates). The lines correspond to the fitted Bayesian linear meta-regression model. 
The dashed black line shows the median posterior estimate and the grey shaded area the 95% credible interval around 
the median. The red dotted lines represent the 95% prediction interval 
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2.4. Discussion 
 
In this systematic review and meta-analysis the prevalence of Streptococcus pneumoniae 
carriage in the nasopharynx of children aged under five was strongly correlated with the 
prevalence of nasopharyngeal carriage in older age groups. Furthermore, we found that the 
proportion of carriage attributed to vaccine serotypes was consistently decreasing with age. 
Our study provides a tool to help make informed predictions, however with some uncertainty, 
on the carriage prevalence and serotype distribution in older children and adults solely based 
on data in children <5y of age, which are more widely available. 
The results of this study showed that despite the important geographic heterogeneity in 
carriage prevalence, there is a stable linear relationship between the carriage prevalence in 
young children and that in older children and adults.  Such relationship also held for VT and 
NVT separately, although with different magnitude given the shift in serotype distribution in 
older age groups, with proportionally more NVT and less VT carriers. While a proportional 
decrease of carriage prevalence by age, as described by a linear correlation with an intercept 
centred around zero, did not describe the data well in most instances, the addition of a flexible 
intercept allowed for a good description of the age-dependent carriage association. 
 
Although the decrease in carriage prevalence through childhood is a well-established fact, the 
between age group correlation in prevalence estimates has – to the best of our knowledge – 
not been previously described. These results are important to help improve our understanding 
of carriage and disease dynamics in the population, assess the potential population-wide 
effects of vaccination programmes and help design appropriate vaccination strategies. Given 
the high carriage prevalence rates found in children in many developing countries the indirect 
impact of routine infant PCV immunization on older children and adult populations in such 
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countries is likely to be high, as we find that carriage rates in those age groups are likely to high 
as well.  
The general decrease in prevalence with increasing age can be caused by numerous factors, 
including  the decrease in the duration of carriage with age [22,23], the reduction in the number 
of effective contacts as age increases, as well as the general maturation of the immune system 
[24].   
 
Immunity induced by S.pneumoniae carriage is complex and still poorly understood [25]. 
Although carriage acquisition leads to the development of capsular antibodies, evidence 
suggests that such antibodies may not be the primary driver of the decrease in duration and 
prevalence of carriage with age [26]. Mouse models have shown that the development of 
immunity against colonization in mice depends on CD4+ T cells rather than serotype-specific 
antibodies as such, in particular T-cells secreting IL-17A   (TH17 cells) [27], and there is evidence 
that TH17 cells play a role in immunity against carriage in humans too [28].  
Yet despite the uncertainty around the exact immune mechanisms, or the contribution of each 
of those towards acquired long term immunity, epidemiological evidence suggest that 
serotype-specific immunity against colonization is induced by acquisition of some serotypes 
such as 6A, 14 and 23F, which are included in PCV formulations and are some of the most 
prevalent serotypes in early childhood [24]. Hence the progressive acquisition of immunity 
against VT serotypes may also explain the shift in serotype distribution towards proportionally 
more NVT as age increases, as immunity against VT serotypes acquired in early childhood may 
reduce the likelihood of acquiring such serotypes later in life [29].  
 
There are several direct applications of our study results. 
Given that most studies are confined to children <5y of age only, the results of this study are 
particularly useful in the context of the progressive introduction of PCV10 or PCV13 in many 
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developing countries, in order to help estimate and appraise the possible impact of the vaccine 
across age groups. For example, nasopharyngeal carriage estimates are central to dynamic 
models of disease transmission [30,31], which can be used to model pre-vaccination dynamics 
and estimate post vaccination trends. With the results of this study, such models could be 
implemented in settings in which pre-vaccination data are only available in young children.  
The quantification of the magnitude of change in carriage prevalence between children <5y 
and older age groups is also helpful in the sample size calculations of nasopharyngeal carriage 
surveys across age groups. 
While the specific associations found between VT and NVT carriage prevalence across age 
groups may not hold for new higher valency vaccines under development, the estimates of 
overall carriage prevalence across age groups may help evaluate the possible population wide 
impacts on carriage of new protein-based or killed whole cell serotype-independent candidate 
vaccines [28]. 
As a practical application of the presented work we predicted the carriage prevalence in older 
children and adults based on carriage in under 5 year olds in an aboriginal population in the 
Northern Territory in Australia [33]. This study was not included in the analysis as it was 
conducted after the introduction of PCV. However, no change in overall carriage prevalence was 
observed in the three first years post PCV in this population. Hence we assumed that under a 
scenario of full serotype replacement overall carriage estimates by age group after PCV 
implementation would match those from the pre-PCV period. Using such data, we estimated 
the prevalence in 5-17y olds and adults to be 58.1% (95% prediction 38.7-77.4%) and 32.4% 
(95%prediction 14.8 – 48.8%) respectively, based on data in children under five. This closely 
matches the study estimates, with the prevalence in 5-17y olds estimated at 60.9% (95%CI 
54.5% - 67.0%) and that in adults estimated at 26.0% (95%CI 22.3 – 29.9%).  
 
Our study also suffers a range of limitations. 
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 We did not restrict our analysis to any particular design and sampling strategy, and recruitment 
bias is likely to have occurred, in particular for studies based on convenience rather than 
random sampling. This is certainly the case for the adult age group, which in many studies 
consisted of the parents of children included in the study rather than a random cross sectional 
adult community sample. Such adults may therefore be more likely to be colonised, and to be 
colonised with a homologous strain to that in the children in the household, as  shown in 
Chapter 4 of this thesis.  
By restricting the analysis to broad age groups, we overlooked changes in carriage prevalence 
within each of those groups. In particular, the prevalence of carriage in the 5-17y olds is known 
to decline between the ages of 5 and 17 years. This may also account for some of the 
heterogeneity seen between studies, as in many studies the age representation of the 5-17y 
olds in the study sample may not have matched that of the general population. 
Between-study heterogeneity may also have resulted from individual confounding factors 
associated with carriage prevalence, which we were unable to account for, such as malnutrition, 
antibiotic use or smoking [32,33]. 
Further, although standard WHO laboratory procedures [14] were reported in all studies, 
differences in swabbing techniques, number of colonies plated, processing of specimens and 
culture may also account for some of the differences seen.  
We could not specifically estimate the carriage prevalence among the elderly as a function of 
that in young children, given the paucity of data. Having specific estimates in elderly would be 
important however, given the particularly high burden of pneumococcal disease in that age 
group and the potential indirect impact of routine PCV on carriage in them.  While no 
significant difference in carriage prevalence between younger and older adults was reported in 
two studies that provided specific data on older adults or elderly [16,17], more data are 
required to enable specific estimates to be made for that age group. 
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Finally, model estimates of VT and NVT prevalence in older age groups as a function of that in 
young children were prone to more uncertainty than in the models based on overall carriage 
prevalence, given that fewer studies reported specific carriage data by groups of serotypes. In 
addition, those models were based on prevalence estimates which were mostly confined to the 
lower prevalence levels, resulting in substantial model uncertainty for high prevalence 
estimates.  Further carriage studies will help improve the precision around such estimates, and 
the analysis can easily be updated with the model code provided in the Supporting Information. 
 
2.5. Conclusions 
 
Information on patterns of nasopharyngeal colonisation in individuals not directly targeted by 
pneumococcal conjugate vaccination is scarce but plays an important role in the consideration 
of the indirect impact of PCVs. We here present evidence that a non-trivial stable relationship 
between child and both adolescent and adult carriage rates holds. Furthermore, we show that a 
similar relationship for the proportion of vaccine type and non-vaccine type carriage is present. 
We exploit these and provide a tool to make an informed prediction of carriage rates in 
adolescents and adults based on childhood carriage rates only, including the associated 
uncertainty. Further carriage studies on broad age ranges will allow narrowing of the prediction 
intervals. If designed accordingly these could also provide the basis for childhood carriage 
informed estimates of carriage in the elderly population which is particularly affected by 
pneumococcal disease. An application  of this model  is undertaken in Research Paper 5 of the 
thesis.  
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2.6.  Supporting information 
 
2.6.1. PRISMA checklist 
The results are reported in accordance with the PRISMA checklist, the full details of which can 
be easily access online in the published version of the manuscript. 
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0086136 
 
 As per checklist, a structured summary was provided: 
1. The introduction included (i) a clear rationale in the context of what is already known, 
(ii) a specific statement about the question being addressed with reference to with 
reference to participants, interventions, comparisons, outcomes, and study design 
(PICOS); 
2. The methods section included (i) a description of the study protocol, (ii) the eligibility 
criteria for inclusion, (iii) the data sources for information, (iv) the full electronic search 
strategy, (v) the process of selecting study, (vi) the methods for data extraction, (vii) the 
list of variables for which data were sought, (viii) the methods used to describe the risk 
of bias in individual studies, (ix) a statement of the primary summary measures, and (x) 
a description of the methods used to handle data and combine data from different 
studies, including measures of consistency, (xi) a description of any assessment 
conducted to reduce the risk of bias and (xii) any additional analyses such as sensitivity 
analyses;  
3. The results section included  (i) an overview of the number of studies screened, 
assessed for eligibility and included in the review, with reasons for exclusion at each 
stage, (ii) a description of which data were extracted, (iii) a presentation of the risk of 
bias for each study and, if available, any outcome level assessment, (iv) For all outcomes 
considered (benefits or harms), present, for each study a summary data and effect 
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estimates and confidence intervals, ideally with a forest plot, (v) a presentation of the 
results of each meta-analysis done, including confidence intervals and measures of 
consistency, (vi) a presentation of any assessment of risk of bias across studies and (vii) 
results of any additional analyses, if done;  
4. We provided a discussion section which (i) summarised the main findings, including 
strength of evidence of the outcome, (ii) discussed the main  limitations of the study 
and (iii) provided a general interpretation of the results in the context of other 
evidence, and implications for future research.  
5. Finally, the PRISMA checklist requires to describe all sources of funding and other 
support, which was done. 
 
2.6.2. Details about data extraction from the respective studies included  
1. Abdullahi et al. [1] : Estimates were directly provided in the paper. 
2. Adetifa et al [2]: Overall carriage estimates were obtained based on the reported 
prevalence by age group and the number of individuals included in each age group. 
Estimates for PCV7, PCV10 and PCV13 serotypes were provided directly in the paper 
3. Bello Gonzales et al. [3]: Estimates were directly provided in the paper. 
4. Cekmez et al [4]:Estimates were directly provided in the paper. 
5. Chen et al. [5]:Estimates were directly provided in the paper. 
6. Dagan et al. [6]:Estimates were directly provided in the paper. 
7. Darboe et al.[7]: We used data published in a subsequent study [8] as the latter 
provided more detailed information on carriage than the original study. A birth cohort 
was followed up to the age of one year, and nasopharyngeal (NP) samples were taken 
at 0, 2, 5, and 12 months. We calculated the carriage prevalence as the average 
prevalence between 0-12 months, based on monthly estimates. The carriage prevalence 
for months for which no NP sample was taken was calculated as the average of the NP 
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prevalence of the two nearest months with available estimates. Similarly, NP samples 
from mothers were taken at their child’s birth 2 months, 5 months and 12 months later. 
We considered the sample taken at birth to be more representative from the carriage 
prevalence in the general adult population than those taken during the first year, 
during which the prevalence in mothers increase as a result of close infant-mother 
interaction. Hence only the carriage prevalence obtained at birth were used for the 
analysis of the carriage prevalence in adults. For the calculation of VT and NVT carriage 
prevalence NT serotypes were excluded from the denominator 
8. Dhakal et al. [9]: Carriage estimates were directly provided in the paper 
9. Granat et al. [10]: Carriage estimates were directly provided in the paper 
10. Greenberg et al. [11]: Carriage estimates were directly provided in the paper 
11. Hammitt et al.[12]: Carriage estimates were directly provided in the paper 
12. Henriqus Normark et al.[13]: Carriage estimates were directly provided in the paper 
13. Hill et al. [14]: Carriage estimates were directly provided in the paper 
14. Hussain et al. [15]: Prevalence estimates were based on the study data later reported 
by Flasche et al [16], where the prevalence by age group was adjusted for multiple 
testing. Sample size by age group was estimated based on the prevalence estimates in 
[16] and the number of cases, by age group. For the calculation of VT and NVT carriage 
prevalence NT serotypes were excluded from the denominator 
15. Inostroza et al. [17]: The samples were obtained from two cities in two different 
populations: (1) Santiago, where children with Invasive Pneumococcal Disease (IPD) 
were sampled as well as their contacts, in addition to a sample of healthy children 
attending day care centres, and (ii) Temuco, where healthy children attending day care 
centre and hospital staff were sampled. For analysis, only samples from Temuco were 
considered. 
16. Kaltoft et al.[18]: Carriage estimates were directly provided in the paper 
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17. Leino et al.[19]: Carriage estimates were directly provided in the paper 
18. Lloyd-Evans et al.[20]: The study included index cases <5 years of age admitted to the 
hospital with a diagnosis of IPD, as well as community based healthy controls <5 years 
of age. Samples of family members of index cases were obtained on the day of 
admission as well as one month later. We included data from samples obtained in 
healthy children <5y in the analysis,  as well as data from the samples from family 
members of cases of IPD obtained one month after the index cases’ hospital admission. 
19. Lo et al. [21]: Estimates were directly provided in the paper. 
20. Mueller et al. [22]: Overall carriage estimates obtained based on the reported 
prevalence by age group and the number of individuals included in each age group. 
21. Nunes et al [23]: The study participants consisted of 120 pairs of HIV positive mothers 
and HIV exposed children and 123 HIV unexposed mother-infant pairs. Swabs were 
collected from infants at five different times (average age of 4m, 7m, 9m, 12m and 
16m). The carriage prevalence in children and mothers was approximated by the 
number of positive swabs in each age group over the total number of swabs collected. 
This calculation was performed to obtain overall carriage estimates. Estimates for PCV7 
and PCV13 serotypes could not be obtained. Only the data from the HIV unexposed 
mother-infant pairs were used in this analysis. 
22. Parry et al. [24]: Estimates were directly provided in the paper. 
23. Regev-Yochay et al. [25]: The study population comprised of children and adults 
attending any of the health care centres in four large cities in Israel for any reason. Of 
the 404 children included, 173 attended for an upper respiratory tract infection (URTI) 
and among adults, 192 of the 1300 included had an URTI on the day. For the purpose 
of the analysis of overall carriage prevalence, children and adults with an URTI were 
excluded. However in the analysis of VT and NVT prevalence and distribution all data 
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were included as data available from the manuscript did not differentiate between 
those admitted or not for URTI. 
24. Regev-Yochay et al. [26]: Overall carriage estimates obtained based on the reported 
prevalence by age group and the number of individuals included in each age group. 
25. Reichler et al.[27]: Exact numbers were obtained based on a bar chart of the 
prevalence by age group and the number of individuals in each age group. We 
included all children <64months in the calculation of the carriage prevalence in <5y 
olds and children in the after kindergarten/after school aged 5-10y in the older children 
age groups. Estimates from a group of children aged 3-7y who attended a Montessori 
were not included as the age band stretched over the 2 age groups. 
26. Reis et al. [28]: Carriage estimates were directly provided in the paper 
27. Sener et al. [29]: Carriage estimates were directly provided in the paper 
28. Turner et al. [30]: A cohort of newborns and their mothers were followed from birth to 
24 months of age, and monthly swabs were taken. After a rapid increase in NP carriage 
prevalence in the first 2 months the prevalence of carriage in children remained stable 
between the ages of 3 and 24 months. The carriage prevalence was also stable in 
mothers. We calculated the carriage prevalence as the total number of positive swabs 
out of all swabs taken (children: 3363/4191 and mothers 1033/4195), and translated 
this in number of cases based on the sample size of children (n=234) and mothers 
(n=231) and the prevalence estimates. Given the stability of the positivity rate by 
monthly age group, we assumed for the analysis that the prevalence in <1y was 
equivalent to that in <2y.Similarly, for VT and NVT serotypes, the calculation was based 
on the average VT and NVT positive swabs (excluding NT) and the numbers of carriers 
calculated in each age group. 
29. van Gils et al.[31]: An individual RCT was conducted. We used carriage estimates from 
the control group only (i.e. unvaccinated). Children were swabbed at 12 months, 18 
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months and 24 months. For carriage estimates in infants (<1y) we only included 
estimates at 12 months of age. However, for the VT and NVT carriage prevalence we 
calculated the average over the three sampling periods, at 12 months, 18 months and 
24 months.  In adults swabs were taken from parents when their children were 12 
months and 24 months old. We calculated the carriage prevalence based on the 
average of samples taken at 12 months and samples taken at 24 months.  
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Abstract  
Background 
Pneumococcal conjugate vaccines (PCVs) reduce disease largely through their impact on 
nasopharyngeal (NP) carriage acquisition of S.pneumoniae, a precondition for developing any 
form of pneumococcal disease. We aimed to estimate the vaccine efficacy (VEC) and duration of 
protection of PCVs against S.pneumoniae carriage acquisition, through meta-regression 
models. 
 
Methods 
We identified intervention studies providing nasopharyngeal carriage estimates among 
vaccinated and unvaccinated children at any time after completion of a full vaccination 
schedule. We calculated VEC for PCV7 serotypes, grouped as well as individually, and explored 
cross-protective efficacy against 6A. Efficacy estimates over time were obtained using a 
Bayesian meta-logistic regression approach, with time since completion of vaccination as a 
covariate.  
 
Results  
We used data from 22 carriage surveys (15 independent studies) from 5 to 64 months after the 
last PCV dose, including 14,298 children. The aggregate VEC for all PCV7 serotypes six months 
after completion of the vaccination schedule was 57% (95%CrI 50 – 65%), varying by serotype 
from 38% (19F) to 80% (4). Our model provides evidence of sustained protection of PCVs for 
several years, with an aggregate VEC of 42% (95%CrI 19 – 54%) at 5 years, although the waning 
differed between serotypes. We also found evidence of cross-protection against 6A, with a VEC 
of 39% six months after a complete schedule, decreasing to zero within five years post 
vaccination. 
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Conclusion 
Our results suggest that PCVs confer lasting protection against acquisition of pneumococcal 
carriage of the seven studied serotypes, for several years after vaccination, albeit with 
differences across serotypes.  
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3.1. Introduction  
Pneumococcal conjugate vaccines (PCVs) reduce disease largely through their impact on 
nasopharyngeal (NP) carriage acquisition of Streptococcus pneumoniae (the pneumococcus), a 
precondition for developing any form of pneumococcal disease (1). Additionally PCVs reduce 
the progression to disease of VT carriers (1). The effect of PCV on carriage also drives the herd 
immunity effect of the vaccine in routine immunization, through a reduction in the transmission 
of vaccine serotypes (VT) in the community (2). Recently, emphasis has been put on the 
importance of carriage as a proxy measure for PCV impact assessments, and for using carriage 
as an additional and essential biomarker in the licensure pathway of new pneumococcal 
vaccines (3, 4).  
 
A recent systematic review of the direct impact of PCVs by dosing schedules (5) showed 
consistent reductions in carriage of the serotypes targeted by the vaccine, including a few years 
after vaccination, with evidence favouring 3-dose schedules over fewer doses. However, 
systematic estimates of the efficacy of PCVs against carriage and the duration of protection 
conferred are lacking.  Such estimates will help improve predictions about the likely impact of 
introducing the vaccine in routine immunization under different epidemiological scenarios. 
Estimates of the rate of waning efficacy are important not only to quantify the level of 
individual protection over time, but also the degree to which vaccinated children contribute to 
reducing community transmission as they age. Efficacy against carriage estimates also provide a 
benchmark against which new vaccines and vaccines under development can be evaluated (3). 
We studied the vaccine efficacy and duration of protection of pneumococcal vaccines against 
carriage, through meta-regression models. 
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3.2. Methods 
3.2.1. Search strategy 
We identified intervention studies reported by Fleming-Dutra et al. (5) in a recent systematic 
review of PCV vaccination schedules, which was based on data published between 1994 and 
September 2010, with post-hoc supplementation of studies published from 2011. We searched 
for any additional study published between 2011 and 31 May 2014 using a similar strategy as in 
(5), using EMBASE and MEDLINE databases. Details are provided in the Supporting Information. 
 
3.2.2. Inclusion criteria 
We considered the following initial criteria for inclusion: (i) intervention studies (ii) providing 
nasopharyngeal carriage estimates in vaccinated and unvaccinated children, (iii) with children 
vaccinated as per routine schedule, including three primary doses (‘3+0’ schedule) or at least 
two primary doses with a booster dose (‘2+1’ and ‘3+1’ schedules). We further restricted our 
analysis to studies of either 7-valent, 10-valent or 13-valent licensed vaccines (PCV7, PCV10 and 
PCV13) or unlicensed vaccines (e.g. PCV9 and PCV11) linked to similar carrier proteins as 
licensed vaccines, including the Corynebacterium diphtheria toxin mutant 197 (CRM197), 
meningococcal outer membrane protein complex (OMPC) or the non-typeable Haemophilus 
Influenzae derived protein D (NTHi). Studies based on vaccines conjugated to other proteins or 
for which immunological equivalence is unclear (such as tetra- and penta-valent vaccines (6-8)) 
were not included.  
Given that PCVs are not known to affect carriage clearance (9, 10), that the average duration of 
vaccine serotype (VT) carriage in infants and young children is somewhere around two months, 
but may vary by setting and serotype (11-14), and that 2-4 weeks are required for the antibody 
response to peak after vaccination, we excluded any data collected earlier than four months 
after complete vaccination, when the prevalence and serotype distribution was considered non-
stationary, as detailed elsewhere (15, 16).  
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3.2.3. Data extraction  
All but four studies were PCV7 trials, with three other trials based on PCV9 and one on PCV10. 
We extracted data on the group of PCV7 serotypes, as well as each individual PCV7 serotype (4, 
6B, 9V, 14, 18C, 19F, 23F). We also extracted data on serotype 6A, one of the most common 
serotypes, which shares immunological traits with 6B but is not included in PCV7, PCV9 or 
PCV10, to explore possible cross-reactive protective efficacy. Other potential cross-reactive 
serotypes, such as 19A, were not studied, due to limited data. 
 
3.2.4. Analysis  
We defined the vaccine efficacy against carriage acquisition (VEC) as the relative reduction in 
the rate of carriage acquisition among vaccinated compared to unvaccinated children, in trial 
conditions. Although acquisition events cannot directly be observed, it is possible to obtain a 
robust estimate of VEC from cross sectional data based on 1 - OR (odds ratio), under general 
assumptions, with the OR defined as the odds of vaccination among the (group of) VT 
serotype(s) (henceforth, the ‘target’ group) to the odds of vaccination among those not carrying 
any VT (henceforth the ‘reference’ group) (15-17). Hence, in calculating the VEC for each 
individual PCV7 serotype, we included in the target group all vaccinated and unvaccinated 
carriers of the particular serotype and in the reference group all non-vaccine serotype (NVT) 
carriers and non-carriers.  Other VT were excluded from the serotype-specific analysis to 
account for vaccine-induced within-host changes in the pneumococcal flora, as explained 
elsewhere (15). We also excluded all VT serotypes from the analysis of VEC against 6A.  Similarly, 
in trials based on vaccines with higher valency than PCV7, data on the additional VT serotypes 
were excluded.  Further details about the methods and assumptions underpinning the 
estimation of VEC from cross-sectional data are described elsewhere (15-17).  The analysis was 
based on summary data by (group of) serotype(s), rather than individual-level data.  
 94 
 
 
We explored whether the proportion of carried VT serotypes out of all VT serotypes differed 
between studies, based on data in unvaccinated children,  and used I
2
 values to quantify 
heterogeneity (18). 
 
We used a Bayesian logistic meta-regression model to estimate the aggregate and serotype-
specific VEC and its waning. In the model, for each study i , 
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, where ViP R and ViP T are the proportion of vaccinated individuals in the reference and target 
groups respectively, i  is the study-specific natural logarithm of the OR and 1 represents the 
coefficient by which the log(OR) changes for each increase in the natural logarithm of time t  
since the peak VEC (i.e. 4 months after vaccination), such that i 1 *log(OR ) log( )i it   , with 
time in months.  
 
We used a random effect model taking the between-study heterogeneity into account by 
assuming that i  were independent and sampled from a normal distribution centred around 
the mean log(OR) of carriage (  ) with a precision , such that ~ ( , )i N    and 
21/  , 
where 
2  is the between-study variance. A fixed effect was assumed for 1 . 
 
The VEC at time t  can therefore be expressed as follows: 
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1 ( * )tVEc e t    
 
We assigned uniform priors to   (unif (-10; 10)),   (unif (-10, 0)),   (unif (0,10)) and 1  (unif 
(0,10)).  The time coefficient 1  was constrained to positive values, with the assumption that the 
efficacy should be declining. This assumption was further tested in a sensitivity analysis, by 
placing an unconstrained prior on 1  (unif (-10,10)) . 
 
Some studies provided more than one estimate. However, we did not adjust for the lack of 
independence due to the limited number of estimates from each study.  
 
We explored the impact of schedule (booster (3+1 or 2+1) vs. non-booster (3+0)) by including 
schedule as a covariate in a multivariable model, and assigned a normal uninformed prior to its 
coefficient ( 2 ~N(0,103)). We used an interaction term between schedule and time to look for 
a difference in the waning by schedule, with a normal uninformed prior on the interaction 
coefficient ( 3 ~N(0,103)).  Studies in which a 23-valent polysaccharide vaccine (PPV23) booster 
dose was provided after a primary schedule (as in (19, 20)) were considered part of the 3+0 
group, given the lack of effect of PPV23 on carriage (19).  
 
Finally, we conducted sensitivity analyses to explore the impact on our pooled VEC estimates of 
omitting any one study.  We also analysed two additional models of waning VEC, including a 
model where time was included as a linear covariate and another model with an asymptotic 
function in which the VEC of carriage approaches zero as time approaches infinity.  Models were 
compared using the Deviance Information Criterion (DIC), a likelihood-based model fitting 
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statistic for Bayesian models similar to the frequentist Akaike Information Criterion (21). Further 
details are presented in the Supporting information.   
 
Posterior distributions were obtained through a Markov Chain Monte Carlo (MCMC) Gibbs 
sampling algorithm based on 2 chains of 100,000 iterations running in parallel, after a burn-in 
of 5,000 iterations.  The model was implemented in R using the jags package (22). 
3.3. Results  
3.3.1. Characteristics of the studies included 
Of the eighteen intervention studies identified in (5), four were based on non-equivalent 
vaccines (6-8, 23) and one provided carriage data three months after the last dose (24), hence 
we ended up with thirteen studies. We identified two additional studies through our literature 
review, including a PCV7 trial with data six months after a 3+1 schedule (25), and another 
PCV10 trial with data collected in the first (26) as well the second year (27) after vaccination. 
Figure S1 (Supporting Information) shows the results of the literature search.  Our analysis 
therefore included 15 individual publications (7, 10, 19, 20, 26-36) providing estimates from 22 
different surveys, spanning from 5 months to 64 months after vaccination, and including 7,485 
samples from vaccinated children, and 6,813 from unvaccinated children. All but four studies 
were based on PCV7. Three were PCV9 trials (29, 32, 37) and one was a PCV10 trial (26, 27). We 
were unable to restrict the latter to PCV7 serotypes only (as all data for PCV10 serotype were 
aggregated), and we explored the sensitivity of our model output to including (or not) data 
from that study. Nine data points were from surveys after booster vaccination (Table 4). Two 
studies (10, 33) were nested within a cluster randomized trial. The clustering was not adjusted 
for, and we explored the impact of those study estimates in the sensitivity analysis (see below). 
Serotype-specific data were obtained for 10 studies (7 PCV7 and 3 PCV9 studies), with 14 data 
points (10, 20, 25, 28, 29, 31-35). 
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Table 4: Studies included in the analysis 
Study Country PCV Schedule Time since last PCV dose Number of children  
PCV7 VEC (95CrI) at each sample 
collection in the survey       Intervention  Control 
Cheung et al. (2009) [29] The Gambia PCV9 3+0 6 months, 16 months 1051,922 1041,925 58% (49%; 65%), 54% (44%; 62%) 
Dagan et al. (2012) [28] Israel PCV7 3+0 6 months 329 170 51% (24%; 68%) 
Kilpi et al. (2001)  Finland PCV7 3+1 6 months 1603 800 41% (23%; 54%) 
Lakshman et al. (2003) [20] UK PCV7 3+1PPV23 29 months, 36 months 150,143 126,188 29% (-49%; 66%), 5% (-59%; 43%) 
Madhi et al. (2007) [31] South Africa PCV9 3+0 64 months 121 150 36% (-25%; 68%) 
Mbelle et al. (1999) [32] South Africa PCV9 3+0 6 months 242 239 62% (43%; 76%) 
Millar et al. (2006) USA PCV7 3+1 27 months 468 281 45% (14% ; 64%) 
Obaro et al. (2000)  The Gambia PCV7 3+0 5 months 98 99 45% (-2%; 70%) 
O’Brien et al. (2007) [10] USA PCV7 3+0, 3+1 7.5 months (3+0), 7.5 months 
(3+1) 
226,239 208,219 65% (40%; 79%), 44% (11%; 65%) 
Palmu et al. (2002) [34] Finland PCV7 3+1 46 months 401 353 46% (-16%; 76%) 
Prymula et al. (2011) [26] Czech Republic PCV10*
$
 3+0, 3+1 8.5 months (3+0) , 204 334 59% (27%; 79%) 
    7 months (3+1), 12 months (3+1) 205,207 330,334 39% (-5%; 65%), 52% (12%; 75%) 
 Prymula et al. (2013) [27] Czech Republic PCV10*
$
 3+1 19 months 106 210 62% (19%; 83%) 
Russell et al. (2010) [19] Fiji PCV7 3+1PPV23 6 months, 9 months 122,114 126,125 83% (53%; 95%), 70% (31%; 79%) 
van Gils et al. (2009) [35] The Netherlands PCV7 2+1 7 months, 13 months 329,333 317,321 70% (56%; 79%), 70% (57%; 80%) 
Yeh et al. (2003) [36] USA PCV7 3+0 6 months 41 28 -4% (-373%; 74%) 
*In this trial two PCV10 arms were included, one receiving pre-vaccination paracetamol prophylaxis and one without prophylaxis. . Only data from the latter and the placebo group were 
included.   
$
Serotype –specific data were not available and VEC in this trial is against all PCV10 serotypes, not PCV7 serotypes as in other studies included
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3.3.2. Vaccine efficacy against carriage and its waning 
We estimated a peak VEC (i.e. 4 months after complete vaccination) of 62% (95%CrI 52 – 72%) 
against all VT serotypes, decreasing to 57% (95%CrI 50 – 65%) six months after vaccination, 
when the number of data points in the model is the highest, and 42% (95%CrI 19 – 54%) five 
years after vaccination (Figure 6, Table 5).  
 
Figure 6: Plot of the model of VEC over time and its 50% and 95% credible intervals, together with 
the individual study estimates 
 
Legend: The plain line shows the model median, the dark grey shaded area the 50% credible interval (CrI) and the light 
grey shaded area the 95% CrI. The circles represent the point estimates of each individual study, with the size of the 
circle proportional to the study size, and the dotted vertical lines show the 95% confidence interval for each study. The 
horizontal axis represents time since complete vaccination 
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There was no evidence of a confounding effect of schedule on VEC (with the coefficient β2 
centred around zero (-0.03 (95%CrI -0.32; 0.63)) or that the waning rate differed by schedule 
(interaction term β3 0.01 (95%CrI -0.24; 0.13)). However, taken individually the median waning 
coefficient 1  was smaller (i.e. ‘flatter’ slope) after a booster than after a 3+0 schedule (Figure 7 
and Table 5). Our model was insensitive to the assumption on the prior of 1 . 
 
Figure 7: The vaccine efficacy and its waning, for schedules with a booster (right panel) and 
without a booster dose (left panel). 
 
Legend:  Left panel: model for 3+0 schedules. Left panel: 2+1 or 3+1 schedules. The plain dark regression line shows 
the model median, the grey shaded area the 95% credible interval (CrI) and the dotted lines the upper and lower 
bounds of the 95%CrI. The circles represent the point estimates of each individual study, with the size of the circle 
proportional to the study size, and the dotted vertical lines show the 95% confidence interval. 
 
The serotype distribution among the unvaccinated children was fairly stable across studies 
(Figure 8), with little or moderate statistical heterogeneity in the distribution of serotypes 
among PCV7 positive samples (serotype-specific I
2
 values of heterogeneity ranging from 0% to 
60%). Serotypes 6B, 23F and 19F were the VT serotypes most commonly found, contributing to 
26%, 22%, 28% respectively of the isolated PCV7 serotypes overall among unvaccinated 
children. Serotype 14 was found in 11% and serotypes 4, 9V and 18C in 3%, 6% and 3% of PCV7 
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samples. Serotype 6A was found in about 9% of unvaccinated children, a little higher than the 
prevalence of 6B (8%, p=0.07). 
Figure 8: Distribution of the serotypes contained in PCV7, in each of the studies included in the 
serotype-specific model of vaccine efficacy 
 
Efficacy estimates differed across PCV7 serotypes. Six months after vaccination the highest VEC 
was measured for serotypes 4 (80%) and 9V (79%), and the lowest for 19F (38%) (Figure 9 and 
Table 5). 
 
The decline in the efficacy over time varied by serotype (Table 5), with the slowest decline for 
serotypes 23F and 19F (median 1 0.09) and more rapid declines for rarer serotypes, although 
credible intervals overlapped for all serotypes (Table 4).  
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We found evidence of protection against 6A, with a peak VEC of 48% (95%CrI 18% – 72%), 
decreasing to zero within five years post vaccination (Table 5, Figure 9).  
Figure 9: Serotype-specific models of vaccine efficacy against carriage, for each of the PCV7 
serotypes as well as for serotype 6A 
 
Legend: The black plain lines represent the model median and the grey shaded areas the model 95% credible interval. 
The squares and vertical dotted bars represent the study-specific point VEC estimates and their 95% confidence interval 
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Table 5: Aggregate and serotype-specific vaccine efficacy at different time points post vaccination, and model coefficient estimates  
 VEC (95%CrI) at several time points after vaccination  Coefficient estimates (95%CrI) 
 Peak (4 months) 6 months 2 years 5 years  µ* 1β  (waning) 
PCV7 serotypes        
4 88% (62%;98%) 80% (54%;92%) 50% (-50%;78%) 18% (-328%;74%)  -2.11 (-3.75; -0.97) 0.46 (0.04; 1.21) 
6B 77% (64%;89%) 72% (62%;83%) 62% (41%;72%) 54% (13%;71%)  -1.48 (-2.20; -1.03) 0.17 (0.01; 0.48) 
9V 89% (71%;97%) 79% 64%;90%) 39% (-31%;69%) -9% (-295%;62%)  -2.17 (-3.43; -1.24) 0.56 (0.11; 1.21) 
14 64% (44%;81%) 57% (40%;71%) 40% (6%;58%) 29% (-44%;56%)  -1.01 (-1.65; -0.57) 0.16 (0.09; 0.47) 
18C 59% (25%;82%) 52% (19%;73%) 34% (-14%;60%) 22% (-75%;58%)  -0.90 (-1.74; -0.29) 0.15 (0.01; 0.50) 
19F 44% (28%;62%) 38% (24%;51%) 25% (3%;39%) 17% (-25%;37%)  -0.58 (-0.96; -0.33) 0.09 (0.01; 0.27) 
23F 64% (49%;81%) 60% (46%;73%) 51% (25%;64%) 47% (3%;62%)  -1.02 (-1.64; -0.67) 0.09 (0.00; 0.36) 
Cross reactive serotype        
6A 48% (18%%;72%) 39% (11%;58%) 16% (-33%%;41%) 0% (-95%;38%)  -0.65 (-1.28; -0.19) 0.15 (0.01; 0.43) 
All PCV7 serotypes        
All schedules  62% (52%;72%) 57% (50%;65%) 47% (35%;56%) 42% (19%;54%)  -0.97 (-1.30;-0.72) 0.11 (0.01; 0.25) 
Booster schedule  63% (49%;80%) 60% (47%;73%) 52% (30%;63%) 47% (6%;62%)  -1.00 (-1.64; -0.68) 0.08 (0.00; 0.36) 
Primary dose schedule  66% (54%;77%) 59% (50%;67%) 42% (23%;54%) 31% (-7%;51%)  -1.10 (-1.49; -0.78) 0.18 (0.01; 0.37) 
* mean log OR of carriage
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3.4. Sensitivity analysis 
Our sensitivity analysis showed no significant impact of any study estimate on the coefficients. 
Estimates were similar after excluding the cluster randomized trial (10, 33), with a VEC of 62% 
(51 – 73%) at 4 months, decreasing to 40% (12 – 54%) at 5 years. Excluding the two estimates 
from Cheung et al. in the Gambia (29), which together accounted for about 28% of all children 
included in the analysis, did not affect model estimates (VEC of 62% (50 – 74%) at 4 months and 
39% (12 – 54%) at 5 years). Finally, overall and booster schedule VEC estimates and respective 
model coefficients were similar with and without data from the PCV10 trial (26, 27). 
We explored two other models of waning, in addition to the main model (Supporting 
Information). In all three models there was good evidence of protective efficacy in the first few 
years after vaccination. A similar DIC was obtained for all three models estimating the 
aggregate VEC, as well as for serotype-specific models, except for serotypes 14 and 19F for 
which the model with the asymptotic time function was outperformed by the other two. Further 
information can be found in the Supporting Information.   
 
3.5. Discussion 
We computed pooled aggregate and PCV7 serotype-specific vaccine efficacy against 
nasopharyngeal acquisition and its waning based on a meta-regression model of cross-
sectional data.  Our results suggest that PCVs confers reasonable protection against acquisition 
of pneumococcal carriage of the seven studies serotypes, for several years after vaccination, 
albeit with differences across serotypes. 
 
Previous studies have explored PCV efficacy against carriage (16) and compared schedules (5), 
however, a pooled estimate was not previously calculated. We found that the distribution of VT 
serotypes was relatively stable across settings, making the pooling of aggregate estimates 
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possible despite differences in the VEC against individual serotypes. An analysis of the 
aggregate VEC based on the pooled individual serotype-specific estimates also showed results 
in line with that of the main model presented, albeit with wider confidence bounds given the 
uncertainty around serotype-specific estimates.   
 
Three serotypes (6B, 19F and 23F) accounted for about 75% of all PCV7 serotypes, but the VEC 
for each of those differed, with high efficacy against 6B and a weaker anti-19F efficacy. A 
possible reason for this divergence is the difference in the amount of antibody required for 
protection as well as differences in the vaccine-induced opsonophagocytic activity (i.e. the 
ingestion and killing of pathogens by phagocytes), despite similar antibody geometric mean 
concentrations (GMCs) following PCV7 vaccination (30, 38). Interestingly, a recent study in the 
UK on the vaccine effectiveness and immune correlates of protection against IPD (39) showed 
that much less antibody is required for 6B and 23F protection than for 19F protection.  The 
polysaccharide capsule of 19F is more resistant to complement deposition than 6B and requires 
higher levels of antibodies for opsonophagocytosis (38). However, although trials (37, 40, 41) 
have shown persistence of serum antibodies several years after vaccination, the exact 
mechanism underlying the protection against acquisition of carriage remains unclear. Such 
mechanisms could perhaps involve mucosal immunological responses (42) in addition to pre-
existing circulating serum IgG, with serological markers incompletely capturing the mucosal 
response.  
 
While natural immunity to colonization in infancy is poor, conjugate vaccines stimulate B-cell 
responses and the generation of memory B-cells (43), which can be naturally boosted.  If 
boosting does contribute to maintaining a protective efficacy against carriage then one might 
expect efficacy to wane faster for rarer serotypes and slower for the more prevalent ones. Our 
results support such a hypothesis to some extent, showing a slower VEC decline for the most 
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prevalent serotypes. This would also mean that VEC may wane more rapidly after routine 
implementation of the vaccine than in trial conditions. 
 
We also found evidence of cross-protective efficacy against 6A acquisition based on data from 
PCV7 and PCV9 trials. Such evidence is supported by trials and observational studies showing 
an impact of PCV7 on 6A disease (44), as well as immunological evidence with the vaccine 
eliciting functional antibody (i.e. antibodies inducing opsonophagocytosis) against 6A (45).  
 
Efficacy estimates against carriage and their waning have several implications for vaccination 
programmes. Despite a stable distribution of serotypes across studies in this analysis, it is likely 
that some geographical variation occurs and serotype-specific efficacies are therefore 
important in predicting the impact of PCV in various epidemiological settings.  Our results show 
good evidence of a direct protection against carriage in the first five years of life, when the 
pneumococcal burden is particularly high, and vaccinated children therefore also contribute to 
reducing transmission for several years. This may be particularly important in settings with low 
vaccine uptake or interrupted delivery.  
 
The population impact on carriage and disease of introducing PCVs under different 
epidemiological scenarios could be explored through dynamic transmission models of 
pneumococcal disease, and our estimates of VEC and their waning are essential parameters for 
such models. 
 
The direct impact on disease is not solely conditioned on the VEC, but also on the efficacy of the 
vaccine against progressing to disease following carriage (1). This explains the higher efficacy of 
PCV against invasive disease, at around 80% (1, 3, 39) . In contrast, the efficacy on disease 
progression against mucosal forms of disease, such as acute otitis media (AOM), is small with 
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most of the disease impact predicted by VEC only (1, 3).  Interestingly, the efficacy against 
pneumococcal AOM diagnosed by myringotomy with middle ear fluid aspiration among Finnish 
children enrolled in a large PCV7 trial (30) was 62% (48 – 72%) in the year following the booster 
dose, and serotype-specific efficacies were lowest for serotype 19F, at about 37%, and high for 
6B (79%) 4 (75%,) and 9V (82%). Those estimates are similar to our aggregate and serotype-
specific VEC estimates, adding to the evidence that VEC is a close measure of the efficacy against 
AOM.  
 
An important question is the applicability of our results to 10- and 13-valent vaccines, given 
that many countries have introduced – or are planning to do so – those vaccines into their 
routine vaccination programmes.  Data on immunological correlates of protection from trials 
generally suggest comparable responses after PCV13 and PCV10 vaccination compared to 
PCV7 (45, 48, 49). However, a recent study comparing IgG concentration and functional 
antibodies in PCV7 and PCV13 vaccinated Navajo and White Mountains Apache children in the 
US (50) found higher functional antibody activity against 19F after PCV13 vaccination, 
compared to PCV7, possibly explained by the inclusion of 19A in PCV13 and the additional 
activity of anti-19A antibodies against 19F. Another trial in the UK showed lower IgG 
concentrations for serotypes 4 and 23F for PCV13 compared to PCV7 recipients after a booster 
dose at 12 months of age. Those differences could translate in differences in aggregate VEC. 
 
The estimation of the efficacy against carriage acquisition from cross sectional data relies on 
several assumptions, the most important being that of stationarity – i.e. that the relationship 
between carriage incidence and carriage prevalence is stable (15, 16). Vaccination will introduce 
some temporary disturbance in the carriage rates of different serotypes, with the average 
prevalence estimates stabilising after some time (51). Auranen et al. (17) suggest that stationary 
levels should not be considered before at least twice the duration of carriage since vaccination. 
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We included studies from four months after vaccination to account for this, which we 
considered to be a good trade-off between ensuring steady-state carriage levels and avoiding 
peak estimates to be affected by waning VEC.   
 
The assumption that PCV do not affect clearance is based on limited evidence (9, 10). Similarly, 
studies have suggested that the vaccine may also impact carriage density (10). In both scenarios 
(reduced duration and reduced density), VEC could represent a combined efficacy estimate 
against acquisition and transmission under the assumption that a reduction in duration of 
carriage and/or carriage density is associated with both a reduction in the likelihood of 
detection and of transmission, as discussed elsewhere (15, 16). 
 
Our study has a number of additional limitations.   
First, our analysis was limited by the number of data points, with wider uncertainty as time since 
vaccination increases and the smaller study sizes for serotype specific analyses, with substantial 
uncertainty around model estimates for the least prevalent serotypes. The small number of data 
points in each schedule subgroup may have limited our ability to detect any difference between 
schedules.  In addition, we were unable to provide concise predictions about the waning later 
than five years after completion of the vaccination schedule. This was due to the lack of data 
and the absence of strong statistical evidence of the superiority of the main model of waning 
presented compared to the two other models tested. 
 
Second, studies were based on the identification of the dominant serotype in single colonies 
and multiple colonization was not taken into account. If the prevalence of multiple colonization 
is low and if there are no differences in the propensity of detecting one serotype over another, 
VEC estimates based on single colonization would nonetheless adequately capture VEC (15). 
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There are several other factors related to vaccine schedules and delivery that may impact on 
VEC (and on the heterogeneity between studies) which we were unable to explore, including the 
timing and spacing of doses  and the co-administration of PCV with different childhood 
vaccines (48). For example, a recent systematic review of the impact of PCV vaccination 
schedules on immunological responses (48) suggests that immune responses to serotype 14 
may be influenced by co-administration of PCV with DTP vaccines, with significantly higher 
GMCs observed with acellular pertussis compared to the whole cell pertussis vaccine. 
 
In addition, although the description of the swabbing and sample processing techniques used 
in the studies included – although sometimes limited – seem to conform to WHO guidelines 
(52), we cannot rule out that some of the between-study heterogeneity may be due to 
differences in such techniques.  
Finally, further research to obtain more precise estimates of VEC after non-complete schedules, 
particularly single catch-up doses, is warranted. This is particularly relevant in the context of 
PCV roll out in low-income settings, as some countries may opt for catch-up campaigns at the 
introduction of the vaccine. 
In conclusion, through this study we provide consistent evidence for a lasting efficacy against 
carriage acquisition of PCV in children during the first few years after completion of vaccination, 
although with differences in efficacy and duration of protection between serotypes.  
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3.6. Supporting Information 
3.6.1. Literature search to complement the existing systematic review  
3.6.1.1. Search strategy 
We searched for any additional study published between 2011 and 31 May 2014 using 
MEDLINE and EMBASE databases, and the same search strategy as in (5), but restricted to 
nasopharyngeal carriage as outcome. 
 
We used the following keywords [all fields] : 
Search #1: pathogen 
“Streptococcus pneumoniae” OR (“Diplococcus” AND “pneumoniae”) OR (“micrococcus” AND 
“pneumoniae”) OR “Pneumococcus” OR “pneumococcal” OR “s.pneumoniae” OR 
“pneumococci” OR “streptococcus” OR “streptococcal” OR “Pneumococc” 
Search #2: outcome 
(“Nasopharyngeal” AND “carriage”) OR (“Nasopharyngeal” AND “colonization”) OR 
(“Nasopharyngeal” AND “colonisation”) 
Search #3: vaccine 
“Vaccine” OR “vaccines” OR “vaccination” OR “vaccinated” OR “immunization” OR 
“immunisation” OR “immunized” OR “immunised” OR “PCV” OR “Prevenar” OR “PCV7” OR 
“PCV-7” OR “PNCRM7” OR “PNCRM-7” OR “PCV10” OR “PCV-10” OR ”PCV9” OR “PCV-9” OR 
“PCV11” OR “PCV-11”. 
 
3.6.1.2. Results 
Combining those three searches yielded 468 citations. After automatic and manual de-
duplication, we ended up with 208 citations to screen.  
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Of those, 179 were excluded based on the title or the abstract. The full text of 29 references 
were screened. Of those, three were from trials meeting our inclusion criteria, including a PCV7 
trial from Israel (28) and a PCV10 trial from the Czech Republic, with two different publications 
(26, 27) (Figure S1 below). Additionally, we also retrieved data from a large Finnish trial 
presented at a conference in 2001 (25), and used illustratively by Auranen et al.(15) 
Figure S1: Flow diagram of the literature search 
 
3.6.2. Comparing models of waning VEC 
Three models of waning VEC were considered.  
For each study i , 
 
Vi
Vi
P
log( )
1 P
i
R
R


      # In all models  
Vi
1 *
Vi
P
log( ) log( )
1 P
i i i
T
T
t   

    # In model 1 (main model presented) 
Vi
1 *
Vi
P
log( )
1 P
T
T
i i it    

   # In model 2 
Vi
* 1
Vi
P
log( )
1 P
i
T
T
t
i i   

   # In model 3 
 117 
 
 
, where ViP R and ViP T are the proportion of vaccinated individuals in the reference and target 
groups respectively, i  is the study-specific natural logarithm of the OR  
 
We used a random effect model taking the between-study heterogeneity into account by 
assuming that i  were independent and sampled from a normal distribution centred around 
the mean log(OR) of carriage (  ) with a precision , such that ~ ( , )i N    and 
21/  , 
where 
2  is the between-study variance. A fixed effect was assumed for 1 . 
 
Therefore, the vaccine efficacy at time t (VECt) is as follows; 
 
*1 ( )tVEc e t       # In model 1   
( )1 ttVEc e         # In model 2 
( )1
t
tVEc e         # In model 3 
 
We used the same priors in all three models. 
 
The models outputs were compared visually (Figure S2) as well as through the Deviance 
Information Criterion (DIC), with the smallest DIC suggesting the best model fit.  
 
In the models of vaccine efficacy against carriage acquisition of all VT serotypes, the DIC was 
the same at 307.7, 307.4 and 307.0 for models 1, 2 and 3 respectively.  Differences in DIC 
smaller than 5 are not considered meaningful in random effects meta-regression models. 
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Figure S2: Model 1 (left panel), model 2 (middle panel) and model 3 (right panel) 
 
Legend: Left panel: model 1. Middle panel: Model 2. Right panel: Model 3. The plain line shows the model median, the 
dark grey shaded area the 50% credible interval (CrI) and the light grey shaded area the 95% CrI. The circles represent 
the point estimates of each individual study, with the size of the circle proportional to the study size, and the dotted 
vertical lines show the 95% confidence interval for each study 
 
The DIC for the modelling of each individual serotype and each model considered are shown in 
Table S1. 
 
The smallest DIC values were consistently seen for model 1 (the main model presented) – with 
the exception of serotype 9V –, but the difference in DIC values between models was not 
considered significant, except for 19F for which model 3 was outperformed by the two other 
models.  
 
Hence, model 1 was presented as the main model in this paper based on a priori assumptions 
about the waning of vaccine efficacy, rather than on strong statistical grounds when comparing 
model 1 to the two other models. 
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Table S1: Deviance Information Criterion (DIC) values for ST-specific models, comparing each of 
the three models considered 
 
 Deviance Information Criterion for each model 
Serotype MODEL 1 MODEL 2 MODEL3 
4 116.7 117.0 119.0 
6B 193.2 193.2 193.5 
9V 142.9 142.0 143.5 
14 174.4 175.3 178.4 
18C 151.9 151.9 153.6 
19F 193.4 193.4 199.5 
23F 192.8 193.3 193.7 
6A 192.7 192.8 193.5 
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Abstract  
 
Background 
Quantification of human interactions relevant to infectious disease transmission through social 
contact is central to predict disease dynamics, yet data from low-resource settings remain 
scarce.  
 
Methods 
We undertook a social contact survey in rural Uganda, whereby participants were asked to 
recall details about the frequency, type, and socio-demographic characteristics of any 
conversational encounter that lasted for ≥5 minutes (henceforth defined as ‘contacts’) during 
the previous day. An estimate of the number of ‘casual contacts’ (i.e. <5 minutes) was also 
obtained. 
 
Results 
 A total of 568 individuals were included. On average participants reported having routine 
contact with 7.2 individuals (range 1-25). Children aged 5-14 years had the highest frequency of 
contacts and the elderly (≥65 years) the fewest (P<0.001). A strong age-assortative pattern was 
seen, particularly outside the household and increasingly so for contacts occurring further away 
from home. Adults aged 25-64 years tended to travel more often and further than others, and 
males travelled more frequently than females.   
 
Conclusion 
Our study provides detailed information on contact patterns and their spatial characteristics in 
an African setting. It therefore fills an important knowledge gap that will help more accurately 
predict transmission dynamics and the impact of control strategies in such areas.  
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4.1. Introduction 
 
Quantification of human interactions relevant to the spread of infectious diseases spread by 
close contact is essential to accurately predict their infection dynamics and the impact of 
control strategies (1, 2).  
Detailed surveys of social mixing patterns have now been undertaken in a number of settings 
(2-12). Studies have shown that people tend to mix with other individuals of their own age (i.e. 
assortative mixing); however, the frequency of contact, the degree of intergenerational mixing 
and the characteristics of mixing tend to vary between settings, depending on factors such as 
household size, population density and local activities, among others (3-11). 
 
Data from low-resource settings remain scarce, with only two studies in Africa published to date 
(10, 12). With the exception of a recent study from China (11), the spatial dispersal of social 
contacts relevant for transmission has often been overlooked, and there is – to our knowledge – 
no published information from low-income settings on the spatial characteristics of social 
contacts.  Spatial mobility is particularly important for epidemic risk prediction of novel and re-
emergent diseases, and for the optimization of routine control programmes (13).  
To address this knowledge gap, we set up a study of social contacts relevant to the spread of 
infections transmitted through the respiratory route or by close contact, in rural southwest 
Uganda.  
 
4.2. Materials and methods 
The study was conducted in four sub-counties of Sheema North Sub-District (southwest 
Uganda), an area with a total of about 80,000 inhabitants. About half (49%) of the district’s 
population is <15 years.  The area is primarily rural. 
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4.2.1. Study design 
Between January and March 2014 survey teams undertook interviews of a subset of individuals 
who were also included in a survey of Streptococcus pneumoniae carriage, asking about their 
social contacts in the 24 hours preceding the survey, including the frequency, type and duration 
of encounters.   
Individuals were selected from 60 clusters randomly sampled from the 215 villages and two 
small towns in the sub-county, with an inclusion probability proportional to the size of the 
village or town. Within each cluster 11 or 12 households were randomly selected. A household 
was defined as a group of individuals living under the same roof and sharing the same kitchen 
on a daily basis. One individual from each household was randomly selected from a list of 
predefined age groups to sample from within each cluster. When nobody in the household was 
from that age group, either someone from another age group was selected providing that the 
quota for that age group had not been reached in the cluster, or the closest neighbouring 
household was visited instead. In case of non-response, another attempt was made later in the 
day or the following Saturday. Our target sample size was 687, including all 327 individuals 
aged ≥15 years and a subsample of 90 children in each of the following age groups: <2 year 
olds, 2 – 4 years old, 5 – 9 years and 10 – 14 years old.  Based on estimates from previous 
findings (12, 14), such sample size provided a precision of just over 1 contact on the mean 
number of contacts per day, and enabled detection of a 20% difference in the average number 
of daily contacts by age group.    
 
4.2.2. Data collection 
Informed consent was sought for individuals aged > 13 years, and consent was sought from a 
parent or guardian otherwise.  
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Participants were asked to recall information on the frequency, type and duration of social 
encounters from the time they woke up the day before the survey until when they woke up on 
the survey day (~ 24 hours). 
 
We defined contacts as two-way conversational encounters lasting for ≥5 minutes.  Participants 
were first asked to list all the places they had visited in the previous 24 hours, the number of 
people they had contact with, their relationship with each individual mentioned, the age (or 
estimated age) of each listed contact and how long the encounter lasted for. Contacts involving 
skin-to-skin touch or sharing utensils passed directly from mouth-to-mouth were defined as 
‘physical’ contacts.  The questionnaire can be found in the Supporting Information. 
 
We defined short contacts lasting less than 5 minutes as ‘casual contacts’.  Participants were 
only asked to estimate the number of casual contacts they had, based on pre-defined 
categories (<10, 10-19, 20-29, ≥30), but were not asked to provide detailed information about 
the nature of the encounter or the socio-demographic characteristics of the person met. Casual 
contacts are generally inaccurately reported in social contact surveys (7), particularly in a 
retrospective design, and most contacts important for the transmission of respiratory infections 
are believed to be close and non-casual rather than casual (6). 
 
The questionnaire was designed in English, translated to Ruyankole, the local language, and 
back-translated to English for consistency. For children <5 years, parents were asked about 
their child’s encounters and whereabouts. Children aged 5 – 14 years were interviewed directly, 
using a questionnaire with a slightly adapted wording to that used for adults.  
The questionnaires and other study material can be found in the Supporting Information. For 
the conciseness of this thesis, not all study material (e.g. questionnaires for all age groups) are 
 127 
 
appended to this Research Paper; however these are available on request and will be published 
with the manuscript. 
 
Geographical coordinates from each participant’s household and the centre of each village 
were taken using handheld GPS devices. The spatial identification of each location in the area 
was done by the research team during the preparation phase of the study.  Geo-referencing of 
each village, hamlet or town in the area was done using GIS imagery as well as by travelling to 
the different villages to collect that information using handheld GPS devices. Given that some 
villages had very similar names, interviewers carried with them a list of all of those (>300) with 
them, so as to avoid transcription errors.  
 
Questionnaires completed in the field were double entered on a preformatted data entry tool 
by two data managers working independently. Data entry conflicts were identified 
automatically and resolved as the data entry progressed. 
 
4.2.3. Ethics statement 
Approval was obtained from the Ethical review boards of Médecins Sans Frontières (MSF), the 
Faculty of Medicine Research & Ethics Committee of the Mbarara University of Science and 
Technology (MUST), the Institutional Ethical Review Board of the MUST, the Uganda National 
Council for Science and Technology (UNCST) and the London School of Hygiene and Tropical 
Medicine (LSHTM). 
 
4.2.4. Analysis 
4.2.4.1. Characteristics of social contacts by time, person and place 
We analysed the frequency distribution of contacts for a set of covariates, including age, sex, 
occupation, day of the week, distance travelled, and type of contact. Encounters reported with 
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the same individual in different settings counted as one contact only. Straight-line distances 
between the centre point of all villages and towns in the dataset were calculated, and these 
were then used to evaluate how far people travelled, based on the reported names of villages 
and town where each reported encounter took place, and their own village or town of 
residence. 
 
We used negative binomial regression to estimate the ratio of the mean contacts as a function 
of the different covariates of interest.  Negative binomial was preferred over Poisson regression 
given evidence of over-dispersion (variance > mean, and likelihood ratio significant (P<0.05) for 
the over-dispersion parameter). We considered variables associated with contact frequency at 
p<0.10 for multivariable analysis, and retained them in multivariable models if they resulted in a 
reduction of the Bayesian Information Criterion (BIC).  
 
Next, we explored whether people reporting a high frequency of casual contacts (≥10 casual 
contacts) differed from those reporting fewer contacts with regards to their socio-demographic 
characteristics. We did so using log-binomial regression to compute crude and adjusted relative 
risks (RRs) for having a high frequency In all analyses we accounted for possible within-cluster 
correlation by using linearized based variance estimators (15). Analyses were also weighted for 
the unequal probabilities of sampling selection by age group.    
4.2.4.2. Age-specific social contact patterns 
We analysed the age-specific contact patterns through matrices of the mean number of 
contacts between participants of age group j  and individuals in age group i , adjusting for 
reciprocity, as in Melegaro et al. (6). 
If ijx  denotes the total number of contacts in age group i  reported by individuals  in age 
groups j , the mean number of reported contacts (
ijm ) is calculated as  ij j
x p  , where jp  is 
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the study population size of age group j . At the population level the frequency of contacts 
made between age groups should be equivalent such that ij j ji im P m P . The expected 
number of contacts between the two groups is therefore Cij = 2)( ij j ji im P m P . Hence, the 
mean number of contacts corrected for reciprocity ( )
C
ijm  can be expressed as ij jC P . 
 
We tested the null hypothesis of proportionate mixing by computing the ratio of observed 
mixing patterns to that of expected mixing patterns if social contact occurred at random.  
Under the assumption of random mixing, the probability of encounter between age groups 
thus depends on the population distribution in each age group, and the contact matrix under 
this random mixing hypothesis was calculated based on the percentage of population in each 
age group. The ratio of observed over expected contacts was then computed, and confidence 
intervals were obtained through bootstrapping, with replacement, for a total of 1,000 iterations. 
This approach is similar to that by Read et al. in a study in China [11]. 
 
4.2.4.3. Epidemic simulations 
Finally, in order to explore the infection transmission dynamics resulting from our contact 
pattern data, we simulated the spread of an immunizing respiratory infection transmitted 
through close contact in a totally susceptible population. The model contained nine mixing age 
groups, with a transmission rate at which individuals in age group j come into routine contact 
with individuals in age group i  computed as /
C
ij ij im  , where i  is the proportion of 
individuals in age group i , and 
C
ijqm  is the next generation matrix, with q representing the 
probability of successful transmission per contact event (16).  We assumed q  to be 
homogeneous and constant across all age groups and conducted a set of simulations for fixed 
values of q  between 25% and 40%, in line with what has been reported with influenza 
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pandemic strains (16, 17). The basic reproduction number ( 0R ) – which corresponds to the 
average number of people infected by one infectious individual in a totally susceptible 
population – was calculated as the dominant eigenvalue of the next generation matrix. We took 
uncertainty estimates in the contact matrices (and hence final size outputs) into account by 
iterating the model on bootstrapped matrices.  
 
We then computed the final epidemic size (i.e. the number of individuals who would have been 
infected during the epidemic) for each specific age group, based on a mass action model 
adapted to account for multiple age classes, as described in Kucharski et al. (18). 
Estimates obtained using the contact data from Uganda were compared to that of Great Britain, 
using data from the POLYMOD study (4) for the latter and a similar approach to compute the 
mixing matrix.  The model was parameterised with social contact data on physical contacts only, 
lasting ≥5 minutes, rather than all contacts, given that physical contacts generally seem to 
better capture contact structures relevant for the transmission of respiratory infections (6), and 
that the definition of physical contacts is more similar and comparable between studies than 
that of overall contacts.  
All analyses were performed in Stata13.1 IC and R version 3.2. 
 
4.3. Results 
4.3.1. Study population 
A total of 568 individuals participated in the survey. This corresponded to an overall response 
rate of 83%, higher among ≥15 years old (98%), and lower among under 2s (68%), 2-4 year olds 
(64%), 5 – 9y olds (82%) and 10 - 14y olds (57%). There were more female (58%) than male 
respondents, but this differed by age group, with fewer females in young age groups and more 
adult females than males (Table S2 in Supporting Information). 
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Table 6: Mean Number of Reported Contacts and Ratio of Means By Socio-demographic 
Characteristic of The Study Population, Sheema, Uganda, January – March 2014. 
CI= Confidence interval; RoM= ratio of means 
  
Variables N Mean number of 
contacts (95%CI) 
Crude RoM  
(95%CI) 
Age adjusted RoM 
(95%CI)  
Age groups     
<2y 61 6.11 (5.42 ,6.81)  0.99 (0.83 ,1.17)  
2-4y 57 6.70 (6.08 ,6.81) 1.08 (0.95 ,1.23)  
5-9y 74 8.50 (7.79 ,9.20) 1.37 (1.18 ,1.59)  
10-14y 51 8.70 (7.52 ,9.90) 1.40 (1.19 ,1.66)  
15-24y 91 6.20 (5.51 ,6.88) ref  
25-34y 55 6.89 (5.99 ,7.80) 1.11 (0.93 ,1.33)  
35-44y 54 7.73 (6.99 ,8.46) 1.25 (1.09 ,1.43)  
45-54y 46 7.74 (6.37 ,9.11) 1.25 (1.01 ,1.54)  
55-64y 26 6.27 (5.01 ,7.53) 1.01 (0.80 ,1.29)  
65+y 48 4.85 (4.18 ,5.53) 0.78 (0.64 ,0.95)  
Sex     
Female 328 7.05 (6.66 ,7.44) ref  
Male 235 7.47 (6.82 ,8.11) 1.06 (0.96 ,1.18)  
Occupation/daily activity 
Pre-school child 93 7.00 (6.30 ,7.70) 1.06 (0.90 ,1.23) 1.26 (1.02 ,1.55) 
Student 166 8.27 (7.56 ,8.98) 1.27 (1.10 ,1.46) 1.30 (1.05 ,1.63) 
Office worker 4 11.34 (9.64 ,13.03) 1.81 (1.20 ,2.73) 1.70 (1.32 ,2.18) 
Shop worker 34 6.82 (5.56 ,8.08) 1.03 (0.84 ,1.25) 1.03 (0.83 ,1.29) 
Agriculture 105 7.30 (6.58 ,8.01) 1.12 (0.97 ,1.30) 1.12 (0.96 ,1.30) 
Other manual worker 40 5.37 (4.36 ,6.38) 0.85 (0.70 ,1.04) 0.85 (0.68 ,1.06) 
At home 60 6.43 (5.62 ,7.24) ref ref 
Unemployed 11 6.44 (2.92 ,9.96) 0.83 (0.60 ,1.15) 1.22 (0.77 ,1.94) 
Retired 8 4.77 (3.75 ,5.80) 0.71 (0.48 ,1.05) 0.89 (0.70 ,1.13) 
Other/unreported 41 6.65 (5.80 ,7.51) 1.02 (0.85 ,1.23) 1.18 (0.98 ,1.43) 
Day of the week     
Weekday 439 7.14 (6.79 ,7.49) ref  
Sunday 124 7.50 (6.56 ,8.44) 1.05 (0.92 ,1.20) 1.04 (0.92 ,1.18) 
Travel outside village/town in previous 24 hours 
No 427 6.57 (6.20 ,6.92) ref  
Yes 139 9.04 (8.35 ,9.73) 1.38 (1.25 ,1.52) 1.35 (1.22 ,1.49) 
Number of casual contacts   
<10 315 5 (1 -15) Ref Ref 
10 -19 119 8 (2-23) 1.43 (1.28, 1.59) 1.39 (1.25, 1.55) 
≥20 56 9 (2-25) 1.64 (1.44; 1.86) 1.61 (1.43,1.83) 
Don’t know 76 8 (0-19) 1.52 (1.37; 1.68) 1.45 (1.29, 1.64) 
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The mean household size was 5.3 (median 5, range 1 – 18). Almost all (98%) school-aged 
children aged 6 – 14 years attended school or college. Among adults, agriculture was the main 
occupation and about 27% of the females were homemakers/housewives (Table 6). 
 
4.3.1. Characteristics of contacts 
4.3.1.1. Contacts (i.e. ≥5 minutes long) 
A total of 3,965 contacts with different individuals were reported, corresponding to an average 
of 7.2 contacts per person (median 7, range 0 - 25) (Figure 10). The majority of contacts were 
physical, thus involving skin-to-skin contact (mean 5.1, median 5 (range 0 – 18)). 
Figure 10: Number of Reported Contacts, Including All Contacts (A) and Physical contacts (B), 
Sheema, Uganda, January – March 2014.  
 
Legend: the vertical dotted lines represent the 5% centile, the median and 95% centile of the total number of reported 
contacts 
 
Over half of all contacts (n= 2,060 (52%)) were with household members, 627 (16%) with other 
relatives, 873 (22%) with colleagues/friends/schoolmates and 402 (10%) with other individuals. 
The duration of routine contacts is shown in Figure S3 (Supporting Information).  
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Most contacts (82%) were with individuals who would be normally seen daily, 520 (13%) with 
people normally seen at least weekly, 4% with people met more rarely and 1% of the reported 
contacts were with people that the participants had never met before. 
 
We found marked differences in the number of contacts by age group, but not by sex. School-
aged children reported the highest daily number of contacts, while the elderly had the fewest 
(Table 6). There was no difference in the mean number of contacts for individuals living in the 
district towns of Kabwohe and Itendero (n=43) and the 523 others living in surrounding villages 
(2-sided P=0.79). Table 6 provides further details about the population characteristics, the mean 
number of contacts by socio-demographic and other covariates, as well as the ratio of mean 
contacts by covariate.  Age was the only confounding factor. 
 
Overall, contacts tended to be assortative, as shown by the strong diagonal feature on Figure 
11, with most of the intergenerational mixing occurring within households (Figure 12). Only 
teenagers and adults reported non-physical contacts (Figure 12).  The quantification of 
assortativity can be seen in Figures S4a-c, which show the ratios of observed contacts, as 
obtained in the survey but corrected for reciprocity, to that of expected contacts under the 
proportionality assumption, for all contacts and physical contacts only. The results show age-
assortativity of contacts, for all age groups (other than <2 year olds) for all contacts, and 
primarily for school-aged children when considering physical contacts only.  
 Reciprocity correction accounted for the differential reporting between age groups, particularly 
higher frequency of contacts reported by small children with older age groups than older age 
groups reported (Figure S5). 
 
There was no statistical difference in the average number of contacts between weekend 
(Sunday) and weekdays (Monday, Tuesday, Thursday and Friday) (Table 6). As shown in Table 6, 
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mean number of reported contacts on Sundays was 7.50 (95%CI 6.56; 8.44), slightly higher on 
average than on weekdays, where the average was 7.14 (6.79; 7.49), which was not statistically 
significant ( P=0.229). The balance of respondents reporting contacts from weekdays and 
weekends reflected the normal proportion of week vs. weekend days in a normal week.  
Taking into consideration that Saturday is sometimes only half a weekend day, the proportion 
of weekend days covered during the survey is representative of the proportion of weekend days 
in a week, whether the weekend is 1.5 days or 2 days long, as shown in the Figure S6. 
 
 About a quarter (n=136 (24%)) of participants reported social encounters outside their village 
of residence, and about 12% of contacts occurred outside participants’ village of residence. The 
majority (56%) of people who travelled outside their village went to places located within a 5km 
radius from the centre point of their village of residence, and 90% stayed within 12km (Figure 
13). Adult males tended to travel more than females (Figure 13). Overall, 29% of males had 
contact with someone outside their village, compared to 20% females (designed-based 
2
, 
P=0.0406). Most (87%) children under five years of age stayed in their village, whereas about a 
quarter or more individuals travelled outside their village among 5 – 14 years old (25%), 15-44 
years old (32%) and ≥45 years of age (25%) , a difference by age group which was significantly 
different (P=0.0081).  
When stratifying by age, the difference between sex were more marked, with no statistical 
difference between males and females <5 years of age (P=0.296) or 5 – 14 year olds (P=0.272), 
but marked differences among adults (≥15 years old), with 42% of males travelling outside of 
their village compared to 24% of females (P=0.0037).  
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Figure 11 : Average Number of Reported Contacts By Age Group, Sheema, Uganda, January – March 
2014   
 
Legend: Numbers in each cell represent the average number of contacts between between age groups corrected for 
reciprocity, and 95% confidence intervals are shown in brackets 
 
 
Most contacts made outside the household as well as those with individuals outside 
participants’ village were mostly assortative (Figure 12), and the proportion of contacts outside 
the village was different by age group (P<0.001); higher among adults, increasingly so as 
distance from home increased (Figure 13).  
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Figure 12: Contact Matrices With Household members and Non-Household Members (Left upper 
and lower panel), for Physical and Non-Physical Contacts (Middle upper and lower 
panel), and for Contacts Made Within and Outside the Village (Right upper and lower 
panel), Sheema, Uganda, January – March 2014 
 
 
4.3.1.2. ‘Casual’ contacts (<5 minutes long) 
Information on the number of casual contacts was reported by 490 (87%) participants.  Among 
those, 64% (n=315) estimated they had fewer than 10 different contacts, 24% reported  
between 10 and 19 casual contacts, 6% reported between 20 – 29 contacts and 6% reported an 
estimated 30 contacts or more.  
 
Individuals who reported high levels (i.e. ≥10 contacts) of casual contacts also tended to report 
more contacts (Table 6). We found no difference between those reporting high number of 
casual contacts (≥10) and others, by age, sex or day of the week (Table S3 in the Supporting 
Information). However, people whose primary activity was at home tended to reported fewer 
casual contacts than others, and there were about 50% more individuals reporting high levels of 
casual contacts among those who travelled outside their village. 
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Figure 13: Distance Travelled By Study Participants in the 24 Hours Preceding the Survey, Overall 
(A) and By Categories of Distance, Age and Sex (B), Sheema, Uganda, January – March 
2014 
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4.3.2. Epidemic simulations 
Finally, we compared patterns of reported physical contacts in Uganda and Great Britain, and 
explored differences in the relative and absolute epidemic size by age group, as well as the 
corresponding 0R , for a hypothetical respiratory infection in an immune-naive population. 
The number of reported physical contacts was similar between Uganda and Great Britain, with 
the average number of contacts by age group ranging from 3.2 (≥65 year olds) to 7.3 (2 – 4 
year olds) in Uganda and from 3.3 (55 – 64 year olds) to 7.3 (10 – 14 year olds) in Great Britain. 
However contacts were more assortative in Britain than in Uganda (Figures 14A & B), some of 
which might be related to differences in household structures and number of household 
contacts, as contacts outside the household were mostly assortative (Figure 12). 
 
The computed mean values of 0R  for a per contact infectivity value ( q ) ranging from 0.25 to 
0.40 was slightly higher in Great Britain than in Uganda (1.51 to 2.41 vs. 1.40 to 2.24). Figure 14F 
shows the values for an infectivity parameter of 0.33. The proportion of people infected in 
younger age groups was also higher in Great Britain, and there were proportionally more adults 
infected in Uganda. However, given the differences in population structure, the total number of 
infections in the population was higher in Uganda than in Great Britain (Figures 14C – E).  
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Figure 14:  Epidemic Simulation Using Matrices on Physical Contacts from Uganda (A) and Great 
Britain (B), for a Hypothetical Respiratory Infection In An Immune-Naïve Population, 
with the Proportion Infected by Age Group (C), the Epidemic Size by Age group (D), 
the Overall Proportion Infected (D) and the Basic Reproduction Number R0 (F). 
 
Legend: A: Matrix for physical contacts in Uganda. B: Matrix of physical contacts in Great Britain. C: Epidemic final size 
simulation: Proportion of individuals infected by age group in Great Britain (blue) and Uganda (grey), with error bars 
representing the 95% confidence interval.  The results are presented for a q  value of 33%. D: Epidemic size by age 
group, based on a total population size of 100,000 in Great Britain and in Uganda. E: Total proportion of people who 
were infected at the end of the epidemic in each setting. F: Estimates of 0R for each setting, based on a q  value of 
33%, with dots showing the mean value and the bars showing the 95% 
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4.4. Discussion 
To our knowledge this is only the third study of its kind in Africa (10, 12), and the first one to 
specifically explore spatial patterns of social contacts. The quantification of mixing patterns is 
key to accurately model transmission dynamics and inform infectious disease control strategies 
(4). Having such data thus fills an important gap, particularly given the high burden of 
respiratory infections in low income settings (19, 20), and the risk of emerging and re-emerging 
diseases transmitted by close interpersonal contact, such as influenza (21), measles (22) or 
meningococcal meningitis (23).  
Our findings share similarities with studies from Africa (10, 12) and other low or lower-middle 
income settings (14, 24), including the high contact frequency among school-aged children and 
that most contacts tend to be age-assortative. We also found substantial mixing between age 
groups, largely driven by intra-household mixing. This may result in a higher force of infection 
from children to adults than would be seen in high-income settings such as Great Britain, as our 
final size epidemic model suggests. The final size model should be seen as an illustration of 
how different social mixing patterns impact on disease epidemiology in different settings, 
rather than a specific quantification of the differences. It shows the importance of using setting-
specific data when modelling disease dynamics and evaluate control strategies. Our data could 
be best applied to evaluate transmission dynamics and the impact of interventions for endemic 
diseases and current epidemics in non-naïve population, such as the ongoing large measles 
outbreak in neighbouring Democratic Republic of the Congo (22).  In our final size model, it is 
also likely that our retrospective design resulted in underreporting compared to a prospective 
diary-based approach (25), which hampers comparisons between countries.  In sensitivity 
analyses we explored the impact of potential underreporting in our retrospective survey design 
compared to a prospective diary-based approach (25), assuming a 25% under-ascertainment 
compared to a diary-based study, with homogeneous underreporting across age groups. In 
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such scenario, the proportion of infections across all age groups is predicted to be higher in 
Uganda than in Britain, disproportionally so in adults, and the 0R to be higher too (see Figure S7 
(Supporting Information)).  
Our results also provide important insights into the local spatial dynamics of routine daily 
human interactions, showing that most contacts tend to occur within the vicinity of people’s 
area of residence, that working age adult males travel most and young children and the elderly 
the least, and that contacts tend to be increasingly age assortative as people travel further away 
from home. Similar patterns were observed in rural and semi-urban China (11). Such findings 
have important implications to predict outbreak dynamics and control strategies given that 
interconnectedness between geographic patches is an essential factor driving epidemic 
extinction or persistence of epidemics hotspots and the effectiveness of control strategies. 
Studies of measles in Niger suggest that dynamics differ from that observed in high-income 
countries in the pre-vaccination era, likely due to different mixing patterns and weaker spatial 
connectivity (26, 27). This, together with important variations in vaccination coverage between 
local geographic patches (28-30), strengthens the need to account for spatial mobility when 
designing efficient control strategies in those settings.  Optimal targeted interventions tailored 
to specific geographic clusters of high transmission have also been key considerations in recent 
cholera outbreaks in Africa, given the limited available vaccine doses (31, 32). Spatially targeted 
approaches are also central to outbreak control in the recent West African Ebola epidemic (33), 
and the current measles epidemic in the Democratic Republic of the Congo, which is sustained 
in part due to inadequate coverage of populations in less accessible geographical clusters (22, 
34). 
In our study the frequency of  contacts was about half that of the number of contacts reported 
in Kenya, (10) or South Africa (12). Although differences between settings are expected, some of 
these are likely to be due to the exclusion of ‘casual contacts’ from our contact count. There 
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might be further differences linked to the definition of social contacts, which was based on 
conversational encounters in our study but not in the Kenyan study (10). When defining 
contacts based on conversational exchanges the household setting tends to dominate over 
other settings, compared to a more inclusive definition (8).  
Both our contact definition and the retrospective study design may have resulted in more 
stable, regular contacts being reported over others. However, the extent to which a more 
inclusive definition reflects contact events relevant for transmission remains unclear. Modelling 
studies suggest that close interpersonal rather than short casual contacts matter more for 
transmission of respiratory infections (6). In addition, for modelling purposes the age-specific 
structure of relative contact frequency matters more than the actual reported frequency, as 
matrices are scaled to fit epidemiological data. Our retrospective interview-based design thus 
offers a simpler and easier alternative to prospective diary based approaches, particularly in 
such settings. Further research should explore what contact information is most relevant and 
how such data should best be captured. Research Paper 4 offers some insight into this 
question, by exploring contact types associated with pneumococcal carriage and acute 
respiratory symptoms based on contact and endpoint data (carriage and acute respiratory 
symptoms) collected at the same time from the same individuals.   
Selection bias may have occurred to some extent, particularly given that more adult women 
were included than men. However, there was no significant difference in the number of 
contacts reported between males and females, including at the weekend, suggesting that 
selection bias was unlikely to be major.  We also tried to reduce selection bias by interviewing 
on Saturdays people who were initially absent on the survey. 
In conclusion, our study fills an important gap for two main reasons. First, we provide 
information by detailed age groups about social contacts and mixing patterns relevant to the 
spread of infectious diseases in a region where such data are scarce. Second, we also provide 
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some insights into spatial characteristics of social encounters. Although this has increasingly 
being recognized as an important component in evaluating epidemic risk and in the design of 
efficient control strategies, it has not previously been quantified in low-income settings, and 
should be explored further.  Our study thus provides essential evidence to inform further 
research and infectious disease modelling work, particularly in similar rural African settings.  
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4.5. Supporting Information 
4.5.1. Tables and Figures 
Table S2: Age and Sex Distribution of Study Participants 
Age category Number (%) female Number (%) male Total number 
<2 years 23 (38%) 38 (62%) 61 
2 – 4 years 26 (45%) 31 (55%) 57 
5 – 9 years 37 (50%) 37 (50%) 74 
10 – 14 years 22 (43%) 29 (57%) 51 
15  - 24 years 53 (58%) 38 (42%) 91 
25 – 34 years 45 (79%) 12 (21%) 57 
35 – 44 years 35 (64%) 20 (36%) 55 
45 – 54 years 35 (76%) 11 (24%) 46 
55 – 64 years 20 (77%) 6 (23%) 26 
65+ years 34 (71%) 14 (29%) 48 
 
Figure S3: The Reported Duration of Contact By Age Group Among Study Participants, Sheema 
District, January – March 2014 
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Table S3. Association Between Socio-demographic Variables and Level of Social Contacts 
 
 
 
 
 
 
 
 
Variables N N (%) with high 
frequency  of casual 
contacts (≥ 10) 
Crude Risk Ratio 
(RR) (and 95%CI) 
Adjusted RR (95%CI) 
Age groups     
<2y 50 10 (20%) 0.57 (0.30 ,1.09)  
2-4y 47 14 (30%) 0.85 (0.50 ,1.45)  
5-9y 52 25 (48%) 1.37 (0.86 ,2.20)  
10-14y 43 19 (44%) 1.26 (0.80 ,1.99)  
15-24y 83 29 (35%) ref  
25-34y 53 14 (26%) 0.76 (0.45 ,1.27)  
35-44y 49 27 (55%) 1.58 (1.11 ,2.25)  
45-54y 43 20 (47%) 1.33 (0.86 ,2.06)  
55-64y 23 7 (30%) 0.87 (0.42 ,1.80)  
65+y 47 10 (21%) 0.61 (0.32 ,1.14)  
Sex     
Female 297 98 (33%) ref  
Male 193 77 (40%) 1.23 (0.96 ,1.59)  
Occupation/daily 
activity 
    
Pre-school child 81 22 (27%) ref ref 
Student 132 53 (40%) 1.22 (0.80 ,1.86) 1.14 (0.74 ,1.74) 
Office/Shop worker 34 19 (56%) 1.68 (1.11 ,2.54) 1.41 (0.90 ,2.21) 
Agriculture/Manual 
work 
132 47 (36%) 1.07 (0.65 ,1.76) 1.00 (0.61 ,1.62) 
At home 60 11 (18%) 0.55 (0.30 ,1.00) 0.51 (0.27 ,0.94) 
Other 51 23 (45%) 1.38 (0.84 ,2.26) 1.27 (0.77 ,2.08) 
Day of the week     
Weekday 385 138 (36%) ref  
Sunday 105 37 (35%) 0.92 (0.67 ,1.26) 1.04 (0.92 ,1.18) 
Travel outside 
village/town in 
previous 24 hours 
    
No 374 118 (32%) ref  
Yes 116 57 (49%) 1.58 (1.23 ,2.04) 1.54 (1.18 ,2.00) 
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Figure S 4a- c: Quantification of the Age-Assortativity of the Contact Matrices for All Contacts, 
Sheema District, January – March 2014. (S4A: median, S4B: lower 95% CI, S4C: upper 95%CI) 
 
Legend: Left panel: all contacts; right panel: physical contacts. A: Median B:Lower 95%CI C:Upper 95%CI 
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Figure S5: Reciprocity Correction of the Contact Matrices for All Contacts, Sheema District, January 
– March 2014.  
 
Legend: A) matrix for all reported contacts, not corrected. B) matrix for all reported contacts, corrected for reciprocity. C) 
Ratio of corrected over uncorrected matrices. Red cells illustrate where age-specific contacts were over-reported before 
correction, and blue cells under-reported. D) shows where participants significantly over-reported the number of age-
specific contacts they had (upper 95% confidence bound) in red, significantly under-reported contacts in blue (lower 
95% confidence bound), or where no significant adjustment was made (grey) 
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Figure S6: Proportion of contacts reported during weekend days, by age group.  
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Figure S7: Epidemic Simulations Using Comparing Uganda and Great Britain, Assuming a 25% 
Underreporting Of Contacts In Uganda.  
 
Legend: A) Physical Contacts from Uganda, B) Physical Contacts from Great Britain, C) Proportion Infected by Age Group, D) 
Epidemic Size by Age group,  E) Overall Proportion Infected, and F) the Basic Reproduction Number R0. 
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4.5.2. Supporting File 1: Social contact questionnaire  
There are three parts to this questionnaire.  We will first ask a few questions about 
yourself/your child and the people you live with.  Second, we will ask you questions about the 
different places you/your child went to yesterday. Finally, we will ask you to remember who 
you/your child met during the day in each of the places you attended, and how long for. 
1. [ID and dates] 
1.1. [Individual participant ID]: |__|__|__|__| 
1.2. [Interview date (dd/mm/yy) ]:  |__|__|__|__|__|__| 
 
1.3. [Date of the “surveyed day” (dd/mm/yy)] : |__|__|__|__|__|__| 
 
1.4. [Day of the week of the “surveyed day”] 
1= Monday     
2= Tuesday     
3= Wednesday     
4= Thursday     
5= Friday     
6= Saturday     
7= Sunday    
  
PART ONE: SOCIO-DEMOGRAPHIC CHARACTERISTICS 
 
2. We would first like to ask a few questions about yourself/your child as well as about the 
people living with you/your child in your household.  
2.1.  Age  |__|__| years  
 
2.2.  [Sex of the participant ] 
 1= Male  
2 = Female 
2.3. What is your/your child’s primary occupation or daily activity [note to the interviewer: 
this is the activity the participant spends the most time doing on a daily basis]? 
1 = pre-school child; 
2= school/college/university student 
3= office worker 
4= shop worker 
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5= agriculture 
6= manual worker 
7= housewife 
8= unemployed 
9= retired 
10= others 
-1= don’t know 
-2 = refused 
2.4. Including yourself/your child, how many people live in your household?  A household 
is the group of individuals living under the same roof and sharing the same 
kitchen on a daily basis 
|__|__|. [-1 for don’t know and -2 for refused] 
 
2.5. How many bedrooms are in your household (only count living and sleeping rooms, 
exclude bathroom, kitchen)?  |__|__|   [-1 for don’t know and -2 for refused] 
 
3. We will now ask three questions about contacts you may have with animals 
3.1. Do you/your child touch the following animals at least once per week?:  
1= chickens, ducks, gees 
2= cows, pigs, goats, sheep 
3= rodent 
4= primates 
5= bats 
6= antelope 
7= none of the above 
 
3.2. In the last month, have you/has your child been bitten or scratched or cut by any of 
these animals? 
1= chickens, ducks, gees 
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2= cows, pigs, goats, sheep 
3= rodent 
4= primates 
5= bats 
6= antelope 
7= none of the above 
 
3.3. In the last month, have you/has your child killed, butchered or cooked any of these 
animals? 
1= chickens, ducks, geese 
2= cows, pigs, goats, sheep 
3= none of the above
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4. Including yourself/your child, could you please list all individuals in your household, as well as the family links between yourself/your child and each of the 
household members. [define the household again] 
Household member 
initials/name 
 
 
Household 
member ID  
Sex Age in years  Relationship 
m
e
 
S
p
o
u
se
 
S
ib
li
n
g
 
C
h
il
d
 
P
a
re
n
t 
G
ra
n
d
p
a
re
n
t 
U
n
cl
e
/A
u
n
t 
O
th
e
r 
 f
a
m
il
y
 
U
n
re
la
te
d
 
M=1 F=2 
 H 0 1 1 2  1 2 3 4 5 6 7 8 9 
 H   1 2  1 2 3 4 5 6 7 8 9 
 H   1 2  1 2 3 4 5 6 7 8 9 
 H   1 2  1 2 3 4 5 6 7 8 9 
 H   1 2  1 2 3 4 5 6 7 8 9 
 H   1 2  1 2 3 4 5 6 7 8 9 
 H   1 2  1 2 3 4 5 6 7 8 9 
 H   1 2  1 2 3 4 5 6 7 8 9 
 H   1 2  1 2 3 4 5 6 7 8 9 
 H   1 2  1 2 3 4 5 6 7 8 9 
 H   1 2  1 2 3 4 5 6 7 8 9 
 H   1 2  1 2 3 4 5 6 7 8 9 
 H   1 2  1 2 3 4 5 6 7 8 9 
 H   1 2  1 2 3 4 5 6 7 8 9 
 H   1 2  1 2 3 4 5 6 7 8 9 
 H   1 2  1 2 3 4 5 6 7 8 9 
 H   1 2  1 2 3 4 5 6 7 8 9 
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PART TWO: SETTINGS 
5. How far do you/your child travel(s) outside your village or town and how often? 
 
Geographical setting How often to you travel to those places 
outside your village or town? 
How long do you spend in that 
place when you go 
M
o
st
 d
a
y
s 
o
f 
th
e
 w
e
e
k
s 
A
t 
le
a
st
 o
n
c
e
 a
 w
e
e
k
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t 
le
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st
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o
n
th
, 
b
u
t 
n
o
t 
e
a
ch
 w
e
e
k
 
L
e
ss
 t
h
a
n
 o
n
ce
 a
 m
o
n
th
 
<
 o
n
ce
 a
 m
o
n
th
 
N
e
v
e
r 
<
1
h
 
1
-2
h
 
H
a
lf
 a
 d
a
y
 
A
 w
h
o
le
 d
a
y
 
N
e
v
e
r 
To a place in another village/town <5km away (<1 hour walk)  1 2 3 4 5 6 1 2 3 4 5 
To a place in another village/town ≥5km away 1 2 3 4 5 6 1 2 3 4 5 
 
6. In the last week,  
6.1. What is the name of the village/town of the furthest place from home you/your child went to? ______________________________ 
 
6.2. [Write the geographic ID of the abovementioned village/town (see geographic ID form)] |__|__| 
 
7. Where did you/ your spend child time yesterday  [between the time of wake up yesterday and the time of wake up today] 
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Setting ID  
Type of place 
If Other, where did you 
go? [free text] 
Name of the village or 
town 
 Time spent in that 
place 
H
o
m
e
 
A
n
o
th
e
r 
h
o
u
se
  
w
o
rk
 
S
ch
o
o
l 
P
la
ce
 o
f 
w
o
rs
h
ip
 
T
ra
n
sp
o
rt
 
Le
is
u
re
 
S
h
o
p
 
G
a
rd
e
n
 
O
th
e
r 
Village/t
own with 
geograp
hic ID  
<
1
5
m
in
s 
1
5
m
in
s 
–
 <
1
h
 
1
 -
 <
2
h
 
2
-<
4
h
 
>
4
h
 
S 0 1 1 2 3 4 5 6 7 8 9 10      1 2 3 4 5 
S 0 2 1 2 3 4 5 6 7 8 9 10      1 2 3 4 5 
S 0 3 1 2 3 4 5 6 7 8 9 10      1 2 3 4 5 
S 0 4 1 2 3 4 5 6 7 8 9 10      1 2 3 4 5 
S 0 5 1 2 3 4 5 6 7 8 9 10      1 2 3 4 5 
S 0 6 1 2 3 4 5 6 7 8 9 10      1 2 3 4 5 
S 0 7 1 2 3 4 5 6 7 8 9 10      1 2 3 4 5 
S 0 8 1 2 3 4 5 6 7 8 9 10      1 2 3 4 5 
S 0 9 1 2 3 4 5 6 7 8 9 10      1 2 3 4 5 
S 1 0 1 2 3 4 5 6 7 8 9 10      1 2 3 4 5 
S 1 1 1 2 3 4 5 6 7 8 9 10      1 2 3 4 5 
S 1 2 1 2 3 4 5 6 7 8 9 10      1 2 3 4 5 
S 1 3 1 2 3 4 5 6 7 8 9 10      1 2 3 4 5 
S 1 4 1 2 3 4 5 6 7 8 9 10      1 2 3 4 5 
S 1 5 1 2 3 4 5 6 7 8 9 10      1 2 3 4 5 
S 1 6 1 2 3 4 5 6 7 8 9 10      1 2 3 4 5 
S 2 0 1 2 3 4 5 6 7 8 9 10      1 2 3 4 5 
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PART THREE: CONTACTS 
We will now ask you to remember who you were/your child was in contact with yesterday [between the time of wake up yesterday and the time of wake up 
today].  
8. How many people have you/your child seen for a very short period of time (<5mins) and with whom you/your child have exchanged at least three words 
yesterday?  (e.g. saying hello to someone on your way, seeing someone in a shop, seeing a few children at school in the playground, etc) 
 
1= 0 – 9 people 
2= 10 – 19 people 
3= 20 – 29 people 
4= >30 people 
5= don’t know 
 
9. Contacts  
 
We would now like you to remember any person with whom you spent 5 minutes or more and with whom you exchanged at least three words in each of those 
settings. Those individuals will be defined as your contacts. For each of them, we would like to know if you had physical contact or non-physical contact. 
Nonphysical contact happens when you haven’t touched the person. Physical contact includes hand shaking, sharing a bike, kissing, embracing, and also sharing a 
glass or other utensils passed directly from mouth to mouth.   
 
 
 
9.1 We will first ask a few more questions about the people you were/your child was in contact with at home yesterday for more than 5 minutes [yesterday  is 
defined as the period from wake up yesterdat to the moment you woke up this morning] 
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Contact initials/name 
[will be removed from the 
questionnaire after the 
interview] 
 
Contact ID 
Place 
ID 
Age 
(yrs) 
Sex (M/F) 
Type of 
contact 
Link to the contact 
How often do you have contact 
with this person in general? 
Total time spent with the person 
in that particular place 
M
=1
 
F=
2
 
P
h
ys
ic
al
 
N
o
n
p
h
ys
ic
al
 
H
o
u
se
h
o
ld
 m
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th
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at
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th
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D
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 o
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o
st
 d
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A
t 
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A
t 
le
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 a
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n
th
 
Le
ss
 t
h
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 a
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N
ev
er
 m
et
 b
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o
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5
 -
  <
1
5
 m
in
s 
1
5
 –
 <
1
h
 
1
h
 -
 <
2
h
 
2
h
 -
 <
4
h
 
>4
h
 
 C 0 1 S 0 1  1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S 0 1  1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S 0 1  1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S 0 1  1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S 0 1  1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S 0 1  1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S 0 1  1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S 0 1  1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S 0 1  1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S 0 1  1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S 0 1  1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S 0 1  1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S 0 1  1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S 0 1  1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S 0 1  1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S 0 1  1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S 0 1  1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S 0 1  1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S 0 1  1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
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9.2 We will now ask a few more questions about the people you were/your child was in contact with in the  other places yesterday for more than 5 minutes 
Contact initials/name 
 
Contact 
number ID 
Place ID 
Age 
(yrs) 
Sex (M/F) 
Type of 
contact 
Link to the contact 
How often do you have 
contact with this person in 
general? 
Total time spent with the 
person in that particular 
place 
M
=
1
 
F
=
2
 
C
lo
se
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 p
h
y
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l 
C
lo
se
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o
n
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 m
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 r
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 d
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5
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<
1
5
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1
5
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1
h
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2
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2
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 <
4
h
 
>
4
h
 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
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 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
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Note that for the survey there was no limit to the number of contacts that could be entered as surveyors were able to add additional sheets as needed.  
A slightly adapted questionnaire was used for children and parents. 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
 C   S    1 2 1 2 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
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4.5.3. Supporting File 2: Guidelines for the survey team 
 
Note that for clarity here is a summary of the guidelines for the social contact survey part of  
the entire survey (which included both a nasopharyngeal carriage survey, with nasopharyngeal 
sampling procedures, collection and transport of specimens etc.) 
 
The field coordinator will call the Village Health Teams to ensure their help for data collection 
during the day of the survey (which will take place 48h later) in the village. VHTs will be told 
that they will receive incentives to participate in the survey. They will be in charge to inform the 
heads of the selected households in the village/ cluster that the survey teams will visit their 
household two days later and that they should try to remember their social encounters during 
the 24 hours preceding the survey day. For households for which a telephone number is 
available, the head of household will be also directly contacted by the study coordinator to 
notify them of the survey team visit two days later. 
 
The teamss will be divided in two groups of three and two teams (A + B + C and D+E) . The 
teams will go by motorbike to visit the selected villages of the day. Teams will visit 10 
households per day in one same village, and D and E will visit 15 households per day.  Fewer 
households need to be visited by teams A, B and C as they will visit villages located further 
away and/or more sparsely populated whereas teams D and E will visit villages that are easier to 
access and survey. 
 
The list of households to be visited by village/cluster, including names of the head of 
households, will be available. A household is defined as people who are sleeping under the 
same roof and sharing the same meal on a daily basis. No matter the age of the household 
members or the relation between the members. 
 
Selection of households 
 
The nurse and the VHT will introduce the team to the household head or to another adult 
member of the family (i.e. anyone aged 18 years or older) in their absence. If either no adult or 
nobody is present in the household at the time of the visit, the team will move to the next 
household on their list and will come back to the earlier household later during the day.  
 
If the head of the household or the participant refuses to participate in the survey, or if 
swabbing is contra-indicated, the household will be replaced by another household from a 
replacement list provided (see list of households form).  
 
 At 6pm the activities in the field will stop. Teams will then assess the number of households 
that were not available to visit and feed this information back to the field coordinator . The field 
coordinator will then call the household heads of the households that were missed to inform 
them again about the survey and tell them that teams will come to visit them again on the 
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Saturday of the same week. If the head of the household tells the field coordinator that no one 
will be present on the Saturday, or if the head of the household cannot be reached by 
telephone, those households will be replaced from a random list(see list of households form) , 
and contact will be made by the field coordinator with those replaced households. 
 
The household head will be carefully introduced to the survey purpose. Social benefit and 
confidentiality should be strongly emphasized (see information participant form). The verbal 
consent of the head of the household should be obtained. If the head of the household refuses 
to participate, teams should not insist on their participation. Teams should make a note about 
their refusal on the list of households (refusal yes/no) and continue with the next household on 
the list. 
 
Selection of participants within households 
 
 All individuals who are members of the selected households in the village/cluster will 
be eligible for study participation except if:  
1. the participant or their representative either refuses or is not able to provide 
informed consent to participate  
2. if they have head or facial injuries that would contraindicate NP swabbing. 
 
 Only one person will be selected per household. To ensure that the sample size is 
reached for each age group, the age group of the individual to select will be 
predetermined using the “age group selection for cluster form” (see age group 
selection for cluster form). If several individuals of the same required age group are 
members of the selected household, the person to be included in the survey will be 
randomly chosen.  
 
 If no one in the household is from the selected age group, the surveyors are entitled to 
include someone from another age group instead, so long as the sampling quota has 
not been reached for all other age groups from the list of households to include. 
 
 If no one can be included, the household should be replaced by another household 
from the replacement list (see list of households form). 
 
 Once the individual is selected within the household, the individual or the caregiver of a 
person less than 18 years old will be carefully introduced to the survey purpose by the 
nurse (see information participant form). 
 
 Written consent from the individual has to be obtained (see consent form over18 and 
consent formunder18). If the selected individual refuses to participate, do not insist on 
their participation. If another household member in the same age group agrees 
participation, undertake the survey with them. Otherwise, move to the next household 
on the list. 
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 When the selected member of the household or their caregiver has given written 
consent to participate in the survey the interviewer will take the GPS coordinates of the 
household (see SOP GPS coordinates). 
 
Contact survey questionnaire 
1. General comments 
 
 You (the interviewer) will have to complete the contact survey questionnaire for the 
individuals marked with a cross in the age group selection for cluster form. 
 
 There are three versions of the questionnaire, each of which are adapted to particular 
age groups: <5y olds, 5-14y olds and ≥15y olds. 
 
 Each team will carry one example of each questionnaire in Ruyankole. The interview will 
be carried out in Ruyankole, but questionnaires should be completed in English. The 
interviewer will conduct the interviews, and the study nurse will record the information 
on the English questionnaire. 
 
 For children <5 years of age, parents/guardians will be interviewed on their behalf. Use 
the appropriate questionnaire for this. When asking questions about their child, replace 
‘your child’ with the child’s name 
 
 Any information for the interviewer or any question that can be filled in directly be the 
interviewer without the help of the interviewee (e.g. date, sex of the interviewee) are 
shown in italics between squared brackets on the questionnaire 
 
 For questions with multiple choices, please circle the appropriate response. In case of 
mistake, strike through the answer and circle the correct one, with a little ‘V’ sign next 
to it to notify the change, as shown here below 
 
 
 
  Write the page number on the bottom right corner of each page of the questionnaire, 
as you go along 
 
 For any numbers (e.g. participant’s age, dates), fill all boxes in. In case of a single digit 
number when a two-digit space is provided, write a zero in the first box (as shown 
below) 
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 During the interview you will ask the study participants to list their household contacts 
and their social encounters in the various settings where they spent their time during 
the previous day. As the number of such contacts and the number of places visited 
during a 24 hour period varies between individuals, the questionnaire comprises of 
tables (each row corresponding to one social contact in a particular setting) which can 
be extended if needs be just by adding extra pages to the questionnaire. Do not forget 
to add page numbers to the extra pages inserted. 
 
 
 
2. Part one: Socio-Demographic Characteristics 
 
 You will first explain the purpose of the survey and define what is meant by social 
contacts (including close physical and nonphysical contact and casual contact). This will 
have to be repeated during the interview when asking about the type of social 
encounters over a 24 hour period. 
 
 You will then write the individual ID on the top left corner of each page of the 
questionnaire. The individual ID will also be used to label household (HH) contacts and 
other social contacts, where the first 4 digits correspond to the individual ID and the 
following digits to the contact-specific ID. 
 
 The “surveyed day” refers to the day for which people are being asked to recall their 
social encounters. For example, if the survey takes place on a Monday at 10 am, the 
participants will be asked to recall their contacts between morning and evening of 
previous day (Sunday). The ‘surveyed day’ will thus be the Sunday. 
 
 The first part includes questions about the individual’s daily activity, their household 
size and structure, and contact with animals. Please go through each question in the 
same order than on the questionnaire.  
 
 Question 4 asks to list all household members and their age, sex and the relationship of 
the study participants with them (sibling, parent etc). It is advisable to list each 
household member’s name in the first column on the left hand side of the table, to 
make household contact identification easier later in the questionnaire. 
 
3. Part two: Settings 
 
  First explain to the participants what is meant by the previous day: from wake up to 
sleep.   
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 You will be asked to enter the number of the village/town visited based on a 
predefined list of settings (see geographic area coding form) 
 
 Promptpeople to remember all the settings they went to by starting in the morning and 
then moving through their day to the evening. 
 
4. Part tree: Contacts 
 
 This is the longest part of the questionnaire. For each of the settings mentioned by the 
participants, you will be asked to record the number of social contacts and their 
characteristics. 
  
 First start by telling the participant how social contacts are defined 
 
 For each setting,start by writing the names or the initials of the contacts, then go 
back to each of the contacts mentioned and ask details about the characteristics of 
the contact (including type of contact, duration etc). 
 
 
 The first setting will always be the household. As some of the social encounters are 
likely to take place with the same individuals in different settings, for each individual 
mentioned in the first setting (i.e. the household), you will ask whether contacts with 
the listed individuals have also taken place in other settings. If yes, you will already 
note the names or initials of such individuals in the tables recording the contacts in 
those other settings. This will also ensure that there is only ONE ID PER INDIVIDUAL, 
even if encounters with the same person take place in different settings. Similarly, as 
you progress through the interview, for each new contact (e.g. contacts in setting 2 
that are not in setting 1), also ask whether contact was made in any other setting 
(e.g. 3, 4, 5 etc).  Please see an example here below 
 
 
 
 If the age of individuals is unknown, write down a best guess, with the letter A (i.e. 
Approximation) before the age, as displayed below 
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 For each new setting, the contact ID number of new contacts (ie. not previously 
encountered in previously listed settings) will one number above the ID number of the 
last new contact mentioned in the previous setting. See example below 
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Abstract 
Background 
Although patterns of social contacts are believed to be an important determinant of infectious 
disease transmission, there is little empirical evidence to back this up. Indeed, few studies have 
attempted to link individuals’ risk of respiratory infection with their current pattern of social 
contacts. Here we assess whether the frequency and duration of different types of social 
encounters are associated with current pneumococcal carriage and self-reported acute 
respiratory symptoms (ARS). 
 
Methods and Findings 
We conducted a survey in Uganda in 2014, in which 566 participants were asked about their 
daily social encounters and about symptoms of ARS in the last two weeks. A nasopharyngeal 
specimen was also taken from each participant.  
We found that the frequency of physical (i.e. skin-to-skin), long (≥1h) and household contacts – 
which capture some measure of close (i.e. relatively intimate) contact –, was higher among 
pneumococcal carriers than non-carriers, and among people with ARS compared to those 
without, irrespective of their age. With each additional physical encounter the age-adjusted risk 
of carriage and ARS increased by 6% (95%CI 2-9%) and 9% (1-18%) respectively. In contrast, the 
number of casual contacts (<5 minutes long) was not associated with either pneumococcal 
carriage or ARS.  A detailed analysis by age of contacts showed that the number of close 
contacts with young children (<5 years) was particularly higher among older children and adult 
carriers than non-carriers, while the higher number of contacts among people with ARS was 
more homogeneous across contacts of all ages 
 
Conclusions 
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Our findings provide key evidence that the frequency of close interpersonal contact is 
important for transmission of respiratory infections, but not that of casual contacts.  Such 
results strengthen the evidence for public health measures based upon assumptions of what 
contacts are important for transmission, and are important to improve disease prevention and 
control efforts, as well as inform research on infectious disease dynamics.  
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5.1. Introduction  
The transmission of respiratory infections is likely to depend on the frequency and age structure 
of human social contacts, as well as other factors including pre-existing immunity from prior 
infection or vaccination [1-3]. To understand the dynamics of such infections, studies to 
quantify social mixing patterns have been conducted in various settings, under the assumption 
that self-reported encounters reflect transmission probabilities of pathogens transmitted 
through close contact [2, 4-11]. Combined with disease transmission models, these data are 
increasingly being used to inform infection control policies [12, 13]. 
  
There is evidence from population-based models that self-reported social mixing patterns can 
reproduce observed aggregated data for chickenpox [14], mumps [4], parvovirus [15], influenza 
[4, 16, 17]) and whooping cough [18].  Moreover, it has been suggested that age-stratified 
social mixing patterns can capture individual influenza risk, as measured by a four-fold rise in 
neutralization titres over the course of an epidemic [17, 18]. However, as yet no study has 
directly  linked individual’s contact patterns with their risk of infection at the same point in time.  
 
To establish how social behaviour shapes individual-level infection, we explored whether the 
frequency and duration of different types of social encounters were associated with an 
individual’s risk of respiratory infection, using nasopharyngeal (NP) carriage of Streptococcus 
pneumoniae (the pneumococcus) and self-reported acute respiratory symptoms (ARS) as 
endpoints.    
 
Streptococus pneumoniae is one of the main causes of pneumonia and sepsis globally [19], 
disproportionally so in low-income settings [19-21]. Colonization of the nasopharynx is a 
precondition to disease, and the main source of human-to-human transmission. Given that 
most episodes of carriage remain asymptomatic, social behaviour is unlikely to change as a 
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result of carriage, making pneumococcal carriage a more suitable endpoint than symptomatic 
illness to explore the association between social behaviour and infection risk, given that people 
tend to limit their contacts during symptomatic illness [22].  In addition, as natural immunity to 
carriage is weak [23], pre-existing immunity is less likely to confound associations between 
disease and social contact patterns than in studies using immunizing infections as biological 
endpoint [16, 17]. 
 
Using individually matched data on carriage, ARS and contact patterns collected in a rural and 
semi-urban area of South West Uganda, we explored whether the frequency and duration of 
different types of social encounters were associated with an individual’s risk of respiratory 
infection. 
 
5.2. Methods 
 
5.2.1. Data collection 
The study was conducted in Sheema North Sub-District (Sheema district, South-West Uganda) 
between January and March 2014. Sixty clusters were randomly selected from the 215 villages 
and two small district towns (Kabwohe and Itendero) in the study area, proportionally to the 
population size of each village and town. In each cluster 11 or 12 individuals were randomly 
sampled from different households to both answer questions about their social contacts and 
their history of respiratory illness in the last two weeks, as well as having a nasopharyngeal 
swab taken.  A household was defined as the group of individuals living under the same roof 
and sharing the same kitchen on a daily basis. 
For the social contact questionnaire, participants were first asked to list all the individuals with 
whom they had a two-way conversational contact lasting for ≥5 minutes during a period of 
approximately 24 hours prior to the survey day (from wake up the previous day until wake up 
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on the survey day). Such encounters were defined as ‘ordinary contacts’. For each reported 
ordinary contact, participants (or their parent/guardian) were asked to estimate the contact’s 
age (or estimated age), how long the encounter lasted for and whether it involved skin-to-skin 
touch or utensils passed from mouth to mouth (either of those defining ‘physical contacts’). For 
very short social encounters (<5 minutes), which were defined as ‘casual contacts’ (e.g. seeing 
someone on the way, encounter in a shop etc.), participants were asked to estimate the number 
of encounters based on pre-defined categories (<10 contacts, 10-19 contacts, 20-29 contacts, 
≥30 contacts), but not to provide further details about each contact.   
Next, participants were asked about respiratory symptoms experienced in the two weeks prior 
to the survey, including any of the following: cough, runny nose, sneezing, sore throat, difficulty 
breathing. 
 
Finally, after the interview was completed, a nasopharyngeal swab was taken from each 
participant.  NP samples were collected, transported and analysed as per WHO guidelines [24]. 
NP swabs (flocked nylon swabs, COPAN, Italy) were inoculated in a skim milk tryptone-glucose-
glycerol (STGG) medium, transported in cool boxes and frozen at the research laboratory at -
20°C within 8 hours of collection. Specimens were inoculated onto a selective agar plate of 5 
mg/L gentamicin-Columbia agar with 5% sheep blood and incubated at 37°C in 5% CO2 
atmosphere overnight. Pneumococcal identification was based on optochin susceptibility 
testing of all alpha-hemolytic colonies and bile solubility testing in case of intermediate 
susceptibility to optochin.  
 
5.2.2. Statistical analysis 
We first performed descriptive analyses, with age-specific probability weights to account for 
different inclusion probabilities by age at the design stage, and adjusted for the clustering by 
village through the use of clustered ‘sandwich’ variance estimators to account for possible 
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correlation within each of the sixty clusters [25]. We explored social contact patterns within and 
between age groups through contact matrices. In such matrices we report the mean number of 
ordinary contacts of participants in age group j with contacts in age group i  ( )ijm , 
adjusted for reciprocity, as in Melegaro et al. [15].  
We then analysed whether and how the frequency distribution of contacts was associated with 
pneumococcal carriage or self-reported ARS.   
We modelled the effect of ‘ordinary’ contacts (defined as contacts ≥5 minutes long) on carriage 
or respiratory symptoms as a function of contact frequency, through a log-binomial model with 
a robust variance estimator, and inclusion probability weights by age group. We treated 
contacts as continuous variables, but assessed departure from linearity through likely ratio tests 
and model comparisons of Bayesian Information Criterion (BIC). In multivariable analysis, we 
considered for inclusion any covariate significantly associated with the outcome at P<0.10 in 
univariable analysis. Model improvement was considered for any decrease in the BIC.  Further 
details are provided in the Supporting Information.  
Next, we used the same analytical approach to assess whether carriage and ARS were 
associated with the level of self-reported ‘casual’ contacts (i.e. <5 minutes long). 
Finally, we explored differences in the social mixing matrices by status of pneumococcal 
carriage and ARS. To do so, we computed the ratio of the mean number of reported contacts 
by participants j  with contacts i  among carriers compared to non-carriers (
C
ijR ) or 
symptomatic compared to asymptomatic individuals (
R
ijR ) , such that   
C
ijC
ij N C
ij
m
R
m 
  and 
R
ijR
ij N R
ij
m
R
m 
 , where C = carriers, R = participants with ARS and N = the total number of 
participants.  Estimates were not adjusted for reciprocity given that subpopulations were not 
closed (e.g. contacts of carriers may not be carriers), and that our aim was to compare reported 
number of contacts rather than calculate a contact matrix. The uncertainty in reported values 
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and ratios was obtained through resampling techniques, drawing random samples from each 
ijm , with the number of draws equal to the study population in each age group j . Ratios and 
uncertainty around them was obtained from the ratio of bootstrapped matrices.   
The same approach as described above was used to compute the differences in ijm  with 
C C N C
ij ij ijD m m
  and 
C R N R
ij ij ijD m m
  . 
All analyses were performed in Stata 13.1 IC and R version 3.2. 
 
5.2.3. Ethics 
Approval was obtained from the Ethical review boards of the London School of Hygiene and 
Tropical Medicine, Médecins Sans Frontières, the Faculty of Medicine Research & Ethics 
Committee of the Mbarara University of Science and Technology, the Institutional Ethical 
Review Board of the MUST, and the Uganda National Council for Science and Technology.  
 
5.3. Results  
5.3.1. Study population 
Of the 687 individuals initially targeted for inclusion, 568 (83%) individuals from unique 
households responded to the survey, with data on both social contacts and carriage or ARS 
available from 566 participants. Participant’s age spanned across age groups and the sex 
distribution was reasonably balanced (58% female). The majority (98%) of children aged 6 – 15 
years attended school or college. More than a third of all adults (36%) worked in agriculture 
and 22% were homemakers/housewife. 
On average, people made seven ‘ordinary’ contacts (defined as contacts ≥5 minutes long),   
ranging from 0 to 25, the majority of which were physical (i.e. ‘skin-to-skin’ ordinary contact or 
indirect physical contact through utensils passed from mouth-to-mouth).  There was no 
evidence that the average number of contacts differed by weekday or between weekdays and 
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weekends (P=0.623).  Children aged 5-9 years reported most contacts and children <5 years the 
fewest (Figure 15). The majority of contacts made by children were physical. The proportion of 
non-physical contacts, contacts outside the household and contacts of short (<1h) duration was 
higher among teenagers and adults than younger children.  
 
The most intense mixing tended to be between individuals of the same age group (i.e. 
assortative mixing), but there was also substantial mixing between age groups. Contact from 
and with children aged <10 years involved proportionally more physical touch than contacts 
between older children and adults (Figure 16A and B). There was no difference in contact 
patterns by sex, for all types of contacts considered. 
 
Four hundred and ninety (87%) participants estimated how many casual contacts (i.e. <5 
minutes in duration) they had the day before the survey. Over a third (36%) of these reported 
10 casual contacts or more, and 11% reported more than 20 casual contacts. Among the 13% 
who did not know how many casual contacts they had, there were proportionally more children 
with over half (56%) under 10 years. 
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Figure 15: Number of reported contacts by age group and type of contact.   
 
Legend: Boxplots showing the median (horizontal line), interquartile range (boxes) and 95% confidence interval around 
the mean (whiskers). The outliers are shown as bubbles above or under the whiskers 
 
Four hundred and ninety (87%) participants estimated how many casual contacts (i.e. <5 
minutes in duration) they had the day before the survey. Over a third (36%) of these reported 
10 casual contacts or more, and 11% reported more than 20 casual contacts. Among the 13% 
who did not know how many casual contacts they had, there were proportionally more children 
with over half (56%) under 10 years.   The mean number of reported ‘ordinary’ contacts was 
higher among individuals reporting ≥10 casual contacts than those reporting fewer than 10 
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contacts (mean 8.9 vs 5.9, P<0.001), as well as among the 78 individuals who did not know how 
many casual contacts they had (mean 8.8, P<0.001).    
Figure 16: Contact matrices and prevalence of Streptococcus pneumoniae carriage and Acute 
Respiratory Symptoms (ARS), by age.  
 
Legend: Contact matrices and prevalence of S.pneumoniae carriage (Panel A) and Acute Respiratory Symptoms (Panel 
B). In panels C and D, the height of each bar corresponds to the point prevalence and the error bar represents the 95% 
Confidence Interval 
 
The prevalence of pneumococcal carriage was strongly age dependent, decreasing from 75% in 
children <5 years to 46% among 5 – 9 year olds, 17% in 10 – 19 year olds, and further 
decreasing to 8% and 7% among 20-39 years and ≥40 years old respectively (Figure 16C). 
Overall, 72 (13%) people reported having suffered from ARS in the two weeks prior to the 
survey. The prevalence of ARS varied much less with age than that of carriage (Figure 16D), 
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ranging from 20% among 5 to 9 year olds to 8% among ≥40 years old. There was no sex 
difference in the prevalence of carriage (age-adjusted RR for males 0.97, P=0.814) or ARS (age-
adjusted RR for males 1.40, P=0.134).   
 
The Table 7 below provides the crude risk ratios by age for prevalence of carriage, and acute 
respiratory symptoms (ARS).   
Table 7: Crude risk ratios by age for prevalence of carriage, and acute respiratory symptoms (ARS).   
Age group Prevalence  Risk ratio (95%CI) 
NP Carriage 
<5 years 75.1% 1.00 
5 – 9 years 45.9% 0.61 (0.48 ; 0.77) 
10 – 19 years 19.3% 0.24 (0.16 ; 0.37) 
20 – 39 years 6.1% 0.08 (0.04 ; 0.15) 
≥ 40 years 4.8% 0.06 (0.03 ; 0.13) 
ARS 
<5 years 17.4% 1.00 
5 – 9 years 20.3% 1.16 (0.63 ; 2.12) 
10 – 19 years 10.3% 0.68 (0.32 ; 1.46) 
20 – 39 years 9.9% 0.56 (0.28 ; 1.15) 
≥ 40 years 7.5% 0.43 (0.22 ; 0.85) 
 
Carriage and ARS were poorly correlated (Pearson’s correlation coefficient R=0.09, ranging from 
-0.08 to 0.29 by age group), and there was no evidence that the risk of ARS was higher among 
carriers compared to non-carriers (age-adjusted relative risk (RR) 1.06 (95%CI 0.85 – 1.33)). 
 
5.3.2. Social contacts as a risk for pneumococcal carriage or ARS 
Overall, the mean number of contacts among carriers was significantly higher than non-carriers, 
and this observation was consistent across age groups, although most differences were not 
statistically significant due to small numbers (Figure 17). In particular, carriers had more physical 
contacts (Figure 17A).  This pattern was also consistent for ARS, with the exception of 5 – 9 year 
olds in whom the mean number of contacts among individuals with ARS was lower for physical 
contacts (Figure 17B).   
 
 185 
 
In univariable analysis, the risk of carriage increased with all contacts, household contacts, 
contacts ≥1 hour long and physical contacts. The latter had the largest effect size, with a 13% 
increased risk for each additional contact reported by participants (Table 8). Physical contacts 
and contacts ≥1 hour were strongly correlated (R = 0.76), particularly among children <5 years 
(R=0.85) and children aged 5 – 9 years (R=0.87), hence their effect could not be disentangled, 
whereas the correlation between physical contacts and household contacts was moderate 
(R=0.61, ranging from 0.47 to 0.70 between age groups). 
 
After age adjustment, physical contacts or contacts ≥1 hour remained most significantly 
associated with carriage, with a 6% increased risk (95%CI 2 – 10%) for each unit increase in the 
number of reported contacts (Table 8). We found good evidence that the number of household 
contacts increased the risk as well (Table 8). There was no confounding effect by other 
covariates and models were therefore only adjusted for age (Supporting Information).  
 
After age adjustment, physical contacts or contacts ≥1 hour remained most significantly 
associated with carriage, with a 6% increased risk (95%CI 2 – 10%) for each unit increase in the 
number of reported contacts (Table 8). We found good evidence that the number of household 
contacts increased the risk as well (Table 8). There was no confounding effect by other 
covariates and models were therefore only adjusted for age (Supporting Information).  
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Figure 17: Mean number of contacts by age group and nasopharyngeal carriage status (Panel A) or 
ARS status (Panel B) 
 
Legend: The graph shows the mean number of contacts among carriers (red, panel A), non-carriers (blue, panel A), 
individuals reporting ARS (red, panel B), and individuals without ARS (blue, panel B). This is shown by age group and for 
all contacts, physical contacts, household contacts and contacts lasting over 1 hour.  
 
 
An increase in physical, household and long (≥ 1h) contacts, were also associated with an 
increased risk of ARS in univariable analysis. There was little or no evidence of a confounding 
effect of age, given the more constant prevalence of ARS across age groups (Table 8). Unlike 
pneumococcal carriage, however, the relative risk was more constant across types of contacts, 
and household contacts rather than physical contacts were most strongly associated with a risk 
for ARS, with a risk increase of 9% (1 – 18%) for each additional reported contact.  
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Table 8: Relative risk of S.pneumoniae carriage and ARS by frequency of contact 
RR in bold:  Associations significant at P<0.05. RR= Risk Ratio. CI= Confidence Interval. NP+= pneumococcal carrier, NP 
- = non-carrier, ARS+ = with ARS, ARS- = without ARS 
 
Next, we analysed whether the number of casual contacts (i.e. contacts lasting < 5 minutes) was 
associated with either pneumococcal carriage or ARS. We found no evidence that the 
prevalence of pneumococcal carriage or the risk of ARS were associated with reporting higher 
levels of casual contacts, as shown in Table 9.  Given the small numbers of individuals reporting 
≥30 casual contacts, we pooled the 56 individuals reporting ≥20 casual contacts into one 
category. 
 
In univariable analysis the risk of pneumococcal carriage was higher in the group of  78 
participants who did not know how many casual contacts they may have had. This was due to 
the higher proportion of children <5 years and aged 5 – 9 years in that group, however, after 
age-adjustment, there was no evidence that the risk of pneumococcal carriage was higher in 
that group. Similarly, a higher number of casual contacts was associated with increased risk of 
ARS, and with no confounding effect of age or other variables on the estimates. 
Contact types Mean contacts Crude RR  Age -adjusted RR  
  (95%CI) (95%CI) 
NP carriage NP+ NP-   
All contacts 8.09  7.53 1.04 (1.00; 1.07) 1.03 (1.00; 1.07) 
Physical contacts  6.83 6.09 1.13 (1.09; 1.17) 1.06 (1.02; 1.09) 
Non-physical contacts 1.25 1.43 0.78 (0.72; 0.86) 0.97 (0.91; 1.05) 
Household contacts 5.64 5.31 1.09 (1.03; 1.14) 1.04 (0.99 ; 1.10) 
Non-household contacts 2.22 2.45 0.98 (0.93; 1.04) 1.03 (0.98; 1.09) 
Contacts≥ 1hour 7.50 6.56 1.08 (1.05; 1.12) 1.06 (1.02; 1.10) 
Contacts <1h 2.38 2.62 0.81 (0.73; 0.92) 0.94 (0.85; 1.03) 
ARS ARS+ ARS-   
All contacts 8.18 7.63 1.07 (1.02; 1.12) 1.07 (1.02; 1.13) 
Physical contacts  6.10 6.26 1.09 (1.03; 1.15) 1.07 (1.00; 1.14) 
Non-physical contacts 2.07 1.36 1.00 (0.89; 1.10) 1.06 (0.95; 1.18) 
Household contacts 5.70 5.31 1.10 (1.02; 1.19) 1.09 (1.01; 1.18) 
Non-household contacts 2.47 2.31 1.04 (0.98; 1.11) 1.05 (0.98; 1.13) 
Contacts ≥ 1hour 7.33 6.74 1.07 (1.01; 1.13) 1.07 (1.00; 1.14) 
Contacts <1 hour 3.14 2.58 1.05 (0.96; 1.15) 1.08 (0.99; 1.18) 
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We found no confounding effect on casual contacts on the relative risk of carriage or ARS as a 
function of the frequency of reported ‘ordinary’ contacts. Finally, we explored the characteristics 
of age-specific mixing patterns by ARS or carriage status in greater detail, with a focus on 
physical contacts and household contacts. 
Table 9: Relative risk (RR) of pneumococcal carriage and ARS by level of reported number of daily 
casual contacts 
  Pneumococcal carriage Acute Respiratory Symptoms (ARS) 
Number 
of casual 
contacts 
N Crude RR  
(95%CI) 
Age-adjusted 
RR  
(95%CI) 
Crude RR 
(95%CI) 
Age-adjusted RR 
(95%CI) 
  (95% CI) (95% CI) (95% CI) (95% CI) 
 0 – 9  315 ref ref ref ref 
10 – 19 119 0.82 (0.52; 1.27) 0.80 (0.55; 1.75) 1.02 (0.65; 1.49) 1.00 (0.65; 1.54) 
≥20 56 0.81 (0.44; 1.49) 1.19 (0.70; 2.04) 0.51 (0.21; 1.27) 0.56 (0.22; 1.39) 
Not 
known 
76 1.52 (1.00; 2.31) 1.07 (0.77; 1.49) 1.01 (0.45; 2.28) 0.88 (0.38; 2.00) 
In bold: Associations significant at P<0.05. RR= Risk Ratio. CI= Confidence Interval 
 
We computed the ratio of the mean number of contacts within and between age groups 
among carriers compared to non-carriers, and among individuals with ARS compared to those 
without. The average number of physical encounters within and between age groups tended to 
be higher for carriers than non-carriers in most instances, albeit with substantial uncertainty 
owing to small numbers (Figure 18).  Carriers reported more contacts with children < 5 years, 
and particularly adult carriers who reported on average more than twice as many physical 
contacts with children under five than non-carriers (Figure 18).  
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Figure 18:  Ratio of the mean reported number of physical contacts between pneumococcal carriers 
and non-carries (panel A) and individuals with ARS compared to those without ARS 
(Panel B).  
 
Legend: The numbers represent the point estimate of the ratio and in brackets the 95% confidence bounds. Blue are 
cells with a point estimate <1 and in red with point estimates >1. 
 
Given that most of such contacts occurred within the household, the effect of physical and 
household contacts with children <5 years was indistinguishable, whereas for older age groups, 
the association with physical contact was stronger than that with household contacts (Figure 
18).  
 
Similar findings were seen for ARS, however, unlike for pneumococcal carriage, symptomatic 
adults did not have more contacts with young children than asymptomatic ones. Results based 
on absolute differences in the mean number of contacts rather than relative means are 
displayed in Figure S8 (Supporting Information), showing the similar associations than the 
reported ratios, but providing a quantified difference in mean number of contacts instead. 
5.4. Discussion  
Our study provided a unique opportunity to explore whether and how social contact patterns 
are associated with someone’s risk of acute respiratory infection in a mostly rural East African 
setting. Our results show that people who tend to have more frequent close contacts are more 
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likely to be pneumococcal carriers or to report acute respiratory symptoms, irrespective of their 
age. In contrast, we found that less intimate or short casual contacts were not associated with 
someone’s infection risk, suggesting that social contacts important for transmission are close 
interpersonal encounters. 
 
 Existing evidence on the association between contact patterns and risk of infection is mostly 
‘ecological’, with very few studies based on individual-level data. Using data of influenza 
A/H1N1 seroconversion in Hong Kong coupled to social contact data in the same population, 
Kwok et al. [16] showed that age rather than social contact patterns were the main driver of the 
individual risk of infection in that setting, and further work by Kucharski et al. [17] on the same 
data further supported the finding that someone’s risk of infection is related to the average 
mixing pattern within their age group rather than their reported number of contacts. However, 
the validation of the ‘social contact hypothesis’ with such data remains difficult, due to 
challenges in accounting for pre-existing levels of protective immunity in the population, 
assumptions around stability of behaviour between the capture of social contact data and that 
of infection (or disease) endpoints,  as well as challenges in capturing influenza infection events 
based on serological data only [16, 17]. 
 
Studying nasopharyngeal carriage of S.pneumoniae as the main biological endpoint enabled us 
to address many of these issues, for several reasons. First, the high prevalence of carriage 
provided the statistical power required to study individually-matched acquisition risk in our 
study. Second, a person’s individual behaviour is unlikely to be affected by carriage given that 
the vast majority of episodes remain asymptomatic, in contrast to symptomatic respiratory 
infections during which social behaviour might change as a result of illness [22].  Most carriage 
episodes in our study were asymptomatic, and our decision to assess the risk for ARS and NP 
carriage separately stemmed from that observation. In addition, given that duration of carriage 
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is relatively short – at most 3 months in young children and no longer than a few weeks in 
adults [26] – , and as no difference in our survey was observed in the mean number of contacts 
between days of the weeks and between survey weeks, it is reasonable to assume that contact 
patterns measured on a given day reflect contact patterns around the time of pneumococcal 
acquisition.   Finally,  as colonisation results in weak protective immune responses and limited 
reduction in serotype-specific reacquisition risk [23, 27], and with over 90 circulating serotypes, 
natural acquired immunity is unlikely to distort the association between carriage and social 
contact patterns, unlike immunizing infection for which individuals with more frequent risk of 
infection due to their social contact patterns are also more likely to be immune.   
 
In contrast, self-reported respiratory symptoms may be influenced by factors such as behaviour 
change in illness [22] or immunity.  The definition itself also presents limitations; although 
respiratory viruses such as the Respiratory Syncytial Virus (RSV), adenovirus, parainfluenza and 
influenza viruses are likely to account for a large proportion of ARS cases [28], the definition 
was used as a non-specific proxy for acute respiratory infection and may have captured other 
infectious and non-infectious conditions. Notwithstanding such caveats, results for ARS were 
similar to those for nasopharyngeal carriage, but also showed a more consistent association 
with all types of non-casual contacts, rather than physical or contacts of long duration only. This 
suggests that the definition may have mostly captured acute infections, and also provides 
further evidence that the number of close interpersonal contacts, and particularly household 
contacts, plays a role in the transmission of acute respiratory pathogens.  
One of the striking features of our analysis of the relative number of mean contacts between 
age groups is that adults colonised with S.pneumoniae reported more than twice as many close 
contacts with children under five than non-carriers, and to a lesser extent also more 
proportionally more contact with adults. The higher number of contacts with children is in 
agreement with observational and modelling studies showing that pneumococcal carriage risk 
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increases with household size and with the number of children <5 years in the household [29]. 
It also supports the finding that carriage acquisition in adults occurs mostly within the 
household as a result of contact with young children who are drivers of infection [30].  In 
contrast, however, we found that adults with ARS reported an equal or lower number of 
contacts with children <5 years than asymptomatic adults.  This likely reflects the 
epidemiological differences between carriage and ARS, given the very high prevalence of 
carriage among <5 year olds and the much less marked difference in age-specific prevalence of 
ARS across age groups, in addition to other potential factors such as acquired immunity among 
adults more frequently exposed to very young children.  Some of the specific details of the 
contact patterns and differences between S.pneumoniae and ARS are harder to interpret, due in 
part to wide statistical uncertainty, particularly among adults in whom the number of carriers or 
symptomatic individuals is small. However, overall the results from our analysis support the 
general finding that increased close contacts are associated with higher risk of ARS or 
pneumococcal carriage.  
 
There is still much debate about how respiratory pathogens are transmitted from person to 
person; whether through close direct or indirect physical contact, through large droplet 
transmission at close range (<1 meter), or through aerosolized particles floating over longer 
distances, particularly in poorly ventilated indoor settings [31, 32]. It is likely that many 
pathogens can be transmitted through a combination of these routes. Yet the contribution of 
each mechanism remains uncertain [31, 32]. It is generally assumed that the main transmission 
route of S.pneumoniae is through direct contact [33], as well as indirectly through shared 
glasses or bottles [34]. Analogously, for other colonising bacteria such as N.meningitidis, close 
contact and intimate kissing are known risk factors among teenagers and young adults [35].  
Similarly, it is believed that influenza and other respiratory viruses are primarily transmitted 
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through direct contact or contact with large droplet transmission at close range rather than 
aerosolized particles [31].   
 
Although our objective was not to demonstrate transmission, our findings strongly support that 
direct close interpersonal contact is an important mode of transmission for pathogenic bacteria 
of the nasopharynx as well as respiratory viruses, and strengthens the scientific evidence for 
public health measures based upon these assumptions, such as hand washing campaigns or 
chemoprophylaxis of close contacts of cases of meningococcal meningitis to name a few. The 
strong association of ARS with household and other close contacts, independently from 
physical touch, might suggest that other mechanisms such as indirect transmission through 
fomites or aerosol transmission may play a role. Elucidating the contribution of such factors in 
this context would be an important question for future research. 
 
Our findings have also several implications for infectious disease research. Contact structures 
are central to transmission models, and appropriate assumptions about what type of contact 
drives infectious disease transmission are essential. Our results suggest that the 
parameterisation of transmission models of S.pneumoniae and similar pathogens using mixing 
matrices based on physical or another measure of close interpersonal contact would more likely 
capture relevant contact patterns than those based on any type of social encounter.  This has 
also implications for the design of contact studies, particularly in low-income settings given the 
scarcity of published data currently available and the need to collect additional data from many 
more settings [7, 8]. In contrast to diary-based approaches that have been used by many [2, 4, 
7, 8], the study design here was relatively simple and only involved a single face-to-face 
interview. A drawback of such retrospective approach is the lack of detailed information about 
very short (i.e. ‘casual’) contacts, as such information was deemed unreliable – and this is further 
supported by evidence that short contacts tend to be inconsistently recorded even in 
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prospective diary-based approached [1]. However, assuming that short contacts do not account 
for much of the transmission, as our study suggests, a more simple retrospective design is a 
potential attractive option in other settings where contact data are lacking, and in which data 
collection through more comprehensive diary-based approaches may be difficult to implement. 
 
There are some additional limitations to our study. We were unable to explore other potential 
confounding factors, such as bed share, ventilation, indoor smoke or hand washing [36], and 
the contribution of such factors should be explored further. Among other important factors, it is 
worth mentioning that our results were not impacted by pneumococcal vaccination, as the 
vaccine had not been introduced in the study area at the time.  Moreover, it remains unclear to 
what extent our results can be generalised to any acute respiratory infection. For example, 
factors such as ventilation and airflow may be of particular importance for aerosolized 
transmission of pathogens such as mycobacteria [7], compared to influenza or S.pneumoniae 
[31, 32], and whether household or physical contacts reflect contact patterns important for 
aerosolized transmission remains uncertain [7]. Finally, while we found a strong association at 
the individual level, our study does not demonstrate causality.  
 
However, in the absence of detailed longitudinal data on acquisition events between every 
single contact —which would be challenging and possibly unrealistic to obtain— our findings 
provide consistent evidence of a ‘dose-response’ association at the individual level between 
close social encounters and acquisition risk for respiratory pathogens, and therefore provides 
robust support both for the social contact hypothesis, and for research and policy work based 
upon this hypothesis. 
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5.5. Supporting Information 
5.5.1. Additional Figures 
Figure S8: Difference in the mean number of physical contact between pneumococcal carriers and 
non-carriers (Panel A) and between individuals suffering and not suffering from 
respiratory symptoms (Panel B) 
 
Legend: Matrices of the mean difference between the mean number of contacts among pneumococcal carriers and 
non-carriers (panel A), and individuals with ARS compared to non-ARS (panel B). The numbers represent the point 
estimate and the lower and upper bound of the 95% credible interval are shown inside the brackets. 
 
5.5.2. Analysis and model comparison 
5.5.2.1. Univariable analysis 
In univariable analysis we explored the risk of pneumococcal carriage or ARS as a function of 
the following covariates: age, sex, and all types of ordinary contacts (all, physical (skin-to-skin), 
household, long (≥1h), non-physical, non-household, short (<1h)). We used a log-binomial 
regression model through a generalized linear model with a robust variance estimator, and 
inclusion probability weights by age group to capture the differences in inclusion by age at the 
sampling stage. 
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We considered contacts as linear predictors, but tested departure from linearity based on BIC 
values and likelihood ratio tests comparing models with contacts as linear variables and as 
categorical variables. On that basis there was no evidence of departure from linearity (BIC larger 
in all cases and P-value of likelihood ratio tests >P=0.10) 
 
5.5.3. Multivariable analysis 
5.5.3.1. Pneumococcal carriage 
Age was first added to each model as an a priori confounding variable. Age-adjustment 
improved all models of pneumococcal risk as a function of all other covariates, leading to 
substantial changes in measures of effect (based on a lower BIC and a likelihood ratio test P-
value <0.05).  
 
We modelled the association between age-adjusted covariates and carriage through the 
following models: 0 1 2log( )AXP Age X      , where A is Age and X was the covariate of 
interest (sex, or any type of ordinary contact (all, physical, etc.)) 
Only all contacts, physical contacts, household contacts and long (≥ 1h) contacts were 
associated with carriage after age adjustment.  There was a strong correlation between physical 
contacts and contacts lasting more than one hour (Pearon’s correlation coefficient R=0.76), 
particularly in children <10 years of age (R>0.85), hence those covariates were not added 
together in a model due to collinearity.  For household contacts correlation was moderate with 
physical contacts (R=0.61) or long contacts (R=0.64) and we therefore explored models 
including both physical contacts and household contacts, as well as contacts ≥1h and 
household contacts, in order to explore their potential confounding effect.   
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Table S4 provides the BIC values for the different models tested for the association with 
physical, household and long contacts. We found that model included a single type of contact 
as covariate performed better than those including two or more, hence only age-adjusted 
estimates were presented in the main paper. 
Table S4: Comparing the BIC for models of pneumococcal carriage risk as a function of physical, 
household and long contact. 
Model [covariates] BIC 
0 1log( )PP P     [P=Physical contacts] -3218 
0 1log( )HP H     [H=Household contacts] -3199 
0 1log( )LP L     [L=Long (≥1h) contacts] -3202 
0 1 2log( )APP A P       [A=Age, Physical contacts] -3312 
0 1 2log( )APP A H       [Age, Household contacts] -3310 
0 1 2log( )APP A L       [Age, Long (≥1h) contacts] -3312 
0 1 2 3log( )APHP A P H         [Age, Physical, Long] -3306 
0 1 2 3log( )ALHP A L H         [Age, Long, Household] -3306 
In bold: best models 
 
5.5.3.2. ARS 
The same approach as for pneumococcal carriage was taken.  Again, age was considered as the 
main a priori confounding factor, given the differences in both carriage frequency and ARS 
prevalence by age.  However, there was no improvement in model performance (no change or 
increase in BIC and non-significant likelihood ratio test) and little or no change in point 
estimates. Adding other variables to the model resulted in worse model performance. 
 
 Table S5 shows the different models explored for covariates associated with ARS at P<0.05 in 
univariable analysis (Physical contacts, household contacts, and contacts >1h). 
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Table S5: Models explored for ARS 
Model [covariates] BIC 
0 1log( )PP P     [P=Physical contacts] -3288 
0 1log( )HP H     [H=Household contacts] -3286 
0 1log( )LP L     [L=Long (≥1h) contacts] -3286 
0 1 2log( )APP A P       [A=Age, Physical contacts] -3285 
0 1 2log( )APP A H       [Age, Household contacts] -3286 
0 1 2log( )APP A L       [Age, Long (≥1h) contacts] -3285 
0 1 2 3log( )APHP A P H         [Age, Physical, Long] -3279 
0 1 2 3log( )ALHP A L H         [Age, Long, Household] -3280 
In bold: best models 
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Abstract 
Introduction 
Catch-up campaigns (CCs) at the introduction of the pneumococcal conjugate vaccines (PCVs) 
may accelerate the impact of PCVs. However, limited vaccine supplies may delay vaccine 
introduction if additional doses are needed for such campaigns. We studied the relative impact 
of introducing PCV13 with and without catch-up campaign, and the implications of potential 
introduction delays 
 
Methods 
We used a dynamic transmission applied to the population of Nha Trang, Vietnam. Four 
strategies were considered: routine vaccination (RV) only, and RV alongside catch-up 
campaigns (CCs) among <1y olds (CC1), <2y olds (CC2) and <5y olds (CC5).  The model was 
parameterised with data on contact rates from Nha Trang, and was fitted to local carriage data. 
Post-PCV predictions were based on best estimates of parameters governing post-PCV 
dynamics, including serotype competition, vaccine efficacy and duration of protection. 
 
Results 
Our model predicts elimination of vaccine-type (VT) carriage across all age groups within 10 
years of introduction in all scenarios with near-complete replacement by non-VT.  Most of the 
benefit of CCs is predicted to occur within the first 3 years after introduction, with the highest 
impact at one year, when IPD incidence is predicted to be 11% (95%CrI 9 – 14%) lower than RV 
with CC1, 25% (21 – 30 %) lower with CC2 and 38% (32 – 46%) lower with CC5. 
 
However, CCs would only prevent more cases of IPD insofar as such campaigns do not delay 
introduction by more than 31 (95%CrI 30 – 32) weeks with CC1, 58 (53 – 63) weeks with CC2 
and 89 (78 – 101) weeks for CC5 
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Conclusion 
CCs are predicted to offer a substantial additional reduction in pneumococcal disease burden 
over RV alone, if their implementation does not result in much introduction delay. Those 
findings are important to help guide vaccine introduction in countries that have not yet 
introduced PCV, particularly in Asia. 
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6.1. Introduction 
 
Disease due to Streptococcus pneumoniae (the pneumococcus) is a leading cause of morbidity 
and mortality worldwide, disproportionally so in resource-poor settings [1-3]. 
 
Ten- and 13-valent pneumococcal conjugate vaccines (PCV10 and PCV13), which cover 10 and 
13 of 94 known serotypes [4],  are steadily being introduced into the routine immunization 
programmes of many low and lower-middle income countries with the support from Gavi, the 
Vaccine Alliance.  In 2015, 50 out of 73 countries eligible for Gavi support have introduced the 
vaccine, and eight additional countries have been approved for introduction and are expected 
to introduce PCV within the next two years [5]. In 2012 Pakistan was the first Asian country to 
introduce PCV for routine use, followed by Nepal, Cambodia and Lao PDR [5]. However, PCV 
has not been introduced into the routine childhood immunisation programme in most of Asia, 
including Vietnam, and globally, the vaccination coverage of PCV remains low, at 25% [6]. 
 
The WHO recommends introducing PCV into childhood immunisation programmes alongside a 
catch-up campaign  (CC) among older children [7].  The aim of such campaign is to provide 
direct protection to age groups at particular risk of pneumococcal disease, as well as to 
accelerate the population impact of the vaccine in a timelier fashion through enhanced herd 
protection [8].  
 
However, the magnitude of the additional impact of different CCs over RV remains unclear.  
Moreover, CCs have so far not been conducted in most Gavi-supported countries over concerns 
that they would lead to vaccine introduction delays given limited vaccine supplies [5].  
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We explored the differential impact on carriage and invasive disease of catch-up campaigns 
targeting various age groups, through a dynamic compartmental model of disease 
transmission, and we explored the possible impact of vaccine introduction delay.   
 
6.2. Methods 
 
The model was applied to the population of Nha Trang (~360,000 inhabitants), an urban and 
semi-rural area in south-central Vietnam.   
 
6.2.1.  Data 
6.2.1.1. Nasopharyngeal carriage 
Two surveys were conducted among children aged 0 – 59 months randomly drawn from the 
population census, with 350 children included in January 2008 [9] and another 350 children in 
July 2008 [10].  
 
Samples were processed and cultured as per WHO recommendations [11]. Serotyping was done 
using polymerase chain reaction with 29 specific primer pairs, and did not differentiate between 
6A and 6B serotypes [9].  Given that both antigens are included in PCV13 but that PCV10 does 
not include 6A, we decided to implement our model for PCV13. 
 
The carriage prevalence (and its uncertainty) of VT and NVT among 5-17 year olds and adults 
(≥18 years) was estimated based on the prevalence and serotype distribution in children <5 
years of age, using a random effect meta-regression model [12].   
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6.2.1.2. Social mixing patterns 
We derived the age-specific contact patterns from a survey conducted in the same area in 2010.  
Study participants were interviewed about their contact on a given day, similarly to the 
approach undertaken in Uganda as described in Research Paper 3 of the thesis. Participants 
were first asked to fill in some background information, and were then asked to remember their 
social encounter occurring in the following 24 hours, before being interviewed about those 
shortly after. As for other social contact studies, the questionnaire recorded information on the 
location and type of contacts, including whether or not contacts included physical (i.e. skin-to-
skin touch).  
 
In the study, household were randomly selected from all non-touristic urban and semi-rural 
areas of Nha Trang (i.e. matching the areas where the nasopharyngeal carriage was 
undertaken)., and one person per household was included in the study. The sample size was 
based on POLYMOD calculations [13), but was higher to account for urban/rural differences.  
 
The corresponding mixing matrix used in the model was derived as in Melegaro et al. [14].  We 
parameterised our model based on physical (skin-to-skin) contacts only, given that 
S.pneumoniae is generally assumed to be transmitted through close interpersonal contact [15], 
in agreement with Research paper 4 of this thesis.  
 
Ethics approval for both the contact and nasopharyngeal surveys was granted by the 
institutional review board of the London School of Hygiene and Tropical Medicine and the 
Ethics Commission of National Institute of Hygiene and Epidemiology, Hanoi and the Nagasaki 
University. A total of 2002 individuals were included in the study.  
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The mean number of contacts per age group is shown in Figure 19 here below for physical 
contacts.  Further results can be obtained on request. 
 
Figure 19: Mean number for physical contacts between age groups of study participants 
 
 
6.2.2. Model structure 
We built an age-structured deterministic Susceptible-Infected-Susceptible transmission model 
of carriage acquisition and clearance, in which we modelled VT jointly and separately from NVT, 
but allowed for co-colonisation, as in previous models [16]. Details about the model structure 
and model equations can be found in the Supporting Information (Part 1). 
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The model comprised of three levels of vaccine-induced immunity; (1) no protection, (2) partial 
protection and (3) full protection. The latter refers to the efficacy and duration of protection 
conferred after completion of the infant schedule (i.e. 2 infant doses and a booster at 12 
months (‘2+1’ schedule)) or the completion of a catch-up programme in older children (2 doses 
in <18 months and 1 dose in ≥18 months). Partial protection was gained form two primary 
infant doses, or after the first catch-up dose in children aged 12 - 17 months.  The difference 
between full and partial protection relied in the magnitude of vaccine efficacy against carriage 
( )CVE  and in the duration of protection. 
 
We applied the model to a population of 81 annual age cohorts (0 to 80 years) divided into 52 
weekly age bands of 100 individuals. In the calculation of the force of infection the population 
figure was adjusted to represent the actual population, based on census data.  
 
6.2.3. Model fitting 
We fitted the model to pre-vaccination nasopharyngeal carriage data using a Markov Chain 
Monte-Carlo (MCMC) algorithm, and estimating the age-specific probability of effective 
transmission in the absence of PCV.  For each unique posterior sample we simulated up to 15 
years after vaccine introduction.  
 
The model was fitted the model to pre-vaccination nasopharyngeal carriage data using an 
MCMC algorithm. Estimates of the age-specific probability of effective transmission, which were 
obtained from the contact and carriage data were updated in the MCMC. Fitting was performed 
using a Poisson log likelihood, as follows: 
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, where  is the modelled number of VT carriers in age group a,  is the observed number 
of VT carriers in age group a,  is the modelled number of NVT carriers in age group a, 
 is the observed number of NVT in age group a. The constant here is independent of the 
modelled number of cases.  
The MCMC was run with 100,000 iterations of the chain and for each accepted set of 
parameters the post-vaccination simulation up to 15 years after vaccine introduction was 
computed, after a burn-in of 20,000 iterations.   
Convergence of the log likelihood was first assessed visually and then with the Geweke test of 
convergence [49]. 
 
In the calculation of the log-likelihood for carriage, model estimates of VT carriage prevalence 
included VT carriers and VT-NVT co-colonization given the higher likelihood of the PCR assay 
to detect VT than NVT colonies in case of multiple colonization [9].   
 
6.2.4. Model parameters and input 
Table 9 displays the value assigned to the different parameters governing transmission and 
vaccination. Uncertainty around parameters was taken into account by sampling from their 
posterior distribution in the MCMC process.  
 
We obtained the vaccine efficacy against carriage conferring full protection ( F
CVE ) and its 
uncertainty from a meta-regression model [17].  We estimated the partial efficacy against 
carriage ( P
CVE ) as 0.78 (95% CI 0.64 – 0.92) that of 
F
CVE  through a meta-analysis of the relative 
risk of VT carriage in 2+0 schedules compared to 3+0 or 2+1 schedules, which included four 
trials and eight entry points [18-21]. Further details are provided in the Supporting Information 
Part Two. 
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We assumed an exponential decay function for the waning of vaccine efficacy, as in previous 
models [16, 22]. We fixed the average duration of protection to 6 years, which best matched the 
output of an asymptomatic meta-regression model of waning efficacy [17], and analysed the 
impact of shorter (3 years) and longer (20 years) average protection in sensitivity analyses, 
based on the 95% credible intervals (CrI) of a model of waning efficacy [17] 
Table 10: Parameters used in the model 
Parameter Value  Source* 
Competition for carriage acquisition  (CN and CV)
$
 0.1 (SD 0.01) [16, 32] 
Duration of carriage (δi)   
0 – 11 months 47.1 days [49] 
12 – 23 months 39.4 days [49] 
24 – 35 months 31.6 days [49] 
36 – 47 months 21.5 days [49] 
48 – 59 months 21.3 days [49] 
5 – 17 years 17.0 days [22, 50] 
18 years and over 18.0 days [22, 50] 
Vaccine efficacy against carriage  
Full protection (VECf) 63% (95%CrI 53 –73 %) [17] 
Partial protection (VECp) 0.78 (95%CI 0.64 – 0.92) * 
VECf 
Meta-analysis of 
[18-21] 
(Supporting 
Information Part 
Two) 
Mean duration of protection against carriage  
In fully protected (DF) 6.0 years  [17](Supporting 
Information Part 
Two) 
In partially protected (DP) 0.78 (95%CI 0.64 – 0.92) * 
DF 
Based on same 
assumptions as 
for Vaccine 
efficacy 
Vaccine efficacy against IPD (VEIPD) 0.80 (0.61 – 0.90) [51] 
Vaccine efficacy against invasiveness  (VEINV) 0.48 (0.34 – 0.65) Derived from 
estimates of [51] 
and [17]  
(Supporting 
Information Part 
Two) 
   
Mixing matrix 
 
Social contact study (Nha 
trang) 
Calculated as in 
Melegaro et al 
[14] 
$
Where 0.1 means a force of infection which is 10% that of a situation with no competition 
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The average duration of protection following particular vaccination was assumed to be 0.78 
(95%CI 0.64 – 0.92) that of a complete schedule, as for vaccine efficacy.  Details are provided in 
the Supporting Information (Part Two). 
 
In our base case model we set the vaccination coverage of both routine and catch-up strategies 
at 90%, in accordance with coverage data from Vietnam for routine immunization programmes 
and supplementary immunization activities [23].   
 
Carriage estimates were translated into estimates of invasive pneumococcal disease based on 
the propensity of VT and NVT serotypes to cause illness as a result of carriage, by age, using 
estimates (and their uncertainty) from Choi et al. [24].  
 
The impact of PCV on IPD was calculated based on VT and NVT disease propensity, as well as 
the vaccine efficacy against progression to invasive disease as a result of carriage (VEinv). The 
latter was obtained from a function linking vaccine efficacy against IPD (VEIPD) with VEC and 
VEinv, where VEIPD =1 – (1- VEc) *(1-VEinv) [25].  VEINV was calculated based  on estimates of VEIPD 
from Lucero et al. [26] and estimates of VEC from le Polain et al. [17] (Table1), as detailed in the 
Supporting Information (Part Two). Supporting Information (Part Two) also provides the details 
of the posterior estimates of the transmission parameters (i.e. the probability of transmission 
given contact) for VT and NVT, by age group, obtained in the fitting process.  
 
Given the limited data on IPD available from Nha Trang and Vietnam [27], our main analysis 
focused on the proportion reduction in IPD, rather than IPD incidence. However, we illustrated 
how the relative IPD change may translate into disease incidence based on a point estimate of 
IPD in <5y olds of 49 /100,000 as reported for Nha Trang [27]. We did not infer disease impact 
among ≥5 year olds given a lack of data. 
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To explore the impact of delayed vaccination, we assumed that for each additional week of 
delay the incidence of IPD during that time would be stable at its pre-PCV level.  
 
6.2.5. Vaccination strategies 
 
We explored four different strategies: (i) routine vaccination only (RV), with two infant doses 
and a booster dose at 12 months of age (‘2+1’), and routine vaccination with a catch-up 
campaign in (ii) <1y olds (CC1), (iii) <2y olds (CC2), and (iv) <5y olds (CC5).  
 
WHO currently recommends introducing PCV either as a three primary infant dose schedule 
(3+0) or as two primary doses with a booster at 12 months of age (2+1 schedule), with the 
choice between schedules guided by setting-specific epidemiological characteristics [7].  We 
here present the predicted impact of a 2+1 programme, given the relatively low prevalence of 
carriage in young children in Nha Trang [27]. 
 
6.2.6. Sensitivity analyses 
We ran the model for coverage levels of 50% and 70% in both routine and catch-up 
programmes, and compared the results with that of the main model (coverage 90%). We also 
explored the impact of duration of protection on our model outputs, based on lower values of 
3 years and 20 years, which span across the range of likely values (Supporting Information Part 
Three). 
 
6.2.7. Ethics 
Ethical approval for both the contact and nasopharyngeal surveys was granted by the 
institutional review board of the London School of Hygiene and Tropical Medicine and the 
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Ethics Commission of National Institute of Hygiene and Epidemiology, Hanoi and the Nagasaki 
University. 
 
6.3. Results 
 
The carriage prevalence in <5 year olds was 41% (95% CI 38 - 46%) overall, 27% (95%CI 23 - 
32%) for VT serotypes and 14% (95%CI 11 - 18%) for NVT serotypes. We estimated the carriage 
prevalence of VT in 5 – 17 year olds and in adults to be 14% (95% CrI 10 – 18%) and 3% (95%CrI 
0 – 7%) respectively, and that of NVT to be 15% (95%CrI 11 – 19%) and 3% (95%CrI 0 – 7%). The 
model fit to the carriage data is shown in Figure 20.  
 
Figure 20: Pre-PCV carriage estimates across age groups for VT (left panel) and NVT (right panel), 
based on survey (plain vertical lines) and meta-regression model (dotted vertical 
lines) estimates, and estimates from the corresponding transmission model.  
 
Legend: Dots and bars correspond to the point and 95% confidence interval for the carriage estimates from the survey 
data (plain dot and plain lines) and the meta-regression model (cross and dotted lines). The dark red and dark blue 
plain lines represent the median transmission model estimate for VT and NVT respectively, the shaded areas the 50% 
credible interval (CrI) around the median and the dotted red and blue lines the 95%CrI 
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6.3.1. Nasopharyngeal carriage 
Our model predicts elimination of VT serotypes across all age groups within 10 years of PCV 
introduction in RV, with near-complete replacement by NVT serotypes, resulting in little or no 
change in the overall carriage prevalence (Figure 21A&B), particularly in children aged >5 years 
and in adults.  CCs are predicted to reduce VT carriage more quickly through combined direct 
and indirect (i.e. herd) effects (Figures 21C&D).  
Figure 21: Predicted trends in nasopharyngeal carriage following PCV13 introduction in Nha 
Trang.  
 
Legend Figure 1: A: Predicted trends in VT, NVT and overall carriage in <5 year olds without a catch-up campaign. B: 
Predicted trends in VT, NVT, and overall carriage in ≥5 year olds in RV. C: Predicted prevalence of VT carriage in <5 year 
 220 
 
olds for each vaccination strategy. D: Predicted prevalence of VT carriage in ≥5 year olds.  In all four panels: plain line= 
median, shaded areas= 50% CrI and dotted line or whiskers= 95% CrI 
 
In children under five years the VT carriage in children is predicted to decrease by >99% within 
6 years and 7 months (95% CI 5y2m - 9 y6m) in RV, 5 years and 11 months (4y6m– 8 y10m) in 
CC1, 5 years and 1 month (3y9m – 7y10m) in CC2 and 3 yrs (2y2m–4y10m) in CC5.  Similar 
trends are predicted in older children and adults (Figures 21C and 21D). And in all scenarios 
NVT would increase proportionally to the decrease in VT. 
 
6.3.2. Invasive Pneumococcal Disease (IPD) 
Our model predicts that the decline of IPD incidence will be proportionally highest among <2 
year olds, falling to about 45% (95%CrI 33% - 57%) of its pre-PCV level and would be almost 
halved (57% (48 – 66%)) in children aged 2 – 4 years respectively (Figure 22A and 22B).   
 
Most of the benefit of catch-up campaigns over routine vaccination in children <5 years is 
predicted to occur within the first three years after PCV introduction, with no noticeable 
difference at 5 years (Figure 22C).  Our model predicts that the relative risk of IPD after CCs 
compared to RV would be lowest about 1 year after PCV introduction, with differences between 
strategies then steadily reducing thereafter until the new equilibrium is reached.  Compared to 
RV, one year after vaccine introduction the number of cases of IPD is predicted to be 11% 
(95%CrI 9 – 14%) lower with CC1, 25% (21-30%) lower with CC2 and 38% (32 – 46%) lower with 
CC5 (Fig 22C). 
 
The impact of each strategy on the cumulative proportion of cases averted in the first 3 years 
post PCV introduction, compared to no vaccination,  is illustrated in Figure 22D. 
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Figure 22: Trends in IPD following PCV introduction in children under five years of age in Nha 
Trang  
 
Legend: A: Predicted trends the cumulative annual incidence of IPD in children <2 years for each vaccination strategy 
considered, at a 90% vaccination coverage B: Predicted trends the cumulative annual incidence of IPD in children aged 
2-4 years for each vaccination strategy considered, at a 90% vaccination coverage C: Cumulative number of IPD cases 
saved for each catch up strategy compared to RV, in children <5 years of age. D: Overall cumulative number of cases 
saved for each vaccination strategy, compared to no vaccination, in the first 3 years post PCV introduction.  In all four 
panels: plain line= median, shaded areas= 50% credible intervals and dotted line or whiskers= 95% credible interval 
 
Based on an average annual incidence risk of 49 cases per 100,000 children <5 years before 
PCV introduction [27], a routine introduction of PCV would result in a total of  74 cases (95%CrI 
62 - 86) per 100,000 children <5 years averted over the first five years of programme 
implementation, considering all IPD (both VT and NVT),  and catch-up campaigns would lead to 
the prevention of an additional 13 (95%CrI 11 – 16) cases with CC1, 25 (95%CrI 21 – 30) cases 
with CC2 and 39 (95%CrI 31 – 49) cases with CC5.  
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6.3.3. Delayed PCV introduction  
We estimated the relative impact on IPD of catch-up campaigns for increasing delays. Our 
results suggest that, compared to RV, more IPD cases would be prevented in children <5 years 
insofar as PCV introduction is not delayed by more than 31 weeks (95%CI 30 – 32 weeks) for 
CC1, 58 weeks (53 – 63 weeks) for CC2 and 89 weeks (78 – 101 weeks) for CC5. Vaccination 
delays would negatively impact under 2 year olds more rapidly than 2 – 4 year old (Figure 23).  
 
6.3.4. Sensitivity analyses 
6.3.4.1. Vaccination coverage 
We explored model outputs with lower vaccination coverage in both cohort and catch-up 
immunization.  Our model predicts a lengthening of the time to near-elimination of VT 
serotypes (and hence, the time reach the new post-PCV disease equilibrium) as vaccination 
coverage lowers but a similar differential impact of catch-up campaigns compared to routine 
vaccination.  Full details are provided in the Supporting Information Part Three.   
 
6.3.4.2. Duration of protection 
A duration of protection of 3 years would increase the time to elimination of VT carriage, and 
thus prevent fewer IPD cases overall, while any average duration of protection longer than 6 
years would not change model outcomes. With a duration of 3 years the median prevalence of 
VT in <5 year olds is predicted to reach near elimination about 2 years later in RV and CC1, 1.5 
years later with CC2 and about 1 year later with CC5.  Similar differences were predicted for the 
≥5 year olds (Figure S13 in the Supporting Information Part Three). The relative impact of one 
vaccination strategy over another was predicted to be similar than with a duration of 6 years.   
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Figure 23: Impact of delayed PCV introduction with a catch-up campaign on VT carriage (panel A) and on IPD cases saved (panel B) in children under five years of age. 
 
Legend: A: <2 year olds. B: 2 – 4 year olds C: <5 years olds. The middle plain trend line corresponds to the median estimate (Green=CC1, Blue=CC2, Red=CC5), the dark shaded areas the 50% CrI and the 
light shaded areas the 95%CrI. The plain horizontal line at 1.00 represents the point below which interventions will be more favourable than a timely RV. 
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6.4. Discussion 
 
We explored the possible impact of introducing PCV13 with and without a catch-up campaign 
in Vietnam through a dynamic transmission model. Our results feed into current debates about 
introduction strategies, particularly in South-East Asia where pneumococcal disease burden is 
high [28], where many countries have not yet introduced PCV [5], and where epidemiological 
data to guide decision making remain scarce [28, 29].  Although Vietnam is Gavi-eligible and is 
expected to introduce PCV in the coming years, it has not yet been approved for introduction 
[5].  Our results provide estimates about how much catch—up campaigns would decrease 
disease burden compared to routine vaccine introduction without a campaign, for different 
scenarios. Our study also shows that although catch-up campaigns would decrease disease 
burden more rapidly across age groups, their impact would only be beneficial insofar as the 
additional supply and operational constraints of their implementation does not delay PCV 
introduction by more than about 6 months to 2 years, depending on the age cohorts targeted 
by those campaigns.  
 
The availability of data on both social mixing patterns – which are central to transmission 
models [13,30, 31] – and carriage in the same population allowed for thorough 
parameterisation of a transmission model. 
 
However, our study has a number of limitations. In the absence of post-PCV data, predictions 
were based on the best available estimates of parameters governing vaccine effects that were 
observed elsewhere [16, 17, 32], which may not fully capture the local characteristics. Given that 
serotypes differ in their pathogenicity, fitness and transmissibility [33, 34], and that vaccine 
efficacy and duration of protection differs by serotype [12], our predictions based on 
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homogeneous characteristics for the group of VT and NVT serotypes may  overlook local 
epidemiological characteristics. This uncertainty was nonetheless captured to some extent by 
sampling from the known uncertainty around those parameters [16].  Moreover, we were not 
able to assess the impact of PCV on pneumococcal pneumonia, the burden of which is much 
higher than that of IPD [35], given the lack of robust data and the challenges in the aetiological 
assessment of clinical pneumonia. Results from several large pneumonia aetiological studies 
[36] might help modelling work on the impact of PCV on pneumonia in the future. 
 
Our predictions are in line with the experience of PCV7 in Europe and North America [37-44], as 
well with post-PCV trends observed in the few studies from resource-poor settings [45, 46].  
What Kilifi has shown.  
 
The implementation of PCV in various settings has consistently shown little or no change in 
overall carriage prevalence, due to replacement effects by NVT serotypes colonising the space 
left vacant by VT in the nasopharynx, but a reduction in severe disease given the lower 
pathogenicity of the latter, in accordance with our model output. Our predictions were also 
robust to estimates of duration of protection of vaccination coverage, and thus provide useful 
estimates of the impact of introducing PCV in a semi-urban Southeast Asian setting.   
 
In situations where the number of vaccine doses available is limited, and ignoring any other 
supply side, staffing and outreach challenges that could potentially delay the implementation of 
CCs, our study can inform whether delaying the introduction of the vaccine to allow for CCs 
would potentially be beneficial, compared to a routine-only strategy.  Moreover, this model also 
provides a framework that could feed into economic evaluations to further guide decisions 
about vaccine introduction with and without campaigns.  
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The generalisability to other settings of the differential impact of CCs needs to be considered in 
light of the epidemiological and socio-demographic characteristics of Nha Trang.  In particular, 
the low prevalence of carriage and an ageing population -  with only 5% of children under the 
age of five years – likely contribute to the rapid predicted reduction of disease due to  PCV 
under all scenarios. Although similar epidemiological and demographic characteristics are 
observed in many other South(east) Asian settings  [47, 48], the differential impact of CCs and 
the establishment of herd effects in settings with a younger population and a higher carriage 
prevalence is likely to differ, and should be addressed with models applied to such settings.  
 
In conclusion, our study offers insights into the current debate about vaccination strategies 
when introducing PCV in South-East Asia. Our model suggests that catch-up campaigns have 
the potential to rapidly decrease carriage and disease across age groups, but are only offering 
added reduction in disease burden insofar their implementation results in little to no 
implementation delay.  
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6.5. Supporting Information  
 
6.5.1. Part 1: Model Structure 
We built a realistic age-structured deterministic Susceptible-Infected-Susceptible (SIS) 
transmission model of carriage acquisition and clearance, similar to Choi et al. [1].  
 
The model considers all VT serotypes jointly and separately from the group of NVT serotypes, 
but allows for VT-NVT co-colonization, thus resulting in four compartments of carriage states, 
namely susceptible, VT carriers, NVT carriers and VT-NVT co-colonized as in Choi et al. [1]. In 
this model movements from the susceptible to the VT or NVT compartments are determined by 
age-specific forces of infection for VT (λVi) and NVT (λNi) respectively, and co-colonization is 
determined by competition parameters (CN and CV), which represent the degree with which 
prior colonization reduces the likelihood of co-colonization. Age-specific recovery rates (ri) 
determine the speed with which individuals revert back from the co-colonized to either VT or 
NVT compartments, and from colonization to susceptible compartments, assuming no natural 
immunity to carriage.  
 
The model comprised of three levels of vaccine-induced immunity; (1) no protection, (2) partial 
protection and (3) full protection (Figure S9). The latter means the efficacy and duration of 
protection conferred after completion of the infant schedule (i.e. 2 infant doses and a booster 
at 12 months (‘2+1’ schedule)) or the completion of a catch-up programme in older children (2 
doses in <18 months and 1 dose in ≥18 months). Partial protection was gained form two 
primary infant doses, or after the first catch-up dose in children aged 12 - 17 months.  The 
difference between full and partial protection lied in the magnitude of vaccine efficacy against 
carriage ( )CVE  and in the duration of protection. 
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We applied the model to a population of 81 annual age cohorts (0 to 80 years) divided into 52 
weekly age bands of 100 individuals. In the calculation of the force of infection the population 
figure was adjusted to represent the actual population, based on census data. 
 
We inferred the impact on IPD based posterior estimates of carriage at each time step, 
case:carrier ratios for VT and NVT by age group [1], the vaccine efficacy against invasiveness 
and the vaccination coverage of each weekly age cohort at each time step.  Details about 
parameters of vaccine efficacy are provided in the Supporting Information Part Two. 
 
The model equations are provided in Text S1 below. 
 
Figure S9: The three groups of vaccine protection states defined in the model and movement 
between groups 
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Text S1: Model equations   
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 i represent the weekly age groups.  
 ϒ is the vaccination coverage for infant doses (inf), the booster dose (boost) and the 
catch-up dose (catch-up).  
 VEfC and VEpC  is the vaccine efficacy against carriage acquisition after full and partial 
vaccination respectively. 
 ωP and ωf  represent the rate of waning immunity after partial and full vaccination 
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6.5.2.  Part Two: Estimates of vaccine efficacy, and transmission probabilities 
6.5.2.1. Vaccine efficacy against carriage  
Full vaccination. We obtained the vaccine efficacy against carriage after full protection (
F
CVE ) 
and its uncertainty from a Bayesian meta-regression model based on estimates from 22 
intervention studies. The details have been published elsewhere [2].  The model of vaccine 
efficacy was run for as many iterations as in our transmission model, so that we could sample 
one estimate of 
F
CVE  at each iteration of the post-vaccination simulations.     
 
Partial vaccination. A systematic review of the impact of pneumococcal conjugate vaccines on 
carriage [3] provided information on intervention studies with 2 primary-dose arms where 
compared with either 2+1 schedules or 3+0 schedules.  
 
We included individual randomized controlled trials providing nasopharyngeal carriage 
estimates within 3 – 20 months after a 2-dose infant schedule (2+0 arm) and after a complete 
schedule (either 3+0 or 2+1 arm). We excluded studies providing carriage estimates within 3 
months after vaccination to account for the delay in producing an immune response, and time 
to carriage clearance under the assumption that existing carriage at the time of vaccination is 
not affected by PCV [2]. 
 
We extracted data on the number of carriers of VT and total number of individuals swabbed in 
each study arm before and after vaccination.  We then computed the relative risk of VT carriage 
among fully vaccinated compared to partially vaccinated children. The pooled estimates were 
obtained through a random effects meta-regression model. 
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We pooled estimates from four studies, including trials in Fiji [4], Israel [5], The Gambia [6] and 
The Netherlands [7], providing together eight different survey points, into a simple random 
effects meta-analysis, not taking into account within-study dependence given the limited 
number of data points per study.   The details of the studies are provided in Table S6. 
Table S6: Studies included in the meta-analysis 
*In this study pooled results were provided for samples taken at 7 months and 12 months of age, and we therefore 
considered the age and time since the last dose as the average between the two, **m=months 
 
 
 The pooled relative risk of carriage among children with a full schedule was 78% (95%CI 64 – 
92%) that of a partial schedule (Figure S10), with no evidence of heterogeneity (I
2
=3%). 
At each iteration of the MCMC, we sampled a value from the relative risk 78% (95%CI 64 – 92%) 
multiplied by a value of the full vaccine efficacy against carriage acquisition (
F
CVE ), to obtain a 
measure of the partial efficacy (
P
CVE ). 
Study Country Schedule Age 
(m**) 
Time 
since last 
dose (m)   
Carriers 
/total 
RR (95%I) 
Dagan (2012)[5]* Israel 3+0 9.5m 3.5m 58/327 0.83 (0.57 – 1.20) 
Dagan (2012)[5]* Israel 2+0 9.5m 3.5m 36/169 ref 
Ota (2011)[6] Gambia 3+0 11m 7m 20/200 0.59 (0.36 – 1.00) 
Ota (2011)[6] Gambia 2+0 11m 8m 33/198 ref 
Ota (2011)[6] Gambia 3+0 15m 11m 24/193 0.80 (0.49 – 1.32) 
Ota (2011)[6] Gambia 2+0 15m 12m 30/196 ref 
Russell (2010)[4] 
[4] 
Fiji 3+0 6m 3m 13/127 0.95 (0.47 – 1.89) 
Russell (2010)[4] 
[4] 
Fiji 2+0 6m 3m 16/148 ref 
Russell (2010)[4] 
[4] 
Fiji 3+0 9m 6m 4/122 0.32 (0.11 – 0.93) 
Russell (2010)[4] 
[4] 
Fiji 2+0 9m 6m 15/146 ref 
Russell (2010)[4] 
[4] 
Fiji 3+0 12m 9m 8/114 1.25 (0.49 – 3.23) 
Russell (2010)[4] 
[4] 
Fiji 2+0 12m 9m 9/143 ref 
van Gils (2009)[7] Netherlands 2+1 18m 7m 51/329 0.64 (0.47 – 0.88) 
van Gils (2009)[7] Netherlands 2+0 18m 14m 79/327 ref 
van Gils (2009)[7] Netherlands 2+1 24m 13m 47/333 0.96 (0.66 -1.39) 
van Gils (2009)[7] Netherlands 2+0 24m 20m 49/332 ref 
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Figure S10 : Forest plot of the relative risk of VT carriage of 3 primary doses (2+1 or 3+0), for four 
different individual randomized controlled trials (RCTs), at eight different time 
points [4-7]. 
 
 
6.5.2.2. Duration of protection 
The duration of protection against carriage acquisition was obtained from le Polain et al [2]. The 
median estimate of a model of waning efficacy, using an asymptomatic function, closely 
matched that of an exponential decay with a mean duration of protection of 6 years (Figure S9). 
Hence, this estimate was taken as the average duration of protection in the main model. For 
sensitivity analyses, we considered mean durations of 3 years and 20 years as the lower and 
higher values, as shown in Figure S11. 
 
In the absence of estimates on the duration of protection of partial vaccination, we assumed 
that the duration of protection of a partial vaccination was 0.78 (0.64 – 0.92) that of a full 
vaccination, as for VEC. 
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Figure S11: Duration of protection of PCV against carriage acquisition 
Legend : Each circle represents the mean vaccine efficacy estimate for each study included in the analysis – see [2]. The 
size of the circle is proportional to the study size. The whiskers on either  side of each circle represent the 95%CrI 
around the point estimate. The dark grey area corresponds to the 50% CrI around the main model estimate of vaccine 
efficacy and its waning (plain black line), and the lighter grey area to the 95% CrI. The blue, red and green dotted lines 
show the waning with an exponential decay function for a mean duration of protection of 6 years, 3 years and 20 years 
respectively.  Figure adapted from le Polain de Waroux et al. [2], with permission from PIDJ 
 
 
6.5.2.3. Vaccine efficacy against Invasive Pneumococcal Disease 
The vaccine efficacy against invasive pneumococcal disease (VEIPD) can be expressed as a 
function of the vaccine efficacy against carriage acquisition (VEC) and the efficacy against 
progression to disease as a result of carriage, which we here term the vaccine efficacy against 
invasiveness (VEinv) [8], where VEIPD = 1 – (1-VEC)(1-VEinv). 
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Based on estimates from a large systematic review by Lucero et al. [9], we assumed VEIPD to be 
80% (95%CI 58 – 90%) and generated a binomial distribution that closely matched those 
estimates . Hence, we calculated VEinv based on the distribution of VEIPD and that of VEC, and 
obtained a value of VEinv at each iteration in our MCMC process.  
  
The mean VEINV was 80% (95%CrI 67 – 90%), the mean VEC was 62% (95%CrI 52 – 73%) and 
mean VEinv was 48% (95%CrI 34 – 65%). The distributions are shown in Figure S12. 
 
Figure S12: Estimates of vaccine efficacy 
 
Legend: density plot of the vaccine efficacy against IPD (left panel), carriage (medium panel) and invasiveness (right 
panel). The x axis displays the vaccine efficacy.  
 
In the model, was assumed no waning of VEinv, and that VEinv would be conferred after 2 primary 
doses, or any catch-up dose.  Although there is evidence that VEC after partial vaccination 
differs from that after complete vaccination (see earlier), evidence that the efficacy against 
progression to invasiveness differs between two and three primary doses is scarce.  
 
Although it is likely that VEinv wanes over time, we did not consider waning in the main model, 
given that most of the direct impact of PCV on IPD occurs in the first few years of life, before 
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establishment of the herd immunity effect (see results), and given the lack of estimates of 
waning of VEINV. 
 
6.5.2.4. Transmission probabilities (posterior estimates) 
The probability of infection for NVT and VT by age group was obtain from fitting the model to 
the nasopharyngeal carriage data. The posterior estimates, including median and 95% credible 
intervals (CrI) are displayed in the Table S7 below 
 
Table S7: Posteriors for the probability of infection by age group 
Age group <3y 3 – 5y 6 – 19y 20+y 
Probability of 
infection with VT if 
contacted  (10
-2
) 
3.8 (2.8 – 5.2) 3.1 (2.2 – 5.7) 1.8 (1.5 – 2.0) 1.0 (0.7 – 1.4) 
Probability of 
infection with NVT if 
contacted (10
-2
) 
1.2 (0.7 – 1.9) 3.8 (2.6 – 4.9) 1.8 (1.4 – 2.1) 1.3 (0.9 – 1.8) 
 
 
6.5.3. Part Three: Sensitivity analysis (coverage and duration of vaccine 
protection) 
6.5.3.1. Vaccination coverage 
We explored model outputs with lower vaccination coverage in both cohort and catch-up 
immunization.  Our model predicted a lengthening of the time to near-elimination of VT 
serotypes (and hence, the time reach the new post-PCV disease equilibrium) as vaccination 
coverage lowers but a similar differential impact of catch-up campaigns compared to routine 
vaccination.   
 
 242 
 
Figure S13 compares predictions of trends in VT carriage for all four strategies and vaccination 
coverage levels of 90%, 70% and 50%.   
  
6.5.4. Duration of protection 
 
A duration of protection of 3 years would increase the time to elimination of VT carriage, and 
thus prevent fewer IPD cases overall, while any average duration of protection longer than 6 
years would not change model outcomes. With a duration of 3 years the median prevalence of 
VT in <5 year olds is predicted to reach near elimination about 2 years later in RV and CC1, 1.5 
years later with CC2 and about 1 year later with CC5.  Similar differences were predicted for the 
≥5 year olds (Figure S14). The relative impact of one vaccination strategy over another was 
predicted to be similar than with a duration of 6 years.   
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Figure S13 Impact of vaccination coverage on VT carriage for each strategy considered, and 
comparing 90%, 70% and 50%  coverage for each of the four strategies, in children 
aged 0 – 59 months 
 
Legend: In all four panels: plain horizontal line= median, boxes= 50% credible intervals and whiskers= 95% credible 
interval, for each of the three levels of vaccination coverage (90%, 70%, 50%) and for all four vaccination strategies. 
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Figure S14: Comparing model estimates with an average duration of protection of 6 years (blue) 
and of 3 years (red)  for each of the vaccination scenarios considered and by age 
group 
 
Legend: Percentage reduction in VT carriage in children <5 years (left) and ≥ 5 years old. In blue is are estimates of the 
main model (average duration of protection of 6 years) and in red are estimates considering a mean duration of 
protection of 3 years. The plain lines represent the median and the dotted lines the 95% credible interval 
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7. Discussion 
7.1. Main findings and strengths  
 
The chapters of this thesis are presented in a sequence that reflects the steps that were taken to 
address the main questions around the epidemiology and transmission dynamics of 
pneumococci, and questions around PCV introduction strategies, which the thesis intended to 
address.  
 
The first research paper of this thesis [1] provided further insight into the dynamics of 
nasopharyngeal carriage, showing a strong correlation between age groups in the prevalence 
of carriage of Streptococcus pneumoniae – i.e. that in populations where the carriage among 
children is high, carriage prevalence in adults is high too, and vice-versa.  Results from Research 
paper 1 [1] also suggest a ‘shift’ from VT serotypes – which are most commonly found in 
childhood [2] – to NVT serotypes,  as age increases [3].  This may be explained by serotype-
specific mucosal immunity acquired against some of the most common childhood serotypes, - 
predominantly VT serotypes - , which leads to colonisation by other serotypes instead.  Under 
such hypothesis, a more balanced distribution between VT and NVT would occur earlier in life 
in high burden settings. Although Research paper 1 was underpowered to address this 
question, a larger systematic collection of nasopharyngeal carriage data, which is currently 
underway (see subchapter 7.3), could make it possible to explore this further.   
 
Research paper 1 [1] was designed to address a specific need, namely that of predicting the 
carriage prevalence, and distribution of VT and NVT serotypes in older children (5 – 17 years 
old) and adults (≥18 years), based on carriage estimates on children <5 years, in order to obtain 
precise estimates for Nha Trang, where data in older children and adults were not available. 
 247 
 
However, the results have in fact wider implications, including for this thesis, as well as for 
further research, in addition to those that have already been discussed in the paper itself.   
 
First, the statistical model was used to help sample size calculations for the nasopharyngeal 
carriage study conducted in Sheema district, Southwest Uganda (Research papers 3 and 4), 
based on limited data from another survey in children <5 years conducted in Uganda [4]. The 
nasopharyngeal carriage study, which is currently being written up (Nackers et al. in preparation 
and [5]), included over 1800 participants, from all age groups. 
 
Second, in light of the increased emphasis on nasopharyngeal carriage as a proxy to monitor, 
predict and evaluate the population impact of PCV [6-9], as well as recent debates around 
pneumococcal vaccination strategies in older adults and elderly in countries where PCV 
programmes are well established [10-13], results from Research paper 1 [1] will help better 
predicting carriage and relative prevalence of VT serotypes among older age groups, in settings 
where only data in children <5 years of age are available. This would also be useful in assessing 
the potential impact of vaccination strategies on invasive disease in older adults and in the 
elderly, based on estimates of invasiveness – and assuming those are stable [14]. 
Finally, Research paper 1 also highlights important differences in the prevalence and vaccine-
type serotype carriage between settings, with a carriage prevalence in under-fives as low as 
21% in Taiwan and as high as 93% in The Gambia, and important differences in the carriage 
prevalence among adults. Stark variations in carriage prevalence estimates have also been 
recently highlighted in two systematic reviews of pneumococcal carriage prevalence [15, 16]. 
Drawing from the results from Research paper 4, it is plausible that differences in 
sociodemographic structures and household sizes, particularly the number of close contacts 
that individuals have on a daily basis, explain some of the patterns seen, and this would need 
further research.  For example, the lower prevalence of nasopharyngeal carriage observed in 
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Nha Trang compared to Sheema district may be driven by differences in socio-demographic 
and social mixing patterns between these settings. Vietnam is currently experiencing a rapid 
demographic transition [17], with low mortality, low fertility rates and increasing life expectancy 
(average of 78 years in the latest census [17]). The average household size has declined in 
Vietnam from 5.1 in the late 1970s to around 3.7 in the 2009 census, largely due to a reduction 
in fertility rates over the last years, and a decrease in both the proportion and absolute number 
of children under five years of age in the community, who now represent just 8% of the total 
population [17]. In contrast, Uganda has one of the youngest populations, with 19% of the 
population aged <5 years, an average of 5.1 members per household, and a life expectancy of 
50.4 years, as reported in the latest Demographic and Health Survey [18].  Drawing further 
parallels, it is interesting to notice that countries in West Africa, which have the highest 
prevalence of carriage (as high as >90% in children <5 years and >50% among adults in data 
from the Gambia) [15, 16] are also settings where household sizes are among the largest (the 
average household size in the Gambia is 8.2, and as high as 9.9 in rural settings [19]). In line 
with findings from Research paper 4  about contacts relevant for carriage acquisition, and 
findings from Research paper 1 of the adult to child proportionality in carriage across settings, 
such socio-demographic factors  may potentially explain some of the epidemiological 
differences observed.  
Pneumococcal transmission dynamics, population herd effects of PCV, and the differential 
impact of catch-up campaigns therefore likely differ in higher burden setting such as Sheema 
district, compared to the results displayed in the Nha Trang model, and further research is 
required to better understand how PCV impact would differ between such settings.  This is 
further discussed in 7.3.  
 
As for the first paper, the rationale for Research paper 2  [20] was primarily to inform the 
modelling work applied to Nha Trang, and specifically compile estimates of vaccine efficacy 
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against carriage acquisition, and of the duration of protection. Previous estimates, in particular 
of the duration of carriage used in transmission models,  were mostly based on anecdotal 
evidence [21]. Hence, the pooled evidence based on data from Europe, North America, South 
Africa and Israel, generated in Research paper 2 , fills an important gap.  The study provided the 
first ever estimates of the vaccine efficacy against carriage at different time points after 
vaccination, thereby improving our understanding of whether and how the protection against 
carriage wanes, and importantly, how this varies between serotypes and schedules.  
The immediate application of Research paper 2 was two-fold. First, given the lack of robust 
estimates on both vaccine efficacy and duration of protection, estimates directly fed into the 
transmission model (Research paper 5).  Bayesian regression model fitting allowed using the full 
posterior estimates of vaccine efficacy in the transmission model.  Efficacy estimates from 
Research paper 2 , in combination with meta-estimates of the vaccine efficacy against IPD [22] 
were also used to  obtain meta-estimates of the vaccine efficacy against invasiveness – for 
which there was no good estimate – using a formula described elsewhere [23], to estimate the 
impact of PCV on invasive disease in the Nha Trang model.  
Second, results from Research paper 2 also provided more robust estimates and more plausible 
uncertainty ranges, on the duration of protection, which resulted in more informed choices for 
sensitivity analyses. 
 
The application of the results from Research paper 2 to specific contexts will depend on the 
distribution of circulating serotypes, given the differences between serotypes highlighted in our 
analysis.  The serotype distribution in the studies included in the paper [20] (n=15) was 
relatively homogeneous, and also consistent with the serotype distribution in Nha Trang [24]. 
Given that Research paper 2 provided the first robust meta-estimates of differences in vaccince 
efficacy against carriage for individual serotypes and between schedules, future transmission 
models applied to settings where the serotype distribution differs substantially from the studies 
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included in Research paper 2, serotype-specific estimates of vaccine efficacy against carriage 
may need to be considered.   
 
 Findings from Research papers 3  provided essential data on the social contact patterns in a 
rural African setting. The comparison of mixing patterns  from Great Britain [25] and Uganda – 
showing more assortative mixing in Britain and more intergenerational mixing in Uganda -,  and 
subsequent differences in simulations of the final epidemic size, emphasised the importance of 
applying setting-specific contact structured to transmission models.  While Research paper 3 
did not directly contribute to other outputs from this thesis, it was novel and informative in 
various ways. First, given the scarcity of contact data from low-income settings, let alone Africa, 
the study filled an important gap by providing very detailed estimates of the structure of social 
contacts between individuals, by age and by type of encounter. It also offered valuable insights 
into the spatial characteristics of social encounters.  Spatial interconnectedness has increasingly 
been recognized as an essential factor driving epidemic extinction or persistence of epidemic 
hotspots, and the effectiveness of control strategies. However,  even though spatial 
components have been explored in details in some studies, such as Read et al. in China [26],  
information on the spatial dimension of social contacts has often been overlooked, and is 
certainly lacking for rural African settings. Research paper 3 is the first study providing 
quantitative information on the local spatial aspect of contacts in a low-income African setting, 
which will be very valuable for infectious disease modellers and epidemiologists, and provides a 
basis for further work on pneumococcal dynamics, particularly to evaluate spatial dynamics and 
PCV strategies in the presence of important social heterogeneity and heterogeneity in health 
service (i.e. in this case vaccination) coverage, as outlined in subchapter 7.3.  
 
In Research paper 4 the combination of both carriage and contact data collected 
simultaneously in the same individuals provided a unique opportunity to better understand the 
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role of human interactions in the spread of respiratory infections, and Streptococcus 
pneumoniae in particular.  Importantly, in the context of the work conducted for this thesis, 
Research paper 4 was key to accurately parameterise the Nha Trang model, as it provided 
evidence supporting the use of physical contacts, rather than all contacts, in model 
parameterisation.  Although it seems obvious that making a greater number of contacts might 
increase the risk of pneumococcal carriage – a hypothesis which also underlays most 
mathematical models, many public health interventions,  and justifies why contact studies in 
various settings are important – the evidence to support this hypothesis is thin, consisting 
largely of ecological analyses or studies conducted over non-contemporary periods [27-32]. By 
shedding light on the type of contacts that are important for the transmission of Streptococcus 
pneumoniae, and the role of children in spreading pneumococci to older age groups, Research 
paper 4 strengthens the scientific evidence for public health measures based upon the 
assumption that the frequency of close social contacts increases infection risk. It also provides 
crucial information to improve our understanding of transmission dynamics of pneumococci, 
and other pathogens transmitted through similar routes, and is central to adequately 
parameterise dynamic transmission models, including the model applied to the population of 
Nha Trang (Research paper 5).  
 
Results from the first four papers all informed the mathematical model applied to the 
population of Nha Trang to explore the differential impact of PCV introduction strategies 
(Research paper 5).   The choice of setting was based on considerations about (i) available data 
on both carriage, social contacts, and estimates of invasive disease, and (ii) the need for a 
model to address questions in a setting that has not yet introduced the vaccine – but is 
considering to do so –, and where results can therefore help guide policy decisions.   
 
 252 
 
Research paper 5 provides the first dynamic model of pneumococcal transmission and control 
developed and parameterised for South-East Asia, where most countries are yet to introduce 
pneumococcal conjugate vaccination, and is therefore particularly relevant for policy decisions 
about PCV introduction in such settings.  Results from the model showed a strong herd 
immunity effect of the vaccine, with near-complete elimination of serotypes targeted by the 
vaccine across all age groups within a decade of PCV introduction, in all vaccination strategies 
considered in the main scenario (i.e. 90% coverage in routine vaccination, and similarly in catch-
up campaigns in <1 year olds, <2 year olds and <5 year olds).  This predicted herd effect is in 
line with the trends seen in many settings following PCV introduction , including the experience 
in Europe and North America and South Africa, the Gambia [33-41] as well as following PCV10 
introduction in Kenya [42].  
 
The main results from the transmission model suggest that most of the benefit of catch-up 
campaigns occurs within the first 3 years of PCV introduction, with the highest impact at one 
year, when a catch-up strategy for <1 year olds would result in an 11% (95%CrI 9 – 14%) lower 
IPD incidence in children <5 years, compared to routine vaccination only,  a strategy targeting 
children <2 years would reduce it by 25% (21 – 30 %), and a 38% (32 – 46%) reduction in 
incidence, compared to routine vaccination is predicted at one year with a catch-up strategy 
targeting all children under five years of age. 
However, results of the model also show that catch-up campaign would only prevent more 
cases of IPD so long as they do not result in a vaccination introduction delayed by more than 6 
months, for catch-up campaigns in <1 year olds, to about 18 months, for catch-up campaigns 
targeting all children under five years. 
 
There are few available data on nasopharyngeal carriage post-PCV implementation in low- or 
middle-income settings. In Kilifi, Kenya, where PCV10 was introduced routinely in 2011 
 253 
 
alongside a catch-up campaign in children under five years of age, VT carriage in <5y olds was 
reduced by about 64% 18 months after vaccine introduction, with a vaccination coverage for at 
least one dose of about 74% [42].   With such vaccination coverage – and assuming it is stable 
and reached on day 1 of the vaccine introduction –, the Nha Trang model predicts a decline in 
VT serotype carriage 18 months after vaccine introduction of 81% (95%CrI 65% - 92%). In a 
large PCV7 cluster randomized trial in the Gambia, the prevalence of VT carriage in 2 – 4y olds 
decreased by about 56% 22 months after vaccine introduction, with a two-dose catch-up 
campaign in <30m olds and a coverage of about 50%. In the Nha Trang model, such catch-up 
campaign with a coverage of 50% is predicted to reduce VT carriage by about 54% (95%CrI 41 – 
64%) 22 months after PCV13 introduction. 
 
However, it is notable that in a setting such as Nha Trang, where the sociodemographic and 
epidemiological characteristics differ from many low-income settings such as those mentioned 
above, VT carriage elimination and herd effects are predicted to be established relatively 
rapidly, even without a catch-up campaign.  Although catch-up campaigns would decrease 
disease burden more rapidly, policy decisions about whether or not to conduct campaigns in 
such setting will crucially depend on results of economic analyses, to which the current model 
outputs could contribute. In its simplest way, a cost comparison between scenarios based on 
the number of additional vaccine doses required in catch-up campaigns compared to the 
additional impact of such campaigns on disease incidence, would provide initial answers. More 
comprehensive economic analyses would need to consider additional delivery, programme 
implementation, storage and other costs. For full cost-utility analyses, estimations of the quality 
adjusted life years (QALYs) gained for different scenarios and health outcomes considered are 
warranted.  While such undertaking was beyond the scope of this thesis, it is worth noting that 
very few economic analyses of PCV programmes have so far been based on dynamic 
transmission models, and are based instead on static models where direct and indirect effects 
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of the model are fixed, or indirect effects not taken into account [43].  Even though medium 
and long term impacts can be estimated through simple static models [6], dynamic 
transmission models such as the model developed in Research paper 5 are essential to appraise 
the population impact of different strategies when both direct and indirect effects are not 
stable, in the first few years post PCV introduction.  Estimates from the Nha Trang model or 
similar models in other settings are important to inform economic analyses used to guide 
policy decisions about whether or not to include PCV catch-up campaigns. 
 
7.2. Limitations 
 
While the Nha Trang model, and the policy questions that were addressed through it, was a 
main objective of this thesis, there are a number of limitations to this model, including the 
available data used for its fitting and several assumptions inherent to its structure, some of 
which were already alluded to in the discussion of Research paper 5, and will therefore not be 
repeated in detail.  Similarly, limitations to Research papers 1 to 4 were discussed in details in 
the respective papers, and will not be repeated here; rather, additional limitations of those 
studies in the specific context of their input into the Nha Trang analysis will be briefly discussed.  
 
As already mentioned in the discussion of Research paper 5, the Nha Trang model was fitted to 
pre-vaccination data only, and predicted trends in post-vaccination depend on the efficacy of 
vaccination against carriage, estimated in Research paper 2,  and the strength of competition, 
which determines the magnitude of replacement in carriage post vaccination. The evidence of 
strong competition between pneumococcal serotypes has been supported by observational 
studies finding little to no reduction in overall carriage rates after the introduction of routine 
vaccination [33-38], as well as evidence from mathematical models [44-48], mouse models [49] 
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and in vitro studies [50].  The competition parameter in the model was chosen to be similar to 
estimates from the UK and Finland [45, 51], which suggest very strong competition between VT 
and NVT and hence pronounced replacement effects after vaccination and the concomitant 
disappearance of VT from the nasopharynx.  
 
The effect of replacement in the nasopharynx on disease rates is crucially dependent on the 
pathogenicity of the replacing serotypes. Although the possible impact on IPD was based on 
invasiveness data from England and Wales, it is impossible to predict the exact serotype that 
will fill the ecological niche created by vaccination, which may result in different degrees of 
pathogenicity. In the US the post PCV7 experience has been marked by a disproportional 
increase in serotype 19A, which is included in PCV13 [34]. In other countries, other serotypes 
such as serotypes 1 and serotypes 5, also included in PCV13, have disproportionally contributed 
to the post-vaccination IPD rates. Post-vaccination surveillance – or at least post-introduction 
monitoring of carriage prevalence and serotype distribution [6] – is therefore warranted to  
better predict long term post-vaccination trends. 
 
Several simplifying assumptions were also made in the model structure. Although individuals 
may develop some immunity as a result of carriage [2, 52], the Nha Trang model assumed no 
natural immunity to pneumococcal infection. Some degree of immunity was nonetheless taken 
into account indirectly in the model, through decreasing the duration of carriage with age and 
differences in susceptibility to infection given contact. The model structure also overlooked the 
complexity of pneumococcal transmission, by assuming homogeneous characteristics for the 
group of VT and NVT serotypes, despite serotypes within each group differing in their 
pathogenicity, fitness and transmissibility [47, 53]. Serotype-specific post-PCV dynamics could 
therefore not be predicted, and it is likely that the differential impact of campaigns on some 
particular serotypes may differ, depending on the serotype-specific characteristics, including 
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prevalence and pathogenicity, and vaccine-related parameters such as efficacy and duration of 
protection.  Exploring serotype-specific transmission parameters through modelling would help 
improve predictions, however there is currently no study that has done so. 
 
Furthermore, there were several limitations in the parameters used in the Nha Trang model.  
Given that the model was fitted to pre-vaccination data only, post-vaccination trends were 
based on a range of assumptions about parameter values which are prone to uncertainty.  Such 
uncertainty was taken into account to a large extent by assigning distributions to most 
parameters based on the best known estimates from the literature [20], and by exploring the 
sensitivity of the results to changes in some of the parameter values.  Finally, in the Nha Trang 
model no heterogeneity was taken into account such as heterogeneity in vaccination coverage, 
individual susceptibility to disease, or population movements. Further work exploring the 
impact of population movement, particularly in the presence of heterogeneous vaccination 
coverage geographically [54], and differences in individual risk factors to disease (such as 
malnutrition or HIV), should further be explored, and is discussed in 7.3 (Ongoing research and 
areas for further work).  
 
In Research paper 2, estimates of vaccine efficacy and duration of protection were almost 
entirely based on data from intervention studies based on PCV7 [20], whereas the transmission 
model was based on PCV13. Although immunological data suggest limited differences in 
efficacy estimates for the three or six additional serotypes in PCV10 and PCV13, as discussed 
earlier, whether aggregate efficacy estimates for PCV13 exactly match estimates obtained in 
Research paper 2 [20] remains to be determined. 
 
Finally, vaccine efficacy estimates for ‘partial protection’ in the Nha Trang model was based on 
a relatively small meta-analysis of incomplete (2 dose) vs complete routine schedules. However, 
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there are a number of efficacy estimates that are lacking for other vaccine dosages, and in 
particular single dose catch-up campaigns to expanded age groups. A better understanding of 
the efficacy and duration of protection of single dose schedules in toddlers is important for 
settings where a single-dose catch-up or single dose mass vaccination campaigns may be the 
most practical and pragmatic vaccination options.  
 
7.3. Ongoing work and areas for further research 
Work undertaken as part of this thesis highlights a number of important additional questions 
on the epidemiology and transmission dynamics of pneumococci, and on how to best optimise 
and evaluate pneumococcal vaccination strategies.  Work from this thesis also lays the basis for 
further projects, some of which are already ongoing.  These include, among others: 
1. A better understanding of the global epidemiology of Streptococcus pneumoniae  
carriage before the introduction of conjugate vaccines, for different geographical and 
sociodemographic settings, and by individual factors such as age and underlying health 
conditions.  
2. Improving our understanding of the serotype-specific pathogenicity for invasive 
disease, but also non-invasive disease such as pneumonia and acute otitis media, the 
impact on which has so far been overlooked in most modelling studies, including the 
Nha Trang model. 
3. Explore additional questions around the best use of PCV in high burden settings, 
including 
a. Humanitarian emergencies, where strategies need to consider reduced dose 
schedules, mass vaccination and expanded target age groups to account for 
the epidemiological conditions and reduced access to health services 
b. Settings where spatial coverage of PCV is highly heterogeneous 
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7.3.1.  A Review of Streptococcus pneumoniae in nasopharyngeal carriage 
globally (RESPICAR study) 
A better understanding of the global distribution of S.pneumoniae in carriage before PCV 
introduction would enable to better tailor, predict and monitor PCV vaccination strategies [9]. 
This is particularly relevant in low income settings where robust surveillance of pneumococcal 
disease remains a challenge. In addition, better estimates of the global distribution and 
prevalence of nasopharyngeal serotype carriage, and differences between settings, is important 
in the context of the development of new pneumococcal vaccines [55].  
 
Adegbola et al. [15] undertook a systematic review of pneumococcal carriage in healthy 
children under five in low- and lower-middle income countries identified based on articles 
published in PubMed between 1990 and 2012. Their study focused primarily on carriage 
prevalence, rather than serotype distribution, and results suggest that the pooled carriage 
prevalence in low income settings tends to be higher than in lower-middle income countries. 
This may be due to the higher frequency of physical social contacts in such settings, as 
suggested by the findings from Research paper 4.  And while Adegbola et al. [15] did not 
explore results for older age groups and adults, we know from the results of Research paper 1 
[1] that the prevalence of carriage in older children and adults is likely to be high in settings 
where the prevalence of carriage is high in children under five. In addition, as the results from 
Research paper 1 suggests, NVT serotypes tend to be proportionally more prevalent in NP 
carriage as age increases [1], and under the assumption that this is related to serotype-specific 
acquired immunity to the most prevalent circulating serotypes, as mentioned earlier, it is 
expected that in high burden settings the shift towards a proportional increase in NVT carriage 
may happen earlier in life given the higher frequency of acquisition events.  However, global 
and regional estimates of the serotype distribution of nasopharyngeal carriage have not been 
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published, and although results from Research paper 2 [20] suggest a relatively constant 
distribution of vaccine-type serotypes in young children in a few settings, limited evidence exist 
about the serotype distribution in other settings.  
Hence, we designed and implemented a large systematic review of Streptococcus pneumoniae 
carriage (RESPICAR) globally, in order to compile estimates of both the serotype distribution 
and carriage prevalence of pneumococci carried in the nasopharynx, across different age bands 
and geographic settings before PCV introduction (PI: Olivier le Polain, Research team: W John 
Edmunds (LSHTM),  Stefan Flasche (LSHTM), Riya Moodley (LSHTM), Tim Pollington (LSHTM), 
Maria Deloria-Knoll (Johns Hopkins School of Public Health) and Kate O’Brien (Johns Hopkins 
School of Public Health)).  
7.3.1.1. Description of the study methodology and preliminary results 
The study, which was funded by the World Health Organisation, (WHO) started in late 2014 and 
is currently (November 2016) being finalised. Articles were retrieved from ten different 
databases, using a very inclusive search strategy and no restrictions by language, age group, 
time or region. The presence of underlying conditions (such as HIV or sickle cell disease) was 
not an exclusion criterion, but was recorded as part of the data entry, such as to conduct further 
analyses among those specific groups.  Studies were included if they provided estimates from 
the community, and studies conducted among specific groups of patients with any form of 
pneumococcal-like illness (e.g. acute respiratory infection, acute otitis media, pneumonia) were 
recorded but not included for data extraction. 
 
The first phase of the screening process, which was based on the screening of title and/or 
abstracts only, identified 14,584 studies (after deduplication of the initial 27,786 citations 
retrieved from the initial search).  After a second screening phase based on full text, a total of 
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244 studies were identified which provided data on both carriage prevalence and serotype 
distribution among community members before PCV introduction. 
Of the studies included for data extraction, 43 (18%) were from Africa, 69 (28%) from Asia, 76 
(31%) from Europe, 33 (13%) from Latin America, 18 (7%) from North America and 5 (2%) from 
Oceania. These studies comprised a total of 511 different surveys or data collection phases, 
including 352 (69%) in children <5 years, 109 (21%) among 5-17 year olds and 50 (10%) among 
adults. We compiled information from a total of 70,901 isolates, including 51,299 isolates from 
children aged less than five years, 16,383 among children aged 5 – 17 years and 3,219 isolates 
from adults aged 18 years and (Figure 24).  
 
Figure 24: Number of nasopharyngeal carriers with information on serotyping, by 
count
 
 
The analysis was based on separate models for serogroups and serotypes within serogroups 
(e.g. serogroup 19 includes serotypes 19A, 19B, 19C and 19F), whereby serogroups were 
modelled as a single multinomial distribution, and the distribution of serotypes within each 
serogroup was also independently modelled assuming a multinomial distribution. The analysis 
was performed in a Bayesian framework, to facilitate the inclusion of small or zero values for 
rarer serotypes, as well as provide a more natural weighting of the contribution of each study 
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than in a frequentist approach. The pooling of studies by age group and by geographic region 
was based upon (and interpreted as a function of) an analysis of heterogeneity. The latter 
included an assessment of the distribution of non-overlapping serotype- and/or serogroup-
specific proportions between studies or groups of studies to compare, using their respective 
posterior samples.  
 
The first main output of this project will be a very detailed and comprehensive description of 
the serotype distribution in carriage globally, by age group and geographical area.  Preliminary 
results show differences in the serotype distribution and rank order of serotypes between 
different regions, but only moderate overall heterogeneity between countries, regions and 
continents.  
 
Pooled data at the continent level show that among children<5 years of age the proportion of 
serotypes covered by PCV10 and PCV13 ranges from 47% (Asia) to 57% (Europe) for PCV10, 
and from 62% (Asia) to 74% (Europe) for PCV13. As hypothesised in Research paper 1 [1], 
preliminary results also suggest a steady shift in the proportional distribution of serotypes from 
vaccine type serotypes in early childhood to non-vaccine type serotypes as age increases.  
Interestingly, while differences in serotype distributions are seen between settings, preliminary 
results suggest that a set of main prevalent serotypes are consistently found across settings.   
Importantly, this large review sets out the basis for further work, including subgroup analyses of 
the serotype distribution, work to explore the pathogenicity of specific strains, as well as work 
to further explore and predict the ‘steady state’ (i.e. medium to long term) impact of 
pneumococcal vaccine introduction in various settings using available and validated modelling 
and statistical tools [6, 56]. 
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7.3.2. Serotype-specific pathogenicity for invasive and non-invasive disease 
7.3.2.1. Invasiveness of pneumococcal serotypes.  
The invasiveness is the probability of invasive disease per nasopharyngeal acquisition, which 
should be calculated as the incidence of disease divided by that of carriage, even though it is 
generally approximated by the incidence of disease divided by the prevalence of carriage (i.e. 
‘case:carrier ratios’ as in Research paper 5).  Invasiveness is known to vary widely between 
serotypes [57-59], and as such, the relative invasiveness of serotypes carried by the vaccine, 
compared to replacing serotypes, is one of the major factors that determine the success of a 
PCV programme, and that of a given vaccine formulation [60, 61].  Although invasiveness is 
thought to be a stable serotype-specific property in children under five [59, 62] – a hypothesis 
which also underpins the impact estimates of the Nha Trang model (Research paper 5) – there 
is only limited evidence to support this. Trotter et al. [58] found similar invasiveness patterns by 
serotypes in children <5 years and older children and adults in the UK, and such findings were 
recently corroborated by Weinberger et al. [57] based on data from Navajo communities in the 
US.  However, it is likely  that invasiveness differs between settings, due to differences in host 
factors, such as immunity patterns, and underlying susceptibility factors such as malnutrition or 
the prevalence of immunocompromising conditions such as HIV [63]. 
A better understanding of the stability – or not – of invasive serotypes between settings would 
therefore enable us to improve our understanding, and our predictions, of the impact of PCV 
globally,  particularly for settings for which only carriage data are available [6], in addition to 
better forecasting the potential impact of new vaccine formulations (such as PCV15 [64]). 
Data from RESPICAR, combined with data from existing systematic reviews of serotypes found 
in invasive disease globally [65], would enable to address some of those questions. This project 
is currently being taken forward (November 2016).  
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7.3.2.2. Propensity of pneumococcal serotypes to cause pneumonia 
As mentioned earlier, one of the main limitations of the Nha Trang model (and most if not all 
modelling studies to date), is the lack of quantification of the potential impact of PCV 
vaccination schedules on non-bacteraemic pneumonia,  despite it being the main cause of 
pneumococcal-related morbidity and mortality globally [66].  This is largely due to the lack of 
robust estimates about the propensity of serotypes (or at the minimum, the group of VT and 
NVT serotypes) to cause non-bacteraemic pneumonia, given that no easily available diagnostic 
test is currently available. The aetiology of pneumonia remains particularly challenging, as 
aetiological diagnosis generally requires invasive techniques, which are risk prone and may not 
alter the clinical management. This hampers the aetiological ascertainment of pneumonia cases, 
and in particular an understanding of the pathogenicity of different strains of pneumococci.  A 
meta-analysis of four large randomised controlled trials of PCV in various settings (including 
Navajo communities in the US [67], The Gambia [68], Philippines [69] and South Africa [70]) 
estimated the efficacy of PCV against clinical pneumonia at 8%, and against radiological 
confirmed pneumonia of 36% [66]. These trials were not designed to determine if changes in 
pneumonia incidence would occur over time as a result of serotype replacement and may 
therefore overestimate the long-term effect of vaccination against this endpoint. 
 
Studies using administrative databases based on robust designs, adjusting for trends or using 
control diagnoses, have been performed in Nicaragua [71], Brazil [72] and in Israel [73]. They all 
found substantial reductions in the burden of pneumonia hospitalisations [71, 72] or of 
community acquired alveolar pneumonia [73], albeit of varying magnitude.  Indirect effects of 
PCV against pneumonia have also been observed [74]. Differences in magnitude may reflect the 
different PCV formulation in the studies, but most probably also result from differences 
between settings in the circulating pneumococci (which would be expected to change with time 
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since introduction of vaccination) and other pathogens causing clinical or radiological 
pneumonia.  
Few studies however have explored the propensity of specific serotypes to cause pneumonia.  
The PERCH study (Pneumonia Etiology Research for Child Health) [75], which was conducted in 
seven different study sites (five African and two Asian countries) may shed more light on this in 
the near future.  Using NP carriage as a proxy indicator of pneumonia aetiology has also been 
used in studies comparing serotype distribution in carriage among pneumonia patients to that 
of healthy individuals drawn from the same communities, with the assumption that carried 
serotypes among pneumonia patients are indicative of aetiology [76]. While this assumption is 
prone to many caveats, not least the fact that antibiotics provided to patients with pneumonia 
may reduce and/or change their nasopharyngeal flora, several studies seem to suggest that 
carried serotypes can be used as proxy measures of pneumonia aetiological agents, particularly 
if the density of carriage is high (with the assumption that a higher density would equate to a 
higher likelihood of causality) [76-79]. 
Thus, a compilation of studies with data on carriage prevalence, density, and serotype 
distribution in carriage among patients with pneumonia, compared to healthy individuals, may 
enable us to enhance our understanding of serotype-specific pneumonia pathogenicity, thereby 
also improving attempts to quantify the impact of PCV on the burden of pneumonia in various 
settings.   Data from RESPICAR, together with additional data on pneumonia, would provide the 
opportunity to further this idea.  
 
7.3.2.3. Propensity of serotypes to cause acute otitis media.  
Finally, while acute otitis media (AOM) is a less severe pneumococcal disease manifestation, it is 
an important contributor to the burden of pneumococcal disease in children worldwide given 
its frequent occurrence, and even modest vaccine efficacy against AOM therefore results in 
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important reductions of the burden of the disease [80]. While aetiological diagnoses based on 
middle ear fluid (MEF) is generally specific, MEF is rarely collected as this procedure is seldom 
useful to guide clinical practice.  In a recent model applied to data from Israel, Flasche et al. [7] 
have shown that monitoring serotypes in carriage can provide an alternative to both monitor 
and predict the impact of PCV on AOM. A further understanding of the AOM pathogenicity of 
various serotypes, based on either MEF serotyping or nasopharyngeal carriage among children 
with AOM, and NP carriage serotyping from the same community or individuals would enable, 
as for IPD and pneumonia, better predictions of the impact of PCV vaccination strategies on 
AOM.   
 
7.3.3.  Additional questions around the best use of PCV in high burden settings  
7.3.3.1. Applicability of the Nha Trang model results to other settings 
Although results from the Nha Trang model (Research paper 5) are informative for that 
particular settings, and perhaps other settings with similar epidemiological and socio-
demographic characteristics, further work is warranted to explore the applicability of (or 
divergence from) the Nha Trang results when similar approaches are applied to other settings. 
This is particularly true for higher burden settings where carriage prevalence and social 
dynamics likely differ.  Serotyping of the positive cultures from the nasopharyngeal carriage 
study in Sheema district (Nackers F, Cohuet S, le Polain de Waroux O, et al., (in preparation) and 
[5]) was only performed later, and modelling work applied to that setting was therefore not 
done in the context of this thesis.  However, a model based on the same structure as the Nha 
Trang model was applied to both pre- and post-introduction NP carriage and IPD data from 
Kilifi, Kenya (Flasche et al., in preparation), another East African setting where both the 
prevalence of carriage, serotype distribution and socio-demographic characteristics are close to 
that of Sheema district, but differ substantially from that of Nha Trang [81].  Results from both 
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Kilifi and Nha Trang models were compared by running both model on the same parameters of 
vaccine efficacy and duration of protection to explore similarities and differences in the 
differential impact of catch-up campaigns in those two different epidemiological contexts, the 
results of which will further feed into economic analyses to help help Gavi, the Vaccine Alliance 
to evaluate whether pneumcoccal catch-up campaigns should be included in their investment 
strategy.  
7.3.3.2. Impact of PCV in the presence of spatially heterogeneous vaccination 
coverage  
 Little attention has been given to the impact of spatial or social heterogeneity in vaccination 
coverage and transmission on the impact of PCV. There is good evidence from various low-
income settings that vaccination coverage for routine childhood vaccines often decreases in 
areas located further away from health centres, as has been reported in studies from 
Bangladesh [82], Mozambique [83], Kenya [84], Tanzania [54] and Malawi [85]. The vaccination 
coverage needed to achieve herd immunity in populations where vaccine coverage varies 
spatially will depend on the transmission dynamics within different geographic areas and the 
degree of mixing between geographical areas [86]. Although such information is likely to be 
setting-specific, assessing the effect of spatial heterogeneity and between-area mixing on the 
transmission dynamics of Streptococcus pneumoniae would enable to better understand the 
population-wide impact of PCVs at different coverage levels and the possible advantage (or 
not) of PCV outreach activities in under-vaccinated areas under various scenarios of spatial 
heterogeneity in vaccination coverage. Even in areas where health facilities are reasonably easy 
to access, children living further away from such facilities tend to be inadequately vaccinated, 
and this was shown recently in the context of PCV introduction in Malawi [85].   The degree of 
‘spillover effect’ from adequately vaccinated areas into poorly vaccinated areas in a rural African 
setting is not known, and such information would help better tailor supplementary 
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immunisation activities, if required, in areas of low vaccine uptake.   Given the availability of 
data on both nasopharyngeal carriage (including serotype distribution) across all age groups, 
and social contact data with spatially explicit information (Research paper 3) from Sheema 
district, a meta-population model could be constructed, in which transmission parameters 
derived from the contact study could be used to calculate the fraction of social contacts 
occurring within defined geographical patches and between geographic patches. 
Scenarios of vaccination coverage such as systematic differences in vaccination coverage across 
patches, with vaccination coverage in patches decreasing proportionally to the patch’s distance 
to a health centre, as well as extremes of vaccination coverage, could further be explored.  
 
7.3.3.3. Optimal PCV strategies in humanitarian emergencies.   
It is unlikely that vaccination schedules adapted to stable settings are adequate for crisis 
settings, where population displacement, overcrowding and intensified social mixing, the 
disruption of preventative and curative health services, as well as increased prevalence of 
malnutrition may impact disease dynamics, resulting in excess disease and death, altered age 
distributions and higher herd immunity thresholds [87-89].  In many crisis-affected settings 
routine immunisation services are heavily disrupted, with vaccination strategies relying on 
supplemental immunisation activities (SIAs) to increase coverage, also among age groups not 
usually targeted through routine immunisation programmes.  
As the number of internally and externally displaced individuals due to complex emergencies is 
increasing and is higher than ever, the need for appropriate and optimised vaccination 
strategies is ever more critical.  The WHO’s Strategic Advisory Group of Experts on 
Immunization in Emergencies recommends for vaccination strategies to be adapted in such 
contexts, including options such as mass vaccination campaigns, reduced dose schedules and 
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vaccination to expanded age groups in order to promptly prevent excess death and mortality 
related to the emergency [90].  
 
In 2013 refugees in Yida, one of the largest refugee camps in South Sudan, were some of the 
first refugees or internally displaced individuals to receive PCV [91]. In September 2016, 
GlaskoSmithKline (GSK) agreed to lower the price of PCV for crisis-affected populations served 
by humanitarian organisations, offering hope that PCV will now be considered more 
consistently in such settings.  
However, PCV will remain expensive compared with other immunisation programmes and 
estimating its impact in stable settings is complex enough. Hence, many questions remain 
around the best use of PCV in complex emergencies, not least because crises settings all differ. 
Nevertheless, a number of important questions are applicable to many including (i) strategies 
for one-off or regular supplementary immunisation activities (SIAs) in areas where overall 
vaccine uptake is low, (ii) the impact of single- versus multiple-dose SIAs, and (iii) the impact of 
an influx of unvaccinated individuals (e.g. refugees or internally displaced) on transmission in 
(partially) vaccinated host communities.  Work from this thesis will be pursued to address some 
of the questions highlighted above.  
 
In Figure 25 for example, an SIA was assumed for all children <2 years or <5 years 18 months 
after the introduction of PCV, based on the Nha Trang model, assuming a very low routine 
vaccination of 20% but a higher (80%) coverage through SIA.  
 
While the setting and model is not appropriate for any adequate inference to an emergency 
setting, it illustrates for a relatively low burden setting a one-off mass vaccination strategy in 
the context of very low coverage of the childhood immunisation programme may result in 
substantial reductions in VT carriage for a number of years.    
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Further research on the optimisation of PCV strategies in such settings is urgently warranted.  
 
Figure 25: VT carriage following a SIA (coverage 80%) conducted 18 months after PCV 
introduction  (routine coverage of 20%) 
 
Legend: grey: RV (20% coverage), blue: SIA in <2years; red: SIA <5 years (SIA conducted at 18 months, 80% coverage) 
 
7.4. Conclusion 
The main focus of this thesis was to explore vaccination programme options at the introduction 
of the pneumococcal conjugate vaccine (PCV) in Vietnam through a dynamic model of disease 
transmission, and more specifically the potential impact on disease of catch-up campaigns 
targeting various age groups. Few countries – in particular low and lower-middle-income 
countries – have conducted such campaigns and there is therefore limited data to inform 
policy. Countries supported by Gavi, the Vaccine Alliance, have so far not been able to 
undertake catch-up campaigns at PCV introduction over concerns that they would lead to 
vaccine introduction delays, given supply and logistical constraints. 
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Work from this thesis provides the first dynamic model of pneumococcal disease applied to a 
population in South-East Asia, where most countries have not yet introduced PCV, and where 
the burden of pneumococcal disease is relatively high. The availability of data on human social 
mixing patterns and of nasopharyngeal carriage prevalence and serotype distribution of 
pneumococci in the same population allowed to thoroughly parameterise a model in that 
setting. Additional studies on the age-specific epidemiology of nasopharyngeal carriage, the 
vaccine efficacy against carriage and its waning, and social mixing patterns relevant to the 
spread of pneumococci directly contributed to improve the quality of the transmission model, 
but also provided important insight into the epidemiology and transmission dynamics of 
S.pneumoniae, which has implications for vaccination programmes.  
 
Despite a number of limitations, results from this thesis feed directly into the current debates 
about vaccine introduction strategies, particularly in South-East Asia, offering insights into the 
impact of different PCV programme options, and providing estimates that could inform vaccine 
introduction strategies in such settings.  
 
Work from this thesis also lays a basis on which to build and pursue further research around the 
epidemiology, transmission dynamics, and optimisation of PCV vaccination strategies, 
particularly in high burden settings where pneumococcal disease still remains one of the most 
important causes of morbidity and mortality. 
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